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SUMMARY
Understanding the mechanisms and factors that govern cell cycle control is key
to developing more effective treatments for human diseases, such as cancer. The human
MASTL gene encodes an AGC family kinase, Greatwall kinase, that is conserved
among higher eukaryotes. The protein contains an unusual bifurcated kinase domain
separated by a stretch of nonconserved amino acids. In Drosophila, mutations in
Greatwall cause the failure of chromosomes to condense resulting in a delayed entry in
to and progression through mitosis. In mitotic Xenopus egg extracts, immunodepletion
of Greatwall results in exit from M phase, characterised by the decondensation of the
chromosomes and the reforming of the nuclear envelope. The addition of purified
Greatwall to egg extracts immunodepleted for Greatwall causes precocious
phosphorylation of Cdc25 and premature entry into mitosis. These reports indicate that
Greatwall plays an important role in the control of mitosis but little is known about the
function of Greatwall kinase in human cells, its structure, or control of its activity.
This project aimed to elucidate the role of this novel kinase in human cells. To
this end, the gene has been cloned and antibodies generated to allow the study of human
Greatwall kinase. RNAi-mediated knockdown of Greatwall in HeLa cells caused
aberrant mitotic progression and apoptosis. To gain further insight into the mechanism
of Greatwall activation, the Greatwall kinase structure was modelled and key motifs of
the kinase fold identified. In particular, a key activating phosphorylation was identified,
and a specific antibody raised to this site, allowing investigation of the regulation of
Greatwall activity at mitotic entry and exit. The use of chemical genetics to attempt to
specifically inhibit the kinase in human cells is described. Finally, evidence is presented
that Greatwall kinase may represent a promising new biomarker and drug target for
cancer therapy.
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CHAPTER 1. Introduction
1.1 The mammalian cell cycle
In 1665 the term ‘cell’ was coined by Robert Hooke who observed small regular
units he described as like those monks would live in while studying a slice of cork under
a microscope. This term is still used today. It is now known that cells probably first arose
on earth around 3.5 billion years ago. Our current understanding of the origins of life
informs us that simple primordial cells were formed by spontaneous chemical reactions.
Over time they evolved, out-reproducing their competitors, and eventually covering the
earth and altering its atmosphere, ultimately giving rise to life itself (Turner 1890;
Alberts 2002).
That all living things are comprised of these basic living units and that one cell
gives rise to another cell by making a copy of itself and dividing is a theory, known as
cell theory, first formed by ideas from Theodor Schwann, Matthias Jakob Schleiden and
Rudolf Virchow in the early 17th century. This theory describes the processes that are
common to and critical for all organisms and are fundamental for life to exist (Turner
1890).
The cell cycle describes the process by which cells can grow and proliferate to
pass on genetic material from one generation to the next. In general it can be broken
down into four distinct phases: interphase, comprising G1, G2 and S phases, and mitosis
(Howard et al. 1951). In interphase cells replicate their DNA during S phase at the end of
which their DNA content is precisely duplicated. This is separated by two gap phases
known as G1 and G2. In G1 new cells grow, coordinate external signals and prepare to
synthesise their DNA. After this, in G2 the final stage of interphase, cells complete DNA
replication and prepare to enter mitosis (Alberts 2002; Morgan 2007).
The cell then commits to enter mitosis where it divides its replicated
chromosomes. Mitosis is divided into distinct phases: In prophase the chromosomes
begin to condense and the nuclear envelope is broken down. Next, in prometaphase and
then metaphase, the mitotic spindle is assembled and the chromosomes are aligned on the
metaphase plate and attached under tension to each spindle pole. After this, in anaphase,
the sister chromatids are separated to each spindle pole, and telophase is the final stage in
14
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which a new nuclear envelope begins to form and the chromosomes start to decondense.
Upon completion of mitosis the cell cleaves in two to form two daughter cells by the
process of cytokinesis (Alberts 2002; Morgan 2007).
Studies of cell cycle control mechanisms in a wide variety of eukaryotes have
revealed that the cell cycle is highly conserved throughout evolution, and is in many
respects common to all eukaryotic organisms. It has become increasingly clear that in
mammalian cells this continuous sequence of cell proliferation is highly controlled in its
timing and sequence, and that this is tightly regulated by complex signalling networks
which comprise of the activation and inhibition of many different effector proteins and
signalling molecules.
1.2 Cell cycle checkpoints and transitions
To prevent aberrant cell proliferation and genomic instability a number of
checkpoints exist. These cell cycle checkpoints ensure that a cell will only transition into
the next cell cycle phase once the previous one has been completed successfully. The
G1/S checkpoint, or restriction point, serves to shift cells between the quiescent phase
and proliferative state. This monitors if a cell is ready to enter S phase and replicate its
DNA by assessing the presence of DNA damage and growth factors. The restriction point
is the time after which a cell is committed to enter S phase and replicate its DNA even if
growth factors are removed (Pardee 1974; Elledge 1996). During the course of the cell
cycle the DNA damage response continues to monitor and sense DNA damage, only
allowing cell cycle progression if conditions are favourable. The DNA damage
checkpoint can arrest the cell cycle in mid S phase (intra-S phase checkpoint) or in late
G2 (G2/M checkpoint) (Zhu et al. 2004b; Ciccia et al. 2010). The cell cycle can also be
arrested at the G2/M transition by the stress response that is activated by a range of stress
agents. Once a certain point, known as antephase, has been reached the cell is then
committed to continue into mitosis (Pines et al. 2001). A final checkpoint known as the
spindle assembly checkpoint (SAC) acts to ensure accurate chromosome segregation and
must be satisfied in late metaphase before the cell can successfully segregate its
chromosomes and divide (Musacchio et al. 2007). These checkpoints act as surveillance
mechanisms and fail-safes to ensure that genomic stability is maintained and that aberrant
15
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cells are not propagated. Mutation or misregulation of checkpoint signalling is common
in human diseases such as cancer (Malumbres et al. 2009a).
1.3 Molecular models of cell cycle control: ordering the cell cycle
To ensure cell cycle fidelity each phase must occur at the right time in the correct
order and this is stringently monitored by the checkpoints. A key question for scientists
was what was the molecular mechanism of these phase transitions? Cell cycle regulation
was initially studied using two principle model systems: genetic manipulations in yeast
and biochemical analysis of early embryonic cell cycles using frog (Xenopus) eggs. This
led to the formation of two seemingly distinct models for control of the cell cycle: the
domino model favoured by the yeast genetists and the clock model favoured by the frog
biochemists. In the later decades of the last century the molecular mechanisms were
unpicked and found to display elements common to both models allowing the two to be
reconciled (Hartwell 1978; Hara et al. 1980).
In the 1970s, Leland Hartwell and Paul Nurse pioneered the search for
temperature sensitive mutants that disturbed the cell cycle of budding yeast
(Sacchromyces cerevisiae) and fission yeast (Schizosaccharomyces pombe). These
mutants were identified by their arrest at distinct stages of the cell cycle. This pointed to
genes that were responsible for control of the cell division cycle. These mutants were
called Cell division cycle (Cdc) mutants or, depending on their size at the time of cell
cycle arrest, Wee mutants. From the phenotypes displayed by these mutants much could
be deduced about the role of the gene affected. From these studies the functions of
normal wildtype genes required for cell cycle regulation were determined. One gene
named Cdc28 in Sacchromyces cerevisiae and Cdc2 in Schizosaccharomyces pombe was
identified to be of critical importance in the control of the cell cycle in these organisms. It
was essential for the cell cycle, for Start (the yeast equivalent of the restriction point) and
for the control of mitosis. Additionally, Wee1 and Cdc25 were identified as important
regulators of Cdc2/Cdc28 (these are discussed in more detail later in this chapter).
Experiments using these mutants revealed that if a cell lacks a gene required for initiating
or completing a particular cell cycle phase, that phase becomes restrictive and prevents a
cell proceeding to later cell cycle phases. This was referred to as the ‘domino model’ of
cell cycle regulation as each cell cycle phase is dependent on the proper completion of
16
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the prior phase. This underlies the concept of checkpoint pathways, as the sequential
order of the cell cycle is dependant on these signalling events to ensure the fidelity of
phase transitions (Hartwell et al. 1970; Nurse et al. 1976; Beach et al. 1982; Hartwell et
al. 1989; Parker et al. 1992; Hoffmann et al. 1993).
In Xenopus egg extracts the rapid early embryonic divisions do not have gap
phases. No cell growth occurs as the eggs undergo cycles of S phase and M phase in
rapid succession. This provides a useful system to functionally analyse and purify the
factors that drive a cell into mitosis. In 1971, Masui et al. postulated the existence of a
cytoplasmic biochemical activity that was sufficient to induce entry into M (maturation)
phase in Xenopus oocytes (Masui et al. 1971). They called this activity Maturation
Promoting Factor (MPF). In the following decades further cell cycle analysis suggested a
mechanism for cell cycle control that was very different to the yeast domino model.
Studies pointed to a ticking ‘clock’ mechanism regulated by a biochemical component,
the MPF, present in the cytoplasm that served as a cell cycle engine to drive the cell from
one phase to another based on a strict timing mechanism (Smith et al. 1971; Hara et al.
1980).
Genetic cross-species complementation assays in yeast had confirmed that Cdc2
and Cdc28 were functionally equivalent proteins. This indicated that Cdc2 was a master
cell cycle regulator in yeast much like the MPF in Xenopus. It took almost two decades
for this activity to be purified but in 1987 a breakthrough study was published by Melanie
Lee and Paul Nurse that used another cross-species complementation assay. Here they
identified the human homologue of Cdc2 and aptly named it CDC2 because it could
replace the function of Cdc2 in fission yeast (Lee et al. 1987). During this time further
illuminating studies in Xenopus had defined the MPF as a complex of a cyclin and a
catalytic kinase subunit (Dunphy et al. 1988). Since Cdc2 and CDC2 were highly
evolutionarily conserved proteins that resembled protein kinases, examination of their
relationship to the MPF was a logical progression. A final cross-species complementation
study revealed that the kinase subunit of MPF in frogs was the same kinase as yeast
Cdc2. This allowed for the formation of a final unifying theory of cell cycle control in
which the same protein kinase acts as a master controller of mitotic transition. Finally the
MPF was identified as a complex of Cyclin Dependent Kinase 1 (CDK1, or CDC2) and
its regulatory subunit, cyclin B (Cdc13), which drives entry from G2 into mitosis (Lee et
al. 1987; Dabauvalle et al. 1988; Dunphy et al. 1988; Labbe et al. 1988; Lohka et al.
1988; Langan et al. 1989; Minshull et al. 1989a; Murray et al. 1989; Gautier et al. 1990).
17
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These numerous studies in yeast and other organisms have led to the current
understanding that the cyclin-CDK complexes are the molecular motors that serve to
drive a cell though the different stages of the cell cycle. This brought together the two
divergent models of cell cycle regulation. These proteins are remarkably conserved from
yeast to humans and govern phase transitions in a sequential order. This has led to a new
understanding of the control of the cell cycle as like that of an automatic washing
machine: the washing machine model. In this model the cell cycle is likened to a wash
cycle. There are a series of stages through which a complete wash cycle must progress
i.e. washing the clothes, rinsing them, spinning them dry. Here each phase must be
completed in turn before entry into the next phase is permitted. This is analogous to the
cell cycle during which the individual stages of cell growth, DNA synthesis and mitosis
must be ordered and completed correctly. In both cases a central control mechanism
triggers each process in a set sequence (Nurse et al. 1976; Felix et al. 1989; Hunt 1989;
Hunt et al. 1992; Hochegger et al. 2001).
It is now known that cyclin-CDKs are regulated by highly interconnected control
systems. These include feedback loops and other regulatory interactions leading to
switch-like activation and inactivation of the cyclin-CDK complexes at different stages of
the cell cycle. These regulatory interactions coordinate with one another to ensure the
correct order and timing of activation/inactivation and will be discussed here in more
detail in the following sections. This system is robust and adaptable relying on multiple
mechanisms and cellular inputs to respond to different conditions or component failures
(Minshull et al. 1989b; Doree et al. 2002).
1.4 Cyclins and Cyclin Dependent Kinases (CDKs) controlling the cell cycle
Cyclins were discovered in 1982 by R. Timothy Hunt while studying the cell
cycle of sea urchins (Evans et al. 1983; Pines et al. 1987; Hunt 2004). They were
originally named cyclins as their concentration varies in a cyclical fashion during the cell
cycle. It is these oscillating levels of cyclins, namely fluctuations in cyclin gene
expression and their subsequent destruction by proteolysis, that drive the cell cycle by
inducing oscillations in CDK activity (Minshull et al. 1990). While CDK levels remain
fairly constant throughout the cell cycle, it is the cyclic rise and fall of these cyclins and
the subsequent CDK activity that is key to satisfy the checkpoints that exist to monitor
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Figure 1.1 Control of the mammalian cell cycle by cyclin-CDKs
(A) Cyclin expression during the cell cycle. D-type cyclin levels are relatively stable throughout the cell
cycle but have an important role in early G1. E-type cyclins are expressed at G1/S to drive S phase entry.
A-type cyclins allow progression into mitosis from S phase and B-type cyclins are responsible for mitosis.
Adapted from Arcadian (2007). (B) Cell cycle control by cyclin-CDKs. Schematic representation of
mammalian cyclin-CDK complexes involved in progression throughout the different phases of the cell
cycle. These are master regulators of the cell cycle. Adapted from Malumbres (2010).
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and licence cell cycle progression (Figure 1.1 A). It should be noted that now cyclins are
classified according to their conserved cyclin box structure and not all cyclins alter in
level through the cell cycle (Fung et al. 2005; Hochegger et al. 2008; Malumbres et al.
2009a).
A cyclin forms a complex with a CDK beginning its activation. The active site of
CDKs is a small cleft between the small amino-terminal lobe and the larger carboxy-
terminal lobe. In 1993 the publication of the crystal structure of CDK2 revealed that
cyclin-unbound CDKs have a helix-loop segment that forms the activation- or T-loop and
interferes with substrate and ATP-binding (De Bondt et al. 1993). Upon binding a cyclin,
conformational changes occur to rearrange the T-loop so the active site is no longer
blocked and key amino acid residues are moved into place for optimal ATP binding.
Cyclins themselves have no enzymatic activity but have binding sites for interactors and
substrates as well as serving to target the CDKs to specific subcellular locations (Evans et
al. 1983; Doree et al. 2002; Petri et al. 2007).
These cyclin-induced conformational changes of CDKs are important for activity
but, in addition, other post-translational modifications of CDKs are required for full
activity. An activating phosphorylation on a threonine adjacent to the active site is put on
by a CDK-activating kinase (CAK) that is necessary for full activation (Jeffrey et al.
1995). The identity of the CAK that performs the phosphorylation varies between
organisms, in humans it is a trimeric complex of ménage à trois-1 (MAT1), CDK7 and its
cyclin, cyclin H (Kaldis et al. 1998). CAK activity is not regulated in a cell cycle
dependant manner and remains high throughout all cell cycle phases. The timing of the
phosphorylation also varies. For example, in budding yeast it occurs before cyclin
binding while in mammalian cells it can only occur after the cyclin has bound. In both it
is the cyclin binding that is the limiting step for CDK activation (Makela et al. 1994;
Russo et al. 1996b; Brown et al. 1999; Lolli et al. 2005).
An additional layer of control occurs in G1 through cyclin dependant kinase
inhibitors (CKIs) (Sherr et al. 1999). These small polypeptides bind to CDK-cyclin
complexes usually in G1, in response to exogenous signals or in response to DNA
damage signalling, blocking the kinase activity. There are two families of CKIs in
mammals, Inhibitors of CDK4 (INK4) and Cip/Kip family. Discovered in 1993 the INK4
family includes INK4A, INK4B, INK4C and INK4D (Canepa et al. 2007). They
specifically bind and inhibit the cyclin D binding CDKs, CDK4 and 6, as monomers. The
crystal structure of CDK6 bound to INK4 indicated that they bind and cause distortion of
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the kinase preventing cyclin or ATP binding (Jeffrey et al. 2000). The Cip/Kip family of
CKIs include p21, p27 and p57. These regulators can be activating as well as inhibitory
regulators of the CDKs (Russo et al. 1996a). They negatively regulate cyclin E-CDK2,
cyclin A-CDK2, and cyclin B–CDK1 complexes by binding to both the cyclin and the
CDK. They also bind to cyclin D-CDK4/6 in early G1 and positively regulate them by
mediating the formation of the complexes (LaBaer et al. 1997). The outcome of this is
the titration of the Cip/Kip family CKIs from cyclin E-CDK2 in G1 allowing its eventual
activation to drive cells from G1 into S phase. The active CDK2 feeds back and
phosphorylates the CKI targeting it for degradation (Sherr et al. 1995). The CKIs
ultimately serve as tumour suppressors to restrict proliferation by preventing
phosphorylation of the retinoblastoma protein (pRB) in G1 until mitogenic signals cause
increased D cyclin expression to achieve sufficient CDK activity to phosphorylate the
pocket proteins. Thereby, releasing the EF2s transcription factors to induce gene
expression required for cell cycle progression (Sherr et al. 1999).
In humans, it is currently known that there are 20 different CDKs that interact
with at least 29 cyclins and cyclin-related proteins. Of these, however, only 10 cyclins are
known to have a direct role in driving the cell cycle; three D-type, two E-type, two A-
type and three B-type cyclins. Four CDKs, CDK1, 2, 4, and 6 are known to have key
roles in cell cycle control (Fung et al. 2005; Malumbres et al. 2009a).
Broadly, there are three interphase CDKs: CDK2, CDK4 and CDK6, and one
mitotic CDK: CDK1. Mitogenic signals are first sensed as described previously by
expression of the D-type cyclins (cyclin D1, D2 and D3) that bind CDK4 and CDK6 in
G1. The formation of the active cyclin D-CDK4/6 complexes causes the partial
inactivation of the pocket proteins (pRB, p107 and p130) to allow expression of E-type
cyclins (cyclin E1 and E2). These preferentially bind to CDK2, activating CDK2 to
further phosphorylate the pocket proteins fully inactivating them. The availability of the
E-type cyclins is tightly controlled during the cell cycle and is limited specifically to the
early stages of DNA synthesis. For this reason, combined with evidence that inhibition
of CDK2 inhibited the cell cycle in human tumour cell lines, it was thought that active
cyclin E-CDK2 complexes were a requirement to drive the G1/S transition. During the
late stages of DNA synthesis CDK2 is activated by the A-type cyclins (cyclin A1 in
germ cells and A2 in somatic cells). These cyclin A-CDK2 complexes drive entry into
mitosis from S phase during G2 and at the end of interphase induce expression of the B-
type cyclins (cyclin B1, B2 and B3). Cyclin A also associates with CDK1 to facilitate
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mitotic entry and is degraded upon nuclear envelope breakdown (NEBD). It is cyclin B-
CDK1 active complexes that drive forward commitment to enter and progress through
mitosis (Figure 1.1 B) (Fung et al. 2005; Malumbres et al. 2009a; Malumbres et al.
2009b).
This classical model that there is a specific CDK to drive each phase of the cell
cycle has been recently cast into doubt by genetic studies in mice. That CDK2, 4, and 6
are not essential for the cell cycle in most cell types has been established by the
systematic knockout of CDK loci in the mouse germline (Santamaria et al. 2007). These
studies determined that these CDKs are instead required for development specifically in
highly specialised cell types. CDK4 is required for proliferation of pancreatic β-cells and 
pituitary lactrophs during post-natal development (Rane et al. 1999; Tsutsui et al. 1999).
CDK6 leads to minor problems in cells of erythroid lineage (Malumbres et al. 2004).
CDK2 knockout mice are viable and do not display any cell cycle defect in somatic cells
but are infertile. Thus CDK2 is essential only in meiosis (Berthet et al. 2003; Ortega et
al. 2003; Duensing et al. 2006).
CDK1 is the only CDK that is essential for the mammalian cell cycle in mouse
embryonic fibroblasts. Knockout mouse models have shown that loss of CDK1 is lethal,
with embryos experiencing a cell cycle arrest preventing development beyond the two
cell stage (Santamaria et al. 2007; Adhikari et al. 2012b; Diril et al. 2012). Even
expression of CDK2 from the CDK1 gene locus, examined by replacement of one gene
for the other by homologous recombination, still resulted in early embryonic lethality
(Satyanarayana et al. 2008).
Ablation of D-type cyclins causes specific developmental defects due to their
differential expression, while if all three D-type cyclins are ablated heamatopoitetic
defects cause embryonic lethality. This is similar to the phenotype seen for mice lacking
CDK4 and 6 and provides evidence that these G1 kinases are functionally activated by
the D-type cyclins (Kozar et al. 2004; Malumbres et al. 2004). Knockout models of
cyclin E1 and E2 are also embryonic lethal due to defects in the endoreduplication of
trophoblast cells (Geng et al. 2003; Parisi et al. 2003). Ablation of cyclin A2 causes early
embryonic lethality indicating its main role is to activate CDK1, while A1 knockout mice
are viable (Murphy et al. 1997). Cyclin B1 is essential and mice in which this gene has
been ablated die in utero. Mice lacking cyclin B2 develop normally but are less fertile
and smaller than wildtype mice (Brandeis et al. 1998). Cyclin B3 knockout has not yet
been carried out.
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Thus it is likely that there is a level of redundancy between the cyclins and their
CDK partners. Their essential and overlapping roles are still to be completely elucidated
but it is clear that in control of the cell cycle the temporal and spatial control of cyclins
and their associated CDKs has many complex layers of regulation. This has led to a
minimal-threshold model of cell cycle control replacing the classical model. In this model
the differences between interphase and mitotic CDKs is not due to substrate specificity
necessarily, but rather result from different localisation and a higher threshold activity
required for mitosis than for interphase (Hochegger et al. 2008; Malumbres et al. 2009a).
1.5 Initiation of cell cycle entry by CDKs
Most adult cells are fully differentiated and in a quiescent state. This resting state
is often referred to as G0 and cells in G1 can enter this state in response to extracellular
factors signalling that continuation through the cell cycle is not appropriate. Once the cell
cycle has been exited they express very few or none of the genes required for the cell
cycle. Thus, in order to enter the cell cycle the transcriptional and translational machinery
required to specifically express these genes must be activated. In the rapid early divisions
of embryogenesis these genes are already active. A repression mechanism acts to
suppress these in cells that terminally differentiate during organogenesis (Classon et al.
2002; Malumbres 2011). This occurs via pRB and other pocket protein family members
p107 and p130. These are transcriptional regulators that repress a wide array of genes
including those of cell cycle regulators (Knudsen et al. 2006). When hypophosphorylated
pRB is active and binds and inhibits the E2F family of transcription factors. These
complexes sequester the EF2 transcriptional activators in an inactive form preventing the
expression of genes necessary to continue through the cell cycle and enter S phase
(Infante et al. 2008). In addition, cell cycle gene expression is repressed via pRB-
mediated recruitment of polycomb-group proteins, repressor complexes, like the
SWI/SNF complex, histone deacetylases and methylases to these genes (Sif et al. 1998;
Macaluso et al. 2006; Sauvageau et al. 2008).
In order for the cell cycle to be reactivated this repression must therefore be lifted.
Mitogenic signals received by the cell serve to lift pRB-mediated gene repression via
activation of the CDKs. These proteins are present even in quiescent cells but are kept
inactive due to the absence of their cyclin activators. Mitogenic signalling pathway
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Figure 1.2 Cyclin D-CDK4/6 activation of E2F in G1
Schematic drawing of E2F activation by cyclin-CDK. CDK4 or CDK6 complexed with cyclin D
phosphorylates pRB. This then releases E2F to transcribe genes needed to drive cell cycle progression.
Phosphorylation is represented by a violet sphere. Adapted from Schafer (1998).
activation leads to the induction of expression of the D and E cyclins that form active
complexes with their CDK4/6 and CDK2 binding partners respectively, which can then
phosphorylate pRB, inactivating it. This allows the induction of transcription of genes
required for cell cycle progression and subsequent cell cycle phases (Figure 1.2)
(Bandara et al. 1991; Schafer 1998; Malumbres 2011).
1.6 S phase
In the next stage of the cell cycle, cyclin E-CDK2 and cyclin A-CDK2 complexes
are key to drive cells out of G1 and to carry out DNA replication in S phase. CDK
activity is not only critical for DNA replication but also to ensure that replication of the
genome occurs only once per cell cycle (Woo et al. 2003).
Cyclin E-CDK2 activity peaks during S phase entry, where it has two main
functions (Woo et al. 2003). Firstly it participates in the release of E2F from pRB, to
enable E2F to exhibit transcriptional control of a number of genes required for S phase
and driving S phase entry (Lundberg et al. 1998). It is thought that the irreversible
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24
CHAPTER 1
inactivation of pRB by cyclin E-CDK2 renders cells independent of mitogenic signals
and corresponds to the restriction point (Malumbres et al. 2001). Secondly, it
phosphorylates components required for the initiation of DNA replication.
Replication of the genomic DNA during S phase is a well choreographed, highly
ordered process involving numerous different proteins (Bell et al. 2002; Tanaka et al.
2010). In eukaryotes, DNA replication is initiated at multiple locations along each
chromosome. These are referred to as replication origins (Mendez et al. 2003). The
replication process begins prior to S phase with the ordered assembly of a multiprotein
complex at the replication origins referred to as the pre-replication complex (pre-RC)
(Mendez et al. 2000; Diffley 2004). Firstly, the Origin Recognition Complex (ORC)
proteins associate with the DNA at origin sites and form a platform to recruit Cdc6 and
Cdt1 (Mendez et al. 2003; Diffley 2004). The recruitment of these two proteins is a
critical step in the formation of the pre-RC and both are required for the subsequent
loading of six Mini-Chromosome Maintenance (MCM) 2 to 7 proteins (Mendez et al.
2000). The MCM2-7 proteins form important components of the pre-RC replicative
helicase activity that unwinds the DNA at the origin sites forming templates for DNA
polymerase (Pacek et al. 2004). These origins are then said to be licensed but the helicase
is still inactive and initiating activation requires the additional binding of multiple
cofactors and two kinases; Dbf4-dependant kinase (DDK) and CDK (Masai et al. 2000;
Diffley 2004). The activation of the pre-RC and initiation of DNA replication is known
as origin firing. Cdc45 is among the cofactors required for DNA replication to begin. It
interacts with the pre-RC and induces loading of RPA and DNA polymerase α to initiate 
origin firing (Mimura et al. 1998; Zou et al. 2000). Phosphorylations by cyclin-CDK2
and DDK are essential for Cdc45 loading onto the origins, although it is not clear
whether it is cyclin E or A that is involved there is evidence that both can functionally
compensate for each other in S phase (Woo et al. 2003; Hochegger et al. 2008; Zhao et
al. 2012). The expression of cyclin E peaks before cyclin A at the beginning of S phase
indicating that cyclin E-CDK2 complexes likely dominate in early S phase and are
replaced by cyclin A-CDK2 complexes later in S phase (Zhao et al. 2012). Other specific
targets of DDK and CDK2 are still to be fully elucidated in human nuclei but they likely
include the MCM2-7 complex, RecQ4, TOPBP1 and Treslin (Tanaka et al. 1997; Garcia
et al. 2005; Xu et al. 2009; Kumagai et al. 2010). Together, these two kinase activities
regulate the formation of the initiation complex and the initiation of replication of
licensed origins at the beginning of S phase.
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Once replication has begun, bidirectional replication forks are established and
both DDK and cyclin E-CDK2 are dispensable for the completion of S phase (Bousset et
al. 1998; Tanaka et al. 2010). They are therefore exclusively required for the initiation of
DNA replication. The inactivation of pRB promotes transcription genes required for
subsequent cell cycle stages, including cyclin A and B, and cyclin A-CDK2 activity
increases as S phase progresses (Schulze et al. 1995; Woo et al. 2003). Cyclin A-CDK2
complexes phosphorylate numerous targets required for completion and exit from S
phase. These include targets that promote activation of pre-RC complexes and also
targets that allow elongation and inhibit the formation of new pre-RC complexes
(Lundberg et al. 1998; Harbour et al. 1999; Arata et al. 2000; Malumbres et al. 2001).
Cyclin A has been shown to be associated with replicating DNA and to colocalise with
replication foci (Fotedar et al. 1991; Cardoso et al. 1993). Cyclin A-CDK2 complexes
have also been shown to phosphorylate several components of the replication machinery
including DNA polymerase α and the processivity factor Proliferating Cell Nuclear 
Antigen (PCNA) (Nasheuer et al. 1991; Prosperi et al. 1994).
In 1970 cell-fusion experiments carried out by Johnson and Rao indicated the
presence of a re-replication block (Rao et al. 1970). The results indicated that only G1
cells are competent to carry out replication of their DNA, while cells that have already
completed this process, i.e. G2 cells, were unable to re-replicate their DNA. This re-
replication block is key to limit replication to only once per cell cycle preventing
genomic instability. It is now understood that this occurs due to the two step nature of the
activation of DNA replication (Mendez et al. 2003; Woo et al. 2003; Remus et al. 2009).
CDK activity is relatively low in G1 and is permissive to pre-RC assembly and origin
licensing (step one). As CDK activity increases in S phase, and cyclin A-CDK2
complexes predominate, DNA replication is initiated and the pre-RCs are activated (step
two). At this stage the high CDK activity inhibits the formation of further pre-RC
complexes preventing their reformation and remains high until the end of mitosis. CDK
activity is therefore critical to ensuring that genomic DNA is replicated exactly once per
cell cycle and is thus transmitted stably over generations. CDK inhibition of pre-RC
formation is mediated in several ways. The CDK initiation of origin firing disassembles
the pre-RC leaving an unlicensed origin and high CDK activity then inhibits the
formation of new pre-RC by several mechanisms (Nguyen et al. 2001; Takeda et al.
2005). These include the phosphorylation of free Cdc6 causing its export from the
nucleus and the phosphorylation of the ORC complex and Cdt1, leading to their
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dissociation from the chromatin and/or degradation (Delmolino et al. 2001; Li et al.
2002; Sugimoto et al. 2004).
The end of S phase is signified by the completion of DNA replication and the cell
then moves into the next cell cycle phase, G2, in which the cell prepares to divide its
newly synthesised chromosomes.
1.7 The G2/M transition - activation of MPF via control of cyclin B
Of the three B cyclins known, cyclins B1 and B2 are expressed in most cycling
cells. They are differently localised, with cyclin B1 being found on the microtubules and
cyclin B2 found associated with the Golgi apparatus. Cyclin B3 expression is restricted to
developing germ cells and the testis in adults, where it is degraded shortly after cyclin B1
(Brandeis et al. 1998; Nguyen et al. 2002).
Cyclin B levels first begin to rise in S phase. Its levels slowly increase throughout
G2 and then climb to high levels, peaking in late G2, and remain high in early mitosis.
Cyclin B must be present at sufficient levels for the formation of an active MPF at the
end of G2 phase to drive mitotic entry (Fung et al. 2005).
The expression of the cyclins required to drive cells from S phase into mitosis
must be repressed until the correct time, at which point their expression must then be
rapidly activated. In order to achieve this, the levels of this protein are temporally
restricted throughout the cell cycle by tight control of transcription and subsequent
proteolysis (Felix et al. 1989; Lindqvist et al. 2009).
This transcriptional control is accomplished via several transcriptional control
elements. The promoters of cyclins A2, B1 and B2 contain CCAAT-boxes. These
invariant DNA sequences are found downstream of the origin of replication of genes
and bind transcription factors required for a gene to be transcribed in sufficient
quantities. These are bound by the trimeric nuclear transcription factor Y (NF-Y),
activating cyclin gene transcription (Katula et al. 1997; Kramer et al. 1997). In addition,
the coactivator p300 binds to the promoters of cyclins B1 and B2 and synergises with
NF-Y to further enhance their transcription. Their promoters also contain E2F binding
elements that can be positive or negative acting. For cyclin B1, E2F1, 2, and 3 bind to
the positive acting site and E2F4 binds to the negative acting site, inhibiting
transcription. Another element, the cell cycle genes homology region (CHR), is
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important for the repression of cyclin A2, B1 and B2 in G1 (Wasner et al. 2003). The
transcription factor B-MYB positively regulates transcription of cyclin A2 and B1 and
its activity is enhanced by phosphorylation by cyclin A-CDK2 in S phase. B-MYB is in
fact itself regulated by E2F transcription factors which induce its expression at G1/S
(Joaquin et al. 2003b; Joaquin et al. 2003a; Zhu et al. 2004a). Cyclin B1 expression is
also activated by the forkhead transcription factor FOXM1. This transcription factor is
essential for timely entry into mitosis as it stimulates the expression of numerous G2-
specific genes (Laoukili et al. 2005). In fact many of these elements, CCAAT boxes,
NF-Y and B-MYB binding and CHR are present in genes involved in the control of the
G2/M transition, including genes for CDK1 and Cdc25. During mitosis the cyclin B1
gene remains in an open chromatin conformation and its promoter remains bound by
NF-Y allowing its expression during mitosis (Sciortino et al. 2001). All these
transcription factors, NF-Y, B-MYB and FOXM1 are controlled by CDK activity.
These led to the efficient transcription of cyclin B only once the activity of cyclin A-
CDK2 has built up sufficiently during S phase and G2 (Bolognese et al. 1999; Salsi et
al. 2003; Fung et al. 2005).
Control of destruction of cyclin B is mediated through the destruction box (D-
box) (Klotzbucher et al. 1996). This is a short N-terminal sequence that targets the
mitotic cyclins to the E3 ubiquitin ligase, the anaphase-promoting complex/cyclosome
(APC/C) (Acquaviva et al. 2006). This multi-subunit complex is crucial for allowing
progression through the cell cycle. The APC/C has two activating/adaptor subunits, the
cell division cycle protein 20 (Cdc20) and cell division cycle homologue 1 (Cdh1). In
mitosis, APC/CCdc20 is critical for the transition from metaphase to anaphase and
APC/CCdh1 becomes active in late mitosis into G1 phase. The APC/C acts by targeting
its substrate proteins to the 26S proteasome for degradation in a highly regulated and
specific manner. The mutation or deletion of the D-box from the N-terminus of these
cyclins leads to inhibition of cyclin degradation. The ubiquitin-mediated proteolysis of
the cyclin B begins at the metaphase/anaphase transition, once APC/CCdc20 becomes
active after correct chromosome alignment has been achieved and the mitotic
checkpoint known as the spindle assembly checkpoint (SAC) has been satisfied. The
active APC/C continues to promote cyclin B degradation until S phase when its levels
can begin to rise again. In this manner, high cyclin B levels and thus MPF activity are
regulated by protein expression and proteolysis during the cell cycle (Pfleger et al.
2000; Sudakin et al. 2001; Yamano et al. 2004).
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The cellular localisation of cyclin B is also regulated (Takizawa et al. 2000).
Cyclin B is shuttled between the cytoplasm and the nucleus. In S phase and the majority
of G2 phase its export from the nucleus outweighs import, making cyclin B
predominantly cytoplasmic (Pines et al. 1991). Cyclin B localisation accumulates
during G2 at the centrosomes as they mature (Pines et al. 1991; Jackman et al. 2003).
Maturation of the centrosomes is also signified by an increased concentration of other
proteins required for mitotic entry and gamma tubulin. This subcellular shuttling of
cyclin B likely contributes to formation of active MPF by concentrating cyclin B in
specific cellular compartments. In prophase, cyclin B rapidly accumulates in the nucleus
allowing CDK activity and mitotic progression (Hagting et al. 1998; Toyoshima et al.
1998; Yang et al. 1998).
1.8 The cyclin B-CDK1 positive feedback loop
The presence of cyclin B at sufficient levels is important for the formation of an
active MPF to drive mitotic entry but additionally CDK1 must be phosphorylated by the
CAK on Thr161 in the T loop to create an active kinase (Tassan et al. 1994). Further
inhibitory phosphorylations elsewhere in CDK1 act to keep it inactive until it is required
to drive progression into mitosis, at which point it becomes dephosphorylated and active.
These inhibitory phosphorylations, unlike the activating phosphorylation put on by CAK,
are vital for the regulation of the cell cycle. These form the basis of the feedback loops
that ultimately control activation of the MPF and mitotic entry (Lindqvist et al. 2009).
The highly conserved kinase, Wee1, phosphorylates CDK1 on tyrosine 15
inhibiting it (Parker et al. 1992). The Wee1 protein was so named because its functional
loss in yeast cells produces a smaller than normal daughter cell after division as mitosis is
induced prematurely (Nurse et al. 1980). This phenotype indicates its role in dictating
cell size in these cells and in coordinating cell size with cell cycle progression, preventing
cells that are too small from entering mitosis and dividing. A second membrane-
associated kinase, Myt1, that is related to Wee1 is found also in vertebrates and
phosphorylates CDK1 on threonine 14 as well as tyrosine 15 also inhibiting it (Mueller et
al. 1995; Fattaey et al. 1997). Wee1 is predominantly nuclear or associated with the
centrosomes while Myt1 is found associated with membrane bound structures in the
cytoplasm (Baldin et al. 1995; Liu et al. 1997).
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Figure 1.3 The cyclin B-CDK1 positive feedback loop
Schematic representation of the cyclin B-CDK1 positive feedback loop that functions to rapidly escalate
the activation of CDK1 to promote and maintain mitotic entry. CDK1 is kept inactive prior to mitotic entry
in G2 by inhibitory phosphorylations on Thr14 and Tyr15 added by Wee1 and Myt1, represented by the
aqua sphere. It is activated when these are removed by the phosphatase Cdc25 at the G2/M transition.
Active CDK1 can then phosphorylate and inactivate Wee1 and Myt1, and phosphorylate and activate
Cdc25. This creates a positive feedback loop that serves to rapidly drive up CDK1 activity and promote
mitotic entry. Activating modifications are shown as purple arrows and inhibitory modifications are shown
in orange.
Phosphatases from the Cdc25 family remove these inhibitory phosphorylations
therefore activating the CDK1 again (Dutcher et al. 1982; Kumagai et al. 1991; Kumagai
et al. 1992). These are dual specificity phosphatases that can dephosphorylate both serine
and threonine residues as well as tyrosine residues (Dunphy et al. 1991). Knockout
mouse models of Cdc25B and C, both separately and together, are viable but Cdc25A
deletion is lethal (Chen et al. 2001; Ferguson et al. 2005). In G2 phase, Cdc25A, B and C
shuttle between the nucleus and the cytoplasm but Cdc25A is predominantly nuclear and
is critical for unperturbed cell cycle progression and cell cycle arrest in response to
checkpoint signalling (Jinno et al. 1994). Cdc25B and C appear to primarily regulate
progression from G2 into mitosis, Cdc25A is active in all stages of the cell cycle.
Cdc25A can bind to different cyclins and dephosphorylate CDKs in vitro and is
transcriptionally controlled by the transcription factor c-Myc as well as by E2F. Cdc25B
CDK1
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and C are also targeted to the centrosomes in G2 and Cdc25B is implicated in the initial
activation of cyclin B-CDK1 here (Hoffmann et al. 1994; Gabrielli et al. 1996; Jackman
et al. 2003; Lindqvist et al. 2005; Boutros et al. 2006).
These regulatory proteins, Cdc25, Wee1 and Myt1 are themselves directly
regulated by CDK1 phosphorylation. Once cyclin B-CDK1 complexes are active they
feedback and promote Wee1 and Myt1 inactivation and further activation of Cdc25
creating a positive feedback loop that rapidly drives up CDK1 activity. Phosphorylation
of Wee1 by CDK1 begins a cascade that targets it for degradation, while the
phosphorylation of Myt1 ultimately inhibits its kinase activity (Booher et al. 1997;
Nakajima et al. 2003; Watanabe et al. 2004; Watanabe et al. 2005). Phosphorylation by
CDK1 of Cdc25C activates it, stabilises Cdc25A and causes relocalisation of Cdc25B
(Hoffmann et al. 1993; Baldin et al. 2002; Mailand et al. 2002b). Thus, CDK1 activation
at the end of G2 phase deactivates its inactivators and activates its activators. Together
these interactions form a positive feedback loop to drive up high levels of cyclin B-
CDK1 activation very rapidly. Once activation of cyclin B-CDK1 has reached a
sufficient threshold nuclear lamina is disassembled and the nuclear envelope is broken
down. The cell is then committed to enter mitosis. It is the balance between these
activating and inhibitory mechanisms that ultimately controls entry into mitosis to
complete the cell cycle (Figure 1.3) (O'Farrell 2001; Boutros et al. 2006; Hochegger et
al. 2008; Lindqvist et al. 2009).
1.9 Further feedback loops controlling mitotic entry
There are in addition multiple layers of feedback regulation that serve to add
layers of complexity to the biochemical signal to enter mitosis.
In numerous CDK substrates phosphorylation by CDK1 creates docking sites for
Polo-Like Kinase 1 (PLK1) (Elia et al. 2003a; Elia et al. 2003b). This serine/threonine
kinase was first identified in Drosophila as a mutant phenotype that caused aberrant
mitosis and ablation of PLK1 from the mouse genome is lethal (Sunkel et al. 1988; Lu et
al. 2008). It is now known to function as a key regulator of the G2/M transition and to
play important roles in centrosome function, bipolar spindle formation and cytokinesis as
well as in meiosis (van Vugt et al. 2004c). At the G2/M transition Wee1 phosphorylation
by CDK1 mediates PLK1 recruitment and subsequent phosphorylation of Wee1 by PLK1
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(Watanabe et al. 2005). This dual phosphorylation forms a phospho-degron that targets it
for ubiquitin-mediated destruction (Freire et al. 2006). PLK1 phosphorylation of Myt1
inhibits its kinase activity and phosphorylation of Cdc25C promotes its concentration in
the nucleus (Nakajima et al. 2003). Functional activation of Cdc25B by PLK1 has
recently been demonstrated. Phosphorylation of Cdc25B by PLK1 causes it to relocate to
the nucleus (Toyoshima-Morimoto et al. 2002). The overexpression of Cdc25B that
drives cells prematurely into mitosis could be overcome by the inhibition of PLK1
(Lobjois et al. 2009). At present it is not clear if PLK1 can directly phosphorylate
Cdc25A. PKL1 can phosphorylate cyclin B in its nuclear export sequence (NES) on
serine 147 or near it on serine 133 but the significance of these phosphorylations is again
unclear (Toyoshima-Morimoto et al. 2001; Yuan et al. 2002; Gavet et al. 2010a). What is
clear is that PLK1 acts in concert with CDK1 to amplify and modulate mitotic entry
signalling. Two CDK1 consensus phosphorylation sites have been shown to be
phosphorylated on mitotic PLK1 (Gavet et al. 2010b). Although the function of these
phosphorylations is not known, it is likely that CDK1 additionally directly
phosphorylates and regulates PLK1 itself (van Vugt et al. 2004b; Daub et al. 2008; Gavet
et al. 2010b). The need for PLK1 activity to allow mitotic entry was seemingly
confirmed by the injection of anti-PLK antibodies into non-transformed human cells
resulting in a late G2 block preventing entry into mitosis (Lane et al. 1996). However,
when performed in transformed human cells the same block was not duplicated and later
studies using specific PLK1 inhibitors suggested that PLK1 is not required for mitotic
entry but for maintaining centrosome and kinetochore function (Lane et al. 1996; Lenart
et al. 2007). PLK1 inhibition resulted in prophase entry but a delay of the transition to
prometaphase. Thus, the relative role of PLK1 in the commitment to mitotic entry
remains to be clearly deciphered.
Consistent with its proposed mitotic roles, PLK1 is localised to the centrosomes
and the kinetochores. This is likely influenced by the presence of its phosphorylated
target substrates (Hanisch et al. 2006; Qi et al. 2006). It is activated by a phosphorylation
in its T-loop on threonine 210 by Aurora A (Macurek et al. 2008). The serine/threonine
kinases, the Aurora kinase family includes, Aurora A, B and C (Nigg 2001). Aurora A
localises to the centrosomes from the end of S phase and likely first activates PLK1 here
(Seki et al. 2008). Aurora A has an important role in formation of a stable bipolar spindle
and fidelity of chromosome segregation (Eyers et al. 2003; Girdler et al. 2006; Barr et al.
2007). It is degraded at the end of mitosis/ beginning of G1 by the APC/CCdh1. Aurora B
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is localised to the kinetochores in early mitosis where it forms a component of the
chromosome passenger complex (CPC) required for proper chromosome alignment at the
metaphase plate. It then moves onto the spindle and eventually the midbody during
cytokinesis where it is required for completion of abscission. It is also responsible for the
mitotic phosphorylation of serine 10 and probably serine 28 of histone H3. This indicates
it likely has additional functions via epigenetic modification of chromatin (Carmena et al.
2003; Ruchaud et al. 2007; Sabbattini et al. 2007; Kelly et al. 2009). Much less is known
about the role of Aurora C. It is expressed at high levels in the testis and has a specific
role in spermatogenesis (Dieterich et al. 2007). Its role in mitosis is largely unknown but
it has been reported to bind members of the CPC and rescue the loss of function of
Aurora B in cultured cells (Sasai et al. 2004). Knockout mouse models of Aurora A and
B are embryonic lethal but Aurora C-/- mice are viable with minor defects in
spermatogenesis (although it should be noted that there may be multiple Aurora C loci in
the mouse genome) (Kimmins et al. 2007; Cowley et al. 2009; Malumbres 2011).
Aurora A is activated by autophosphorylation of threonine 288 in its T-loop
(Walter et al. 2000; Littlepage et al. 2002). It must then bind to its cofactor Bora to allow
it to phosphorylate PLK1 on threonine 210 (Seki et al. 2008). In turn, PLK1 has been
shown to regulate Aurora A activity and localisation in mitosis, indicating that there is
considerable cross talk amongst these two mitotic kinases (Scutt et al. 2009; Lens et al.
2010). Additionally, although Bora has been shown to bind PLK1 even if CDK1 is
absent, CDK1 phosphorylation of Bora enhances its binding of PLK1 (Hutterer et al.
2006). In this way CDK1 may enhance the Aurora A-mediated activation of PLK. This
adds a layer of positive feedback with CDK1 stimulating its own activation via the
stimulation of PLK1 activation. Aurora A has been found to directly phosphorylate
Cdc25B at the centrosome at the G2/M transition, implicating it in the initial activation of
cyclin B-CDK1 here in concert with PLK1 (Dutertre et al. 2004; Cazales et al. 2005).
Furthermore, there is some evidence that Aurora A is itself required for mitotic entry.
The injection of anti-Aurora A antibodies delayed entry into mitosis in human cells
suggesting it may play a role in the initiation of mitosis possibly by facilitating the
translocation of cyclin B-CDK1 to the nucleus allowing full activation to be achieved
(Marumoto et al. 2002). The precise mechanisms of these signalling networks remain to
be completely understood but it is clear that layered feedback loops exist governing
cyclin B-CDK1 activation ensuring that PLK1 and Aurora A are activated with correct
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timing to facilitate centrosome maturation and bipolar spindle formation concomitantly
with cyclin B-CDK1 activation and timely mitotic entry (Lindqvist et al. 2009).
The centrosomes are the microtubule nucleating centres of the cell and are
important for mitotic spindle formation and chromosome stability (Abal et al. 2002;
Chevrier et al. 2002). They are duplicated in each S phase and separated during the G2/M
transition to form the mitotic spindle poles. Although the exact mechanisms of the
centrosome cycle remain to be elucidated, it is important for timely disjunction,
separation and positioning to form the spindle poles. CDK1, PLK1 and the motor protein
Eg5 all play a role in this control (Blangy et al. 1995; Smith et al. 2011). Increasing
evidence suggests that signalling at the centrosomes must be tightly controlled at the
G2/M transition to mediate coordination of control networks facilitating commitment to
mitotic entry (Hagan 2008). As mentioned previously, important mitotic regulators are
recruited and concentrated at the centrosome in late G2, including cyclin B, PLK1, Mps1,
Aurora A, Cdc25B and C (Bornens 2002; Blagden et al. 2003; Tyler et al. 2007; Hagan
2008; Tyler et al. 2009). This implies an important additional role for the centrosome
mediating the signalling feedback loops required for timely mitotic entry.
The concentration of the many proteins required for the mitotic entry network is
further compounded by the activation of transcription factor FOXM1 by PLK1 (Fu et al.
2008). This forms an addition layer of feedback in which CDK1-dependent activation of
PLK1 via Aurora A/Bora serves to ultimately stimulate further cyclin B-CDK1
activation.
1.10 The mitotic entry network
Thus there are multiple feedback loops that act in concert to form a complex
mitotic entry signalling network that allows the required level of cyclin B-CDK1
activation to be achieved. This forms a bistable switch-like mechanism in which once
sufficient cyclin B-CDK1 activity has built up the whole cellular pool of cyclin B-CDK1
is rapidly activated (O'Farrell 2001). To protect against inappropriate triggering of this
system, Wee1 and Cdc25 act as highly sensitised substrates for cyclin B-CDK1 activity.
Low levels of cyclin B-CDK1 activity are only able to phosphorylate Wee1 on sites that
do not inhibit its activity. Once CDK1 activity has built up to a higher level it can
phosphorylate Wee1 and cause its inhibition (Kim et al. 2007). At the same time Cdc25
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can be rapidly activated by a relatively low level of CDK1 activity (Trunnell et al. 2011).
This results in the requirement for a threshold level of CDK1 activity to be achieved
before the amplification loop is triggered. But once this level has been reached the switch
is triggered and CDK1 activation is rapid and complete (Pines et al. 2011).
In addition to the proteins and feedback loops discussed here it is likely that many
additional components and signalling networks are also involved. These have been
indicated by recent proteomic studies that have revealed that several thousand proteins
become phosphorylated during mitotic entry. Many of these components and signalling
networks are still to be elucidated (Daub et al. 2008; Dephoure et al. 2008).
Additionally, the relative contribution of each of the known components or
feedback loops of the mitotic entry signalling network is not yet well resolved. Studies
using RNA interference (RNAi) mediated depletion or chemical inhibition of individual
components imply that there is at least some redundancy in these signalling networks
(Lindqvist et al. 2009). Surprisingly even centrosomes themselves are not essential for
mitosis in all cells. Human HeLa cells continued normally through the cell cycle after
their removal by laser ablation (La Terra et al. 2005). Although not all components of the
network are absolutely required for mitotic entry there is evidence that all components
are needed in order for a cell to enter mitosis with correct timing and for proper
coordination of all mitotic events. A CDK1 mutant that cannot be inhibited by Wee1 or
Myt1 led to abnormal mitosis and the expression of active cyclin A-CDK2 by injection
led to the effective ablation of G2 phase and caused cells to display mitotic abnormalities
(Furuno et al. 1999; Pomerening et al. 2008). This implies that although there is
redundancy in the network all components and feedback loops must function in concert
with correct timing to allow error free cell division.
1.11 Antephase
In mammalian mitosis cyclin A-CDK is required for cells to enter and progress
through prophase (Furuno et al. 1999; Fung et al. 2007). Here the nucleoli are
disassembled, the chromosomes condense and cyclin B-CDK1 is activated. Once
activation of cyclin B-CDK1 has been achieved it is then required to allow progression
into metaphase. It is required for completion of chromosome condensation, NEBD and
completing the formation of the mitotic spindle (Rieder 2011). The period in which the
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chromosomes begin to condense at the end of G2, just before a cell becomes committed
to enter mitosis regardless of environmental conditions, is termed antephase (Chin et al.
2010). Until the rapid accumulation of active cyclin B-CDK1 in the nucleus the process
of prophase chromosome condensation can still be reversed (Rieder et al. 2000). Once
this point is passed, however, a cell has committed to enter mitosis and only death can
prevent it from breaking down its nuclear envelope and entering mitosis (Mazia 1961;
Pines et al. 2001). The point of no return, when a cell cannot reverse mitotic entry, occurs
approximately 10 minutes before NEBD at the time when cyclin B-CDK1 accumulates in
the nucleus. Before this, various insults can cause the cell cycle to arrest, preventing or
delaying entry into mitosis. This can be triggered by two main checkpoint control
pathways; the DNA damage checkpoint pathway and the stress response pathway
(Mikhailov et al. 2005; Bartek et al. 2007). Both checkpoint control pathways ultimately
act to inhibit cyclin B-CDK1 activation until conditions are favourable for the cell to
enter mitosis. The DNA damage checkpoint will be discussed in more detail later in this
chapter. The stress response checkpoint pathway is also known as the antephase
checkpoint and can be triggered by ultra violet (UV) light exposure, heat shock, osmotic
shock and mitotic stress (Matsusaka et al. 2004). This pathway is based on two proteins;
the E3 ubiquitin ligase ‘Checkpoint protein with an FHA domain and RING finger’
(Chfr) and the Mitogen Activated Protein (MAP) kinase family member p38 kinase
(Alonso et al. 2000; Nebreda et al. 2000; Matsusaka et al. 2004). Chfr is necessary to
activate the checkpoint in response to mitotic stress, such as microtubule spindle poisons,
and is thought to act upstream of p38 (Scolnick et al. 2000; Chaturvedi et al. 2002). Once
p38 is activated by stress stimuli or Chfr signalling, it activates a signalling cascade that
promotes Cdc25B binding to the 14-3-3 protein, sequestering it in the cytoplasm, slowing
cyclin B-CDK1 activation and delaying mitotic entry (Conklin et al. 1995; Karlsson-
Rosenthal et al. 2006). It can also produce a more sustained block by phosphorylating
p53 causing it to dissociate from Murine double mutant 2 (Mdm2) and induce the
expression of the CDK inhibitor p21 (Alberts 2002; Bulavin et al. 2002; Kang et al.
2002; Mikhailov et al. 2005).
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1.12 Mitosis
Once a cell has committed to enter mitosis the nuclear envelope is broken down.
This allows the dynamic microtubule arrays emanating from the mature separating
centrosomes to interact with the chromosomes to form a bipolar spindle (Rieder 2011).
On each replicated chromosome or sister chromatid, a kinetochore must attach to an
opposing spindle pole. They must do this in a manner that results in each being attached
to just one opposing pole. This ‘amphitelic’ or biorientated attachment ensures faithful
segregation of the chromosomes in anaphase with one copy of each being delivered to the
two resulting daughter cells. During the process of forming the bipolar spindle sister
kinetochores can become erroneously attached. These attachments are rapidly dealt with
by a correction mechanism based on Aurora B at the inner kinetochore. This is important
to prevent chromosome missegregation and the production of aneuploid progeny (Rieder
et al. 1995; Scutt et al. 2009; Xu et al. 2010; Hegarat et al. 2011).
The kinetochores are multiprotein complexes that form at the centromeres of
sister chromatids. Key regulators at the kinetochores are Aurora B kinase and its
antagonising phosphatase Protein Phosphatase 1 (PP1). Aurora B with Inner Centromere
Protein (INCENP), survivin and borealin comprises the chromosome passenger complex
(CPC) (Vader et al. 2006; Ruchaud et al. 2007). Aurora B is only fully active when it is
recruited to the centromeres as part of the CPC. PP1γ is recruited to the outer kinetochore 
by kinetochore-null 1 (KNL1) and inactivates Aurora B as it comes into contact with it.
This forms a gradient of Aurora B activity that is high at the centromere decreasing
towards the outer kinetochore. This is further propagated by Aurora B feeding back and
phosphorylating PP1γ, preventing its binding to KNL1. When a microtubule is first 
captured by the kinetochore improper attachments fail to push the kinetochore away from
the centromere and high Aurora B activity destabilises it. Correct end-on attachment
pushes the kinetochore away from the centromere and high Aurora B activity allowing
the attachment to be stabilised (Cimini 2007; Kelly et al. 2009; Maresca et al. 2009; Liu
et al. 2010; Rosenberg et al. 2011).
To minimise chromosome missegregation cells have evolved the spindle
assembly checkpoint (SAC). This delays anaphase onset until all 92 kinetochores of a
human cell have achieved biorientation and attached to a single pole that is opposite to
the pole their sister kinetochore has attached to (Rieder et al. 1995). This is mediated by
targeting the APC/C activator/adaptor Cdc20. When Cdc20 binds to the APC/C it allows
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it to recognise specific substrates, including cyclin B and securin, and targets them for
degradation (Izawa et al. 2011). The SAC proteins Mitotic Arrest Deficient (Mad)
proteins, Budding Uninhibited by Benzimidazole (Bub) proteins and Monopolar Spindle
1 (Mps1) kinase accumulate at unattached kinetochores and the APC/C and Cdc20 also
accumulate here (Chen et al. 1996; Abrieu et al. 2001; Kallio et al. 2002; Acquaviva et
al. 2004; Musacchio et al. 2007). The mechanism by which the SAC proteins target
Cdc20 has been, and still is to some extent, controversial. The current dominant model
focuses on Mad2 and its ability to exist in two conformations, an open conformation (O-
Mad2) and a closed conformation (C-Mad2). C-Mad2 can catalyse O-Mad2 binding to
Cdc20 after which it is converted to the closed conformation (Luo et al. 2002; De Antoni
et al. 2005). C-Mad2 is stably bound to unattached kinetochores via Mad1 where it can
continuously promote O-Mad2 binding to Cdc20 via an Mps1 dependant mechanism.
The Mad2-Cdc20 complex is then sequestered by binding to the BubR1-Bub3 complex
preventing Cdc20 from associating with and activating the APC/C (Sudakin et al. 2001;
Nilsson et al. 2008; Hewitt et al. 2010; Bolanos-Garcia et al. 2011). Upon microtubule
binding two mechanisms are thought to silence the SAC: the dissociation of Mps1 and
the Mad1-Mad2 complex removal via dynein-mediated microtubule-dependant transport
(Howell et al. 2001; Jelluma et al. 2010).
Aurora B has also been suggested to play a role in SAC signalling independently
of its role in error correction (Santaguida et al. 2011). It is proposed that Aurora B
prevents PP1γ binding to KNL1 at kinetochores and that this KNL1 mediated PP1γ 
recruitment is required for silencing of the SAC. This therefore is only achieved once
microtubule binding pushes the kinetochore away from the centromere allowing it to
move away from high Aurora B activity enabling PP1γ recruitment. PP1γ can then 
dephosphorylate checkpoint components silencing the SAC (Vanoosthuyse et al. 2009).
The chromosomes are aligned at the spindle equator forming the metaphase plate,
and once correct biorientation is achieved, anaphase is initiated and the sister chromatids
are separated. This can only occur once the SAC has been silenced and this only happens
once the last unattached kinetochore has been stably attached. Even a single unattached
kinetochore can delay anaphase for several hours (Rieder et al. 1994). Once the
checkpoint activity is extinguished Cdc20 is released and the APC/C is activated (Fang et
al. 1998a; Fang et al. 1998b). APC/CCdc20 then initiates anaphase by targeting securin and
cyclin B for ubiquitin-mediated degradation. These are both inhibitors of separase.
Securin is a small protein that binds and sequesters separase while cyclin B-CDK1
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inhibits it by direct binding and phosphorylation. Once they are degraded CDK1 is
inactivated and separase is activated. Separase is a cysteine protease which cleaves the
centromeric cohesin ring. Cohesin is the protein complex responsible for tethering the
sister chromatids together preventing premature segregation. It is loaded onto the
chromosomes in S phase along their entire length. The majority of cohesin molecules
found along the chromatid arms are removed in prophase by the phosphorylation of the
Smc3 cohesin complex subunit by PLK1 and Aurora B. This results in dissociation of the
cohesin complex from the DNA, except at the centromere where it is protected by
Shugoshin. This keeps the centromeric cohesin intact and ensures sister chromatids
remain together until anaphase onset. Once activated separase cleaves the kleisin subunit
of the cohesin ring complex resulting in the complete loss of cohesion between the sister
chromatids (Hornig et al. 2004; Hauf et al. 2005; McGuinness et al. 2005; Kitajima et al.
2006; Tang et al. 2006).
The sister chromatids then migrate to their facing pole during early anaphase, or
anaphase A. Pole-ward movement occurs predominantly via the shortening of the
kinetochore microtubules. In late anaphase, or anaphase B, the spindle lengthens and
elongates, moving the spindle poles apart along with the centrosomes to where the two
daughter cells will be formed. This process requires kinesin and dynein motor proteins as
well as microtubule dynamics (Brust-Mascher et al. 2004). The inactivation of CDK1
and activation of mitotic phosphatases lead to the removal of inhibitory phosphorylations
on Cdh1. It can then bind and activate the APC/C. APC/CCdh1 targets important substrates
for degradation to allow mitotic exit. Targets of active APC/CCdh1 include PLK1 and
Aurora B, mitotic cyclins and also Cdc20 (Li et al. 2009). This results in predominant
APC/CCdh1 activity. It remains active into G1 and maintains low levels of CDK activity
by degrading cyclins until mitogenic-mediated increases in CDK activity phosphorylate
and inactive Cdh1 (Li et al. 2009).
During telophase a nuclear envelope reforms around each set of sister chromatids
and nucleoli reappear. Next, cytokinesis ensures complete segregation of the two sets of
chromosomes. The astral microtubules emanating from the spindle poles send signals to
the cortex or midzone activating the assembly of an actin and myosin contractile ring.
Here the cleavage furrow develops and ingresses until the midbody is formed. At the end
of cytokinesis the midbody is physically cleaved in two by abscission and two daughter
cells are formed (Minshull et al. 1989a; Guse et al. 2005; Murthy et al. 2005; Brennan et
al. 2007; Neef et al. 2007).
39
CHAPTER 1
1.13 Phosphatases regulating mitosis
Since the discovery of the CDKs, kinases have been hailed as the master
regulators of mitosis. Recently, however, the role of the phosphatases that reverse the
kinase signalling events is beginning to be highlighted and appreciated as a crucial
aspect of the control of mitotic entry and exit (Bollen et al. 2009). Studies are now
revealing that the timely ordering of mitotic events, in fact, appears to be a result of a
delicate interplay between both the kinases and their counteracting phosphatases
(Domingo-Sananes et al. 2011). They have long been thought of as silencing signalling
events by ubiquitous and broad acting dephosphorylation. This viewpoint is now being
challenged and phosphatases are emerging as highly specific inhibitors of precise
signalling pathways that are critical for control of mitotic events (De Wulf et al. 2009;
Domingo-Sananes et al. 2011). In keeping with this developing appreciation for the
important role of phosphatases in carefully counterbalancing kinase activity to control
cellular activities, recent work has highlighted the importance of several key
phosphatases in mitotic processes.
The dual-specificity Cdc25 phosphatases are required for mitotic entry, as has
been described in some detail here already. These important phosphatases are required
to remove inhibitory phosphorylation of CDKs to activate their activity throughout the
cell cycle and crucially to activate the MPF at the G2/M transition to drive mitotic entry
(Kumagai et al. 1991; Lindqvist et al. 2005; Domingo-Sananes et al. 2011).
Another well characterised mitotic phosphatase is Cdc14. This is another dual-
specificity phosphatase that controls mitotic exit in budding yeast. Its release from the
nucleolus in anaphase promotes dephosphorylation of CDK1 substrates and mitotic exit
(Visintin et al. 1998). There are two human isoforms of Cdc14, A and B (Li et al.
2000). These target proteins that are phosphorylated by proline-directed kinases.
Cdc14A has been implicated in centrosome separation, mitotic spindle formation and
chromosome segregation (Kaiser et al. 2002; Mailand et al. 2002a). Cdc14B is
sequestered in the nucleolus of interphase human cells and released in mitosis and has
been implicated in assembly and disassembly of the mitotic spindle and promoting
mitotic exit (Dryden et al. 2003; Cho et al. 2005; Rodier et al. 2008). Very recently
Cdc14B has also been shown to dephosphorylate and inhibit Cdc25 inactivating CDK1
in anaphase; implicating Cdc14B as having an important role in promoting mitotic
progression (Tumurbaatar et al. 2011).
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The conserved serine/threonine phosphatases PP1 and Protein Phosphatase 2A
(PP2A) have also recently been highlighted as important regulators of mitotic events.
PP1 has been discussed here where relevant, highlighting its emerging role in mitotic
events. Roles have been described for PP1 in the inhibition of Aurora A activity until
MPF activation to promote ordered mitotic entry, in antagonising Aurora B activity at
the kinetochore in metaphase, and participation in the SAC. In addition to these, PP1
has been reported to be required for chromatin decondensation and timely
dephosphorylation of mitotic phospho-proteins and nuclear envelope reassembly (with
PP2A) at mitotic exit (Thompson et al. 1997; Vagnarelli et al. 2006; Wu et al. 2009;
Schmitz et al. 2010).
PP2A has been implicated in prevention of precocious separation of
chromosomes in anaphase. PP2A, in complex with its regulatory B56 subunit, is
recruited to the centromeres by Shugoshin and keeps cohesion subunits in an
unphosphorylated state, counteracting PLK1 phosphorylation (Kitajima et al. 2006;
Tang et al. 2006). Also PP2A, in complex with is regulatory B55α subunit, has been 
implicated in Golgi reassembly after mitotic exit (Schmitz et al. 2010). Additionally,
PP2A has recently emerged as an important part of the signalling network required to
allow proper mitotic entry and progression (Mochida et al. 2009; Lorca et al. 2012).
It has long been a source of debate in the literature as to which phosphatase is
the key counterbalancing phosphatase of mitotic CDK substrates. It has been known
since the late 1980s that okadaic acid, a specific phosphatase inhibitor, could drive
Xenopus oocytes into M phase (Goris et al. 1989; Felix et al. 1990). Pointing to the
important role for phosphatases in control of cell proliferation in general and igniting
the hunt for phosphatases responsible for permitting entry into and exit from mitosis.
Although it is now known that Cdc14 is the key phosphatase responsible for the
completion of mitosis in budding yeast (Visintin et al. 1998), for a long time the identity
of phosphatase(s) involved in higher eukaryotes remained elusive. However, recent
work has significantly moved our understanding forward. In particular, findings by
Mochida et al. (2007; 2009) that PP2A activity oscillates inversely to CDK1 activity
throughout the cell cycle (i.e. it is high during interphase and low during mitosis) and
that the depletion of its B55δ isoform from Xenopus egg extracts significantly advanced
entry into mitosis, suggested that it might be counterbalancing CDK1 activity.
Although, mitotic exit was not notably blocked by its specific depletion, indicating that
in higher eukaryotes regulation of mitosis is likely complex (this is discussed further in
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Chapter 5) (Mochida et al. 2009). This work coincided with the work described
throughout the remainder of this chapter and throughout this thesis, and considerably
contributed to the emergence of a new picture of the regulation of mitotic entry and
progression.
1.14 The Greatwall kinase
In February 2004 a report was published by Yu et al. describing a novel kinase
that could play a previously unknown role in the mitotic entry network (Yu et al. 2004).
They reported that this kinase was required for proper chromosome condensation and
mitotic progression in flies (Drosophila). Subsequent work would find that this highly
conserved kinase played a key role at the G2/M transition in all cells and would
ultimately change the way people thought about mitotic entry.
1.15 Greatwall discovery in Drosophila
In 2004, Yu et al. published the finding of mutations in a gene encoding a novel
nuclear protein that resulted in the production of an inactive kinase in Drosophila.
Expression of the inactive kinase led to failure of the chromosomes to condense and
delayed entry into and progression through mitosis. These mutations were isolated in a
Drosophila gene, previously uncharacterised, that caused larval brains to have an
elevated mitotic index indicative of mitotic arrest combined with irregular chromosome
condensation (Figure 1.4 A). They named this gene Greatwall (gwl) as the mutant
phenotype indicated a significant role for this protein in protecting chromosome structure
(Yu et al. 2004).
The gwl gene encodes an AGC family kinase that is conserved in insects and
vertebrates. The AGC kinases are a diverse family of serine/threonine kinases that target
amino acids for phosphorylation that are surrounded by basic amino acids (Tamaskovic
et al. 2003). The Greatwall protein is composed of a bifurcated kinase domain that is split
by a region of ~ 500 amino acids. In a comparison of Drosophila and human Greatwall
an overall amino acid sequence identity of 59% was identified. The homology between
these proteins extended beyond the kinase domain and included short amino acid
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Figure 1.4 Greatwall, a novel cell cycle regulator
(A) The Greatwall mutant phenotype. Immunofluorescent staining of chromosomes from wildtype and gwl
mutants. Taken from Yu et al. (2004). Here the condensin component Barren is stained green, phospho-
histone H3 is stained red and the DNA signal is blue. Greatwall wildtype neuroblasts are shown in panels A
to D, while gwl mutant neuroblasts are shown in panels E to H. (B) Schematic drawing of the structure of
the Greatwall proteins. Taken from Yu et al. (2004). The conserved kinases in Drosophila and human
Greatwall are compared. The bifurcated kinase domains are indicated, with the N-terminal portion
indicated in aqua and the C-terminal portion indicated in orange with the inserted unrelated amino acids
that show a limited degree of homology shown in grey. The sections indicated in pink and purple are less
well conserved regions found in all Greatwall kinases but not in other kinases. Four of the mutant
Greatwall alleles identified encoded missense mutations within the conserved amino acids of the
serine/threonine kinase catalytic domain, while the fifth allele encoded a nonsense mutation that truncated
the protein (Yu et al. 2004).
sequences flanking the split kinase domain sections (Figure 1.4 B) (Yu et al. 2004).
In Drosophila, once DNA replication has been completed, the activation of cell
cycle regulators leads to chromosome condensation. Late in G2 the activation of cyclin
A-CDK induces the initial stages of chromosome condensation and later, at early
50 57 205 244 675 705 829 846
A
B
Drosophila
Human
28 35 180 222 708 739 864 878
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prophase, the nuclear accumulation and activation of cyclin B-CDK1 triggers the
breakdown of the nuclear envelope.
The defect most notable in the larval brains containing the mutated gwl was the
undercondensation of their chromosomes. This was observed by immunofluorescent
staining when the mutant larval brains had been treated with colchicine. Aberrantly
condensed chromosomes appeared to clearly have two sister chromatids and to still
recruit phospho-histone H3 and the condensin component Barren, indicating that the
chromosome condensation apparatus was unaffected (Figure 1.4 A) (Yu et al. 2004).
The progression of the cell cycle was stalled in mitosis in the fixed brains of all of
the five identified mutant gwl alleles. The proportion of the cells in mitosis was 2.5-fold
higher and the proportion of cells in anaphase or telophase was decreased by 85-90 %,
indicating that a non-functional Greatwall kinase leads to the delay or arrest of cell cycle
progression prior to anaphase onset. Cells that had progressed into anaphase or telophase
displayed lagging chromosomes or chromosome bridges but spindles at all stages of
mitosis were morphologically normal. In live cell imaging experiments of neuroblast
cells from mutant and control flies expressing GFP-tagged histone H2AvD, progression
through prophase was delayed and lasted >10 times longer than wildtype controls. The
progression into metaphase was also delayed after NEBD in gwl mutant cells with 20%
never achieving a stable metaphase. This was not due to spindle defects as was seen to
occur even in the presence of the spindle poison colchicine. Additionally, 30 % of the
colchicine-treated gwl mutant cells failed to condense their chromosomes properly or
achieve NEBD for periods longer than four hours. Therefore, the Greatwall gene is
clearly implicated in late G2/M for chromosome condensation and timely NEBD in flies.
The delay seen in metaphase is likely due to the activation of the spindle checkpoint, as
sister chromatids were never separated in gwl mutant cells after NEBD and they showed
elevated levels of cyclin B that would be expected if the checkpoint was active. In
support of this, immunofluorescent staining showed that Bub1, the key checkpoint
protein, localised to and accumulated on gwl mutant kinetochores (Yu et al. 2004).
These defects seen in the gwl mutant flies were not a consequence of DNA
replication problems. BrdU incorporation was normal as compared with control flies and
all mitotic cells had double the DNA content of interphase cells. The mutant phenotype
might have arisen as a consequence of an early G2/M phase checkpoint reversing the
progression of chromosome condensation and NEBD. This was ruled out using caffeine
at concentrations that disrupts normal checkpoints activated in response to DNA damage
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and would lead to the shortening of the period of chromosome condensation before
NEBD if such a checkpoint had been activated by the loss of functioning Greatwall. This
did not occur in live cell imaging experiments; instead Greatwall deficient cells never
achieved NEBD when caffeine treated.
The phenotype analysis attributed to the defective Greatwall mutations was
validated by RNAi knockdown of the gwl gene in tissue culture Drosophila cells. In these
cells the chromosomes were again undercondensed and showed an increased mitotic
index with a decreased proportion of cells in anaphase/telophase.
Greatwall antibodies were used as immunofluorescent probes to characterise the
cellular localisation of Greatwall kinase. It was visualised in the nucleus of interphase
cells and throughout the cells in mitosis with no notable chromosome or spindle
localisation. This localisation was confirmed by expression of a GFP-tagged Greatwall,
leading the authors to conclude that it does not play a structural role on the chromosomes
themselves (Yu et al. 2004).
1.16 Greatwall kinase and cyclin B-CDK1
In 2006, the same group published a second paper examining the role of
Greatwall in Xenopus egg extracts taking advantage of its conservation in all vertebrates
(Yu et al. 2006). Antibodies raised against the Xenopus Greatwall detected a band of
approximately 98 kilo Daltons (kDa) that shifted up significantly in mitotic extracts. This
shift was likely due to phosphorylation as it was lost upon lambda (λ) phosphatase 
treatment. This mitotic hyperphosphorylated form of the Greatwall showed activity in [γ-
32P]ATP incorporation assays while Greatwall from interphase extracts did not. Thus, the
hyperphosphorylated mitotic Greatwall represents the active form of the kinase. A much
reduced activity was seen with a mutant kinase dead version of Greatwall that has two
mutated residues, G41S and D173A, predicted to be essential for an active kinase
domain, indicating that this mitotic activity is likely due, at least in part, to
autophosphorylation.
Depletion of Greatwall from Cytostatic Factor (CSF) Xenopus egg extracts
resulted in exit from M phase and reversion to interphase. This was characterised by
decondensation of the chromosomes and reforming of the nuclear envelope of
demembranated sperm nuclei in CSF extracts. MPF activity rapidly returned to
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interphase levels. Concurrently the phosphorylation of other proteins Wee1, Myt1,
Cdc25, Plx (Xenopus PLK) and MAP kinase, which should become phosphorylated upon
mitotic entry, were also rapidly lost. This was not due to the degradation of cyclin B as its
protein levels remained constant. Additionally, the introduction of a non-degradable form
of cyclin B failed to rescue this phenotype and was not able to hold the CSF extracts in M
phase in the absence of Greatwall. This reversion to interphase can be explained by the
accumulation of inhibitory phosphorylations on CDK1 inactivating it, thus preventing
sufficiently high levels of MPF activity necessary to promote and sustain mitosis (Yu et
al. 2006).
The addition of Ca2+ to control extracts induces mitotic exit and initiation of a
new round of S phase but this was not seen in Greatwall depleted extracts, indicating that
exit from mitosis seen in the absence of Greatwall is not a normal exit. Further more,
when pre-treated/activated recombinant Greatwall, hyperphosphorylated by incubation in
CSF extracts, was reintroduced to the depleted extracts, M phase was restored. A pre-
treated kinase dead version of the Greatwall (G41S and D173A) was unable to rescue this
phenotype, indicating a role of Greatwall in maintenance of M phase in these extracts.
In cycling Xenopus extracts the loss of the Greatwall kinase results in a
phenotype that is strikingly similar to the phenotype reported in flies. The depletion of
Greatwall led to the prevention of entry into mitosis specifically at the G2/M phase
transition with no apparent effects on DNA replication or on the activation of the DNA
damage checkpoints. This block was again rescued by the addition of wildtype
Greatwall but not kinase dead Greatwall.
Mass spectral analysis of recombinant Greatwall phosphorylated in vitro by MPF
revealed five sites that were potentially phosphorylated by CDK1 and conserved in
vertebrates. Sequential mutation (from a serine or threonine to alanine) revealed only one
mutation, T748A, which was unable to rescue the depleted CSF extracts to M phase. This
suggests that there is at least one CDK1 phosphorylation site in Greatwall that is
important for its activation. To further support the interaction of the Greatwall protein
with MPF complex, it was found that only MPF pre-treated recombinant Greatwall was
autophosphorylated in [γ-32P]ATP incorporation assays. Untreated recombinant
Greatwall and kinase dead Greatwall did not autophosphorylate in vitro and were unable
to rescue the CSF extracts to M phase. This leads to the conclusion that MPF is an
important activator of Greatwall or may perform a priming phosphorylation necessary to
achieve high activity (Yu et al. 2006).
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How Greatwall might fit into the mitotic entry network is hinted at by the use of
constitutively active CDK1, CDK1AF, in which Thr14 and Tyr15 are replaced by non-
phosphorylatable residues alanine and phenylalanine, preventing inhibition by Wee1 and
Myt1 (Krek et al. 1991; Pomerening et al. 2008). Introduction of CDK1AF compensated
for the loss of Greatwall in restoring M phase in CSF extracts, although a five-fold higher
amount was required in comparison with endogenous CDK1. This implies that Greatwall
forms part of an autoregulatory loop that generates and maintains high MPF activity to
support mitosis. Interaction with the MPF is unlikely to occur via regulation of Wee1 or
Myt1. Wee1 and Myt1 are negatively controlled in CFS extracts by the MAP kinase
pathway. The MAP kinase pathway remained active after the MPF was inactivated
suggesting that the deregulation of the pathway was not due to aberrant activity of Wee1
or Myt1. As described in flies, caffeine failed to overcome the cell cycle block seen in
Greatwall depleted cycling extracts and cannot therefore be a result of a G2 arrest due to
activation of a DNA damage checkpoint. A weak interaction of Greatwall with Plx in co-
immunoprecipitation experiments was observed and active Greatwall failed to
phosphorylate Cdc25 in in vitro kinase assays. The role that PLK1 plays in the regulation
of Greatwall still remains to be clarified in vivo but potentially Greatwall acts through
PLK1 to contribute to Cdc25 activation, thus acting as an upstream trigger of MPF
activity (Jackson 2006; Yu et al. 2006).
1.17 Greatwall kinase and Cdc25
A third paper published by Zhao et al. in 2008 investigated the potential role of
Greatwall in the regulation of the phosphatase Cdc25 in Xenopus egg extracts (Zhao et al.
2008). In cycling egg extracts Cdc25C was phospho-shifted on immunoblots but not in
Greatwall depleted extracts. The maintenance of the mitotic phosphorylation on Cdc25C
was dependent on the presence of Greatwall but did not rely on the presence of PLK1
which was removed by immunodepletion, or on CDK1 activity which was inhibited by
roscovitine. This suggests that Greatwall might be a key regulator of Cdc25 activity.
Greatwall purified from M phase arrested insect Sf9 cells has the required mitotic
phosphorylations to be active and was added to cycling egg extracts immunodepleted for
Greatwall. This resulted in precocious phosphorylation of Cdc25C and a premature entry
into mitosis advanced by as much as an hour when compared to normally cycling
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extracts. An effect that was not seen when activated kinase dead Greatwall (G41S) was
added or when wildtype non-activated Greatwall was added, indicating that activated
(hyperphosphorylated) Greatwall is sufficient to promote premature entry into mitosis
(Zhao et al. 2008).
In meiotic maturation of progesterone stimulated Xenopus oocytes, Greatwall was
expressed at a steady level in prophase I to metaphase II and became
hyperphosphorylated upon entry into M phase. Active Greatwall was injected into
immature oocytes arrested in G2 and induced maturation indicative of entry into meiotic
M phase. The breakdown of the germinal vesicle began three hours later despite the
absence of progesterone and was almost complete after seven hours. This effect was not
seen with the activated kinase dead form of Greatwall, indicating that active Greatwall is
sufficient to promote premature entry of oocytes into meiosis even in the absence of
progesterone.
Further, activated Greatwall induced phosphorylation of Cdc25C in the absence
of activity of CDK1, Plx or MAP kinase or in the presence of an activator of cAMP-
activated protein kinase (PKA) that normally blocks mitotic entry. Interestingly, the
observed G2 arrest caused by Greatwall depletion could be overcome by the addition of
the potent phosphatase inhibitor, okadaic acid. This suggests that Greatwall and okadaic
acid are inducing similar effects on cell cycle control and raises the possibility that
Greatwall antagonises the activity of an unknown okadaic acid-sensitive phosphatase.
In this proposed model the unidentified phosphatase would act to remove specific
mitotic phosphorylations on key mitotic proteins to prevent the activation of MPF to
sufficient levels necessary for M phase entry. Greatwall would act to inhibit this crucial
okadaic acid-sensitive phosphatase that would otherwise inhibit M phase induction by the
removal of M-phase-specific modifications from mitotic phospho-proteins including
Cdc25. This phosphatase must be turned off by Greatwall activity to allow accumulation
of phosphorylations mediated by a variety of mitotic kinases on Cdc25 and other proteins
to achieve entry into and maintain progression through mitosis (Zhao et al. 2008).
1.18 Greatwall antagonises PP2A
The existence of a key phosphatase that specifically counteracts M phase entry
has long been postulated to exist (Goris et al. 1989; Picard et al. 1989; Picard et al. 1991;
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Mochida et al. 2007). The identity of this unknown phosphatase that is regulated by
Greatwall and acts to counteract M phase entry was determined by two papers published
in 2009.
This was investigated by Vigneron et al. (2009) through depletion of Greatwall in
Xenopus CSF extracts. This depletion caused MPF inactivation, indicated by the rapid
(within five minutes) dephosphorylation of its substrates early mitotic inhibitor 2 (Emi2),
Cdc27 and Cdc25 and its re-phosphorylation on Tyr15. This was accompanied by DNA
decondensation as previously described. This phenotype was rescued by wildtype but not
a kinase dead Greatwall. Co-depletion with Wee1 or Myt1 individually or together failed
to reverse this phenotype although a small delay of MPF inactivation was observed in
Greatwall and Wee1 depleted extracts. Interestingly the triple depletion of Wee1, Myt1,
and Greatwall caused mitotic exit despite the lack of Tyr15 phosphorylation on MPF and
its activity in kinase assays remaining at a high level. That Greatwall depletion promoted
mitotic exit even in the presence of high cyclin B-CDK1 levels suggests its primary role
is to regulate a phosphatase activity rather than to regulate the MPF feedback loop
directly (Vigneron et al. 2009).
Another study by Castilho et al. (2009) supported these findings. Tagged 25-
amino acid peptides, each containing a single CDK phospho-site, were in vitro
phosphorylated by cyclin A-CDK2 and added to extracts depleted of Greatwall. In this
experiment four of the seven CDK phospho-sites tested were rapidly dephosphorylated in
the depleted extracts but not in untreated or mock-depleted extracts. This
dephosphorylation was okadaic acid sensitive and further confirmed that Greatwall acts
by inhibiting a phosphatase that is directed against CDK phospho-sites. Further, once
Greatwall is active, its suppression of the anti-CDK phosphatase is independent of MFP
activity. This was demonstrated by the loss of phosphatase inhibition, indicated by
dephosphorylation of CDK-phosphorylated PP1γ, before the loss of MPF H1 kinase 
activity in Greatwall depleted extracts. Additionally the supplementation of constitutively
active CDK1AF did not prevent phosphatase activation in these depleted extracts
(Castilho et al. 2009).
The Greatwall depletion phenotype could be rescued in CSF extracts by the
addition of microcystin, a potent PP1 and PP2A dual inhibitor (Vigneron et al. 2009).
Greatwall was depleted from CSF extracts and microcystin was subsequently added and
analysis carried out after addition at 0, 30 and 60 minutes. Initially, the characteristic
phosphorylation of MPF on Tyr15 and dephosphorylation of MPF substrates was
49
CHAPTER 1
observed, but was reversed after 30 minutes. The MPF lost Tyr15 phosphorylation once
more and its substrates were again phosphorylated. This clearly implies a role for PP1 or
PP2A in the reversal of the phenotype seen in the absence of Greatwall. To elucidate
which of these two phosphatases was the crucial Greatwall regulated phosphatase,
okadaic acid was used. It was found that a dose of 500 nM okadaic acid was the
minimum dose required to reverse the Greatwall depletion phenotype. At this
concentration okadaic acid has been described to only inhibit 20% of PP1 but 70% of
PP2A, indicating that it is PP2A that is responsible for the reversion of the Greatwall
depletion phenotype (Felix et al. 1990; Favre et al. 1997). In support of this, the PP1
inhibitor, Inhibitor 2, failed to rescue the effect of loss of Greatwall (Vigneron et al.
2009). The addition of an active form of PP2A also, after Greatwall depletion and
okadaic acid addition, again restored mitotic exit. Furthermore, a yellow fluorescent
protein (YFP) -tagged Greatwall co-immunoprecipitated from HEK 293 cells with PP2A
subunits and vice versa. The same result was obtained from CSF extracts with
endogenous proteins. The physical interaction of Greatwall with PP2A subunits suggests
that Greatwall binds to PP2A in cells and that it is this phosphatase that may be the target
of Greatwall regulation for entry into and maintenance of mitosis. To confirm that
Greatwall can inhibit PP2A activity, c-Mos, a known PP2A substrate that is
phosphorylated by active MPF activity, was used in in vitro kinase assays (Vigneron et
al. 2009). C-Mos was initially incubated with immunoprecipitated MPF from CSF
extracts and incubated with [γ-32P]ATP. The radiolabeled c-Mos was then incubated with
immunoprecipitated PP2A from CSF extracts that had or had not been depleted for
Greatwall. The PP2A phosphatase activity was shown to be three-fold less from extracts
containing Greatwall i.e. the dephosphorylation of c-Mos was three-fold less in these
extracts. Thus, dephosphorylation of MPF substrates by PP2A is regulated by Greatwall
in mitotic Xenopus egg extracts (Castilho et al. 2009; Vigneron et al. 2009).
PP2A is a highly abundant serine/threonine phosphatase conserved throughout
eukaryotes. It is known to have roles in numerous cellular processes including cell
division, cytoskeleton organisation, gene regulation and protein synthesis (Janssens et al.
2008; De Wulf et al. 2009). The basis for this broad functional diversity can be attributed
to its complex structure and regulation. It is a holoenzyme that is comprised of a
structural scaffold A subunit (also known as PR65) and a catalytic C subunit. Both A and
C subunits have two isoforms, α and β, and this core PP2A structure can exist 
independently or complex with variable regulatory B subunits. Substrate specificity
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and/or subcellular localisation are regulated by the B subunits. These are comprised of
structurally unrelated subfamilies: B/B55/PR55, B’/B56/PR61, B’’/PR72 and
B’’’/PR93/PR110. In turn each subfamily has many different structurally related
isoforms. This huge variety of B subunits with the two isoforms of the A and C subunits
result in over 70 possible PP2A holoenzymes that could each have different specificities
and functions (Xu et al. 2006; Janssens et al. 2008).
  The PP2A-B55 family, in particular the δ isoform (B55δ), has been previously 
shown to specifically dephosphorylate CDK phospho-sites in vitro and in vivo and to be
critical for entry into mitosis, although exit from mitosis likely requires the action of
additional phosphatases (Mochida et al. 2009). That the B55δ isoform accounts for as 
much as 70% of total B55 subunits present in Xenopus egg combined with these findings
suggest that PP2A-B55δ could be the target of Greatwall activity. Its immunodepletion 
from CSF extracts that were also Greatwall depleted, rescued the mitotic exit defect seen
upon Greatwall depletion alone. It is therefore likely that it is the PP2A-B55δ that is the 
major phosphatase regulated by Greatwall, although it is possible that other less abundant
B55 subunits are also targets of Greatwall regulation. In addition, this interaction is
unlikely to be direct as in vitro kinase assays provided no indication that Greatwall was
able to phosphorylate any component of the PP2A holoenzyme (Castilho et al. 2009).
Further experiments carried out by Lorca et al. (2010) supported this idea. They
found that, in concert with the MPF autoregulatory feedback loop, the Greatwall
mediated inhibition of PP2A was required to promote correct first embryonic cell
division in Xenopus egg extracts.
Thus, entry into mitosis requires not only sufficient levels of MPF activation, but
additionally, the Greatwall regulated suppression of a phosphatase, PP2A, that would
otherwise remove necessary MPF phosphorylations. This provides a new insight into the
regulation of mitotic entry, implicating not only CDK kinase activity but also
counterbalancing phosphatase activity as critical to allow proper entry into and
progression through mitosis.
1.19 Greatwall substrates
In 2010 two groups established α-Endosulfine (Ensa) and cyclic adenosine 
monophosphate (cAMP)-regulated phospho-protein 19 (Arpp19) as the elusive substrates
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of Greatwall that mediate its inhibition of PP2A. Using the kinase substrate tracking and
elucidation (KESTREL) method (Cohen et al. 2006), Mochida et al. (2010) identified
Greatwall substrate, Ensa, from interphase Xenopus egg extracts, while Gharbi-Ayachi et
al. (2010) identified Arpp19 using biochemical fractionation of CSF Xenopus egg
extracts and in vitro Greatwall kinase assays; Both reported Arpp19 and Ensa
identification as substrates of Greatwall.
Arpp19 was first identified as a major substrate for PKA. It was found to be
conserved in all vertebrates but absent in invertebrates. Arpp19 is ubiquitously expressed
in all tissues but its levels decrease with development. In adult tissues Arpp19 was only
found expressed in the brain and pancreas. Interestingly it was also found to be highly
expressed in nine (all that were tested) malignant cell lines (Girault et al. 1990). Ensa is a
close relative of Arpp19 and was first identified as an endogenous ligand of the
sulfonylurea receptor K+ channels in the pancreas. Its expression was also found
throughout the central nervous system (Virsolvy-Vergine et al. 1992; Peyrollier et al.
1996). In Drosophila, oocytes with mutant Ensa display a prolonged prophase and fail to
progress to metaphase despite high MPF activity (Von Stetina et al. 2008). Targeted
mutagenesis identified a single serine, serine 62 in Arpp19 and serine 67 in Ensa, as the
site phosphorylated by Greatwall (Gharbi-Ayachi et al. 2010; Mochida et al. 2010).
Additionally, cyclin A-CDK2 phosphorylated Arpp19 (at serine 28) and Ensa (at
threonine 28) as did PKA (on serine 109 in both) (Mochida et al. 2010).
Greatwall phosphorylated Arpp19 and Ensa were able to strongly inhibit the
PP2A-B55δ holoenzyme in in vitro phosphatase assays. The non-phosphorylated forms
or forms phosphorylated with CDK or PKA were not inhibitory (Mochida et al. 2010).
Mochida et al. (2010) reported that in Xenopus egg extracts only Ensa was detected at
significant levels by immunoblotting and the majority of this was phosphorylated in
mitotic extracts in a serine 67 dependent manner. In cycling extracts, Ensa depletion
resulted in failure to enter mitosis despite high MPF activity as judged by H1 kinase
activity. Add back of wildtype Ensa rescued induction of mitosis but an S67A Ensa
mutant that could not be phosphorylated by Greatwall did not (Mochida et al. 2010).
Accordingly, the addition of thio-phosphorylated Ensa or Arpp19 to interphase egg
extracts that have been previously depleted of Greatwall, allowed the loss of Greatwall
phenotype to be rescued and induced mitotic entry (Gharbi-Ayachi et al. 2010). This was
not seen if Ensa and Arpp19 were not thio-phosphorylated as phosphorylated forms were
rapidly dephosphorylated and could not induce mitotic entry in the absence of Greatwall.
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Figure 1.5 The Greatwall pathway
Schematic representation of the potential role of Greatwall in mitotic entry and maintenance in mammalian
cells. Greatwall is activated in late G2 and phosphorylates its targets, Ensa and/or Arpp19, crucially
inactivating PP2A-B55δ. This prevents PP2A antagonising CDK phosphorylation, allowing mitotic 
phosphorylations to accumulate on targets and activation of the CDK positive feedback loop to drive cells
into mitosis. Further potential interactions have been omitted for simplicity in this model. Activating
modifications are shown as purple arrows and all inhibitory modifications are shown in orange. The
unconfirmed activation of Greatwall by CDK1 is indicated with a dashed line.
This suggests that endogenous Greatwall phosphorylation of Ensa and Arpp19
counterbalances their dephosphorylation. Phosphorylated Ensa and Arpp19 on serine
67/62 was seen to increase with Greatwall phosphorylation at mitotic entry and decrease
with Greatwall dephosphorylation at mitotic exit. However, in contrast to Mochida et al.
(2010), the second group found that only depletion of Arpp19, and not Ensa, prevented
cycling egg extracts entry into mitosis and exit from mitosis in CSF extracts. Add back of
thio-phosphorylated protein rescued mitotic entry in cycling extracts and okadaic acid-
mediated PP2A inhibition overcame the mitotic exit phenotype in CSF extracts (Gharbi-
Ayachi et al. 2010). It not clear why the two groups found differing importance of
Arpp19 and Ensa in their preparations. It is possible that the high sequence identity
between Arpp19 and Ensa (88% between the human proteins) has meant that the
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experiments and antibodies used were not rigorous enough to distinguish between them.
Furthermore, that Arpp19 is present in far lower concentrations in these extracts could
mean that its importance was effectively masked in the first study. Whether Arpp19 has a
distinct role in this pathway to Ensa remains to be established (Haccard et al. 2011), but
it is clear that both these proteins can act downstream of Greatwall to inhibit PP2A to
allow correct mitotic entry and progression. Therefore, at the G2/M transition the
activation of Greatwall, possibly by CDK1 itself, leads to the phosphorylation of
Arpp19/Ensa which then inhibits PP2A-B55δ. This allows CDK1 activity to predominate 
and drive entry into mitosis (Figure 1.5).
1.20 Greatwall in recovery from the DNA damage checkpoint
As mentioned previously, many cell cycle control proteins are implicated in
eliciting cell cycle arrest in response to assaults by DNA damaging agents. This response
is known as the DNA damage checkpoint and serves to arrest cells in response to DNA
damage before entry into mitosis. Such agents include UV light, mutagenic chemicals, or
ionising radiation (IR) that can come from exogenous sources, i.e. UV light emitted by
the sun. DNA damage can also be a result of endogenous cellular processes that include
oxidation, alkylation or hydrolysis of bases, bulky adduct formation and mismatch of
bases due to replication errors. This response engages repair machineries to restore the
DNA and elicits the arrest of cell cycle progression to allow this repair via complex
networks of signal transduction (Zhou et al. 2000).
The cell cycle arrest is mediated by master kinases ataxia telangiectasia mutated
(ATM) kinase and ataxia telangiectasia and Rad-3-related (ATR) kinase. ATM primarily
responds to direct DNA damage (DNA double strand breaks and disruptions in chromatin
structure) while ATR is critical for response to stalled replication forks during DNA
synthesis (Kastan et al. 2004). These conditions often occur together so ATM and ATR
are often active simultaneously and perform in concert to elicit DNA damage checkpoint
activation (Harrison et al. 2006; Cimprich et al. 2008).
In response to double strand breaks (DSBs), ATM homodimers
autophosphorylate and dissociate. The active ATM monomer can then phosphorylate
numerous substrates including p38, p53 and structural maintenance of chromosomes 1
(Smc1) (Yazdi et al. 2002). P38 phosphorylation promotes the 14-3-3 protein
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sequestering Cdc25B (Thornton et al. 2009). Thus the DNA damage checkpoint pathway
overlaps with the stress response checkpoint pathway. ATR is recruited and activated by
the presence of single stranded DNA at stalled forks and has been suggested to be
required for S phase even in the absence of DNA damage. Crucially ATM and ATR
phosphorylate and activate checkpoint effectors Chk1 and Chk2. Phosphorylation of
Cdc25A mediated by Chk1 and Chk2 on serine 123 leads to its rapid degradation in
response to checkpoint activation and the Cdc25 phosphatases are major targets of the
DNA damage checkpoint response. Overexpression of Cdc25A causes a bypass of the
IR-induced S and G2 checkpoints, as well as the DNA replication checkpoint (Shreeram
et al. 2008). Phosphorylation of p53 by Chk2 activates it leading to expression of the
CDK inhibitor p21. Additionally, cyclin B1 and B2 are transcriptionally repressed when
cells are arrested in G2 in response to DNA damage checkpoint signalling. This
repression is dependant on the presence of functional transcriptional control elements
including the NF-Y binding motif and CCAAAT box (Fung et al. 2005). Thus DNA
damage checkpoint signalling acts to inhibit CDK activity until cell cycle progression is
favourable (Kastan et al. 2004).
This signalling must be turned off upon satisfaction of DNA repair. This process
of checkpoint recovery involves the deactivation of the checkpoint mediators and
subsequent activation of activators of cell cycle progression. Work carried out by Peng et
al. (2010) suggested a novel role for Greatwall in recovery from DNA damage. They
utilised an elegant in vitro system in which the addition of double stranded
oligonucleotides to Xenopus egg extracts mimics DNA damage and elicits the DNA
damage response, indicated by Chk1 phosphorylation. The subsequent removal of these
double stranded oligonucleotides mimics DNA repair and allows the study of recovery
from this signalling response. In this system, immunodepletion of Greatwall amplified
the response to DNA damage, inhibiting recovery, while addition of wildtype but not
kinase dead Greatwall actually inhibited the DNA damage response, speeding recovery
up. Moreover, Greatwall was directly inhibited by DNA damage checkpoint activation
raising an interesting possibility that it might be a target of ATM/ATR or Chk1/Chk2
(Medema 2010). Thus indicating that Greatwall might be an important target of the DNA
damage checkpoint and that its reactivation is then required to allow recovery from the
checkpoint (Peng et al. 2010).
PLK1 is known to play an important role in DNA damage checkpoint recovery
(van Vugt et al. 2001; van Vugt et al. 2004a; van Vugt et al. 2004b). It phosphorylates
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Figure 1.6 Greatwall promotes cell cycle restart after a DNA damage-mediated cell cycle arrest
Schematic representation of Greatwall as a new regulator that promotes recovery from the DNA damage
checkpoint arrest. Once DNA has been repaired, PLK1 is activated and phosphorylates and activates its
targets, including Cdc25 (promoting activation of CDK1) and Greatwall (promoting inhibition of PP2A).
This leads to activation of CDK1 to allow cell cycle progression into mitosis. Furthermore, Greatwall itself
is activated upon checkpoint recovery leading to inhibition of PP2A independently of PLK1. In addition it
can likely activate PLK1 by activation of the Bora/Aurora A complex. Evidence that Greatwall directly
interacts with PLK1 via a binding motif in its N-terminal domain but does not directly phosphorylate it
suggests that this interaction might serve to mediate Aurora A-Greatwall interactions (Peng et al. 2011).
Therefore PLK1 and Greatwall function in a synergistic manner to promote checkpoint recovery and
mitotic entry after a DNA damage-mediated cell cycle arrest. Activating modifications are shown as purple
arrows and all inhibitory modifications are shown in orange. Proposed unconfirmed interactions are
indicated with dashed lines.
substrates required for maintenance of checkpoint activation and CDK inhibition and
targets them for proteolysis. These include Wee1 and Claspin (Mamely et al. 2006).
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Claspin is an adaptor protein that is required to allow ATR/Chk1 interaction and
subsequent Chk1 activation in response to DNA damage (Freire et al. 2006; Cimprich et
al. 2008). After a damage-mediated cell cycle arrest PLK1 is critical to allow re-entry
into the cell cycle and progression into mitosis (Bartek et al. 2007; Clemenson et al.
2009). A recent report by Peng et al. (2011) found evidence of a functional relationship
between Greatwall and PLK1 in checkpoint recovery in Xenopus egg extracts. Here
depletion of Greatwall or Plx significantly delayed the deactivation of checkpoint
signalling in a manner that was not synergistic. Further, pre-activated Greatwall addition
to the extracts promoted checkpoint inactivation in the absence of Plx, suggesting that
their roles in this process are distinct from one another. The depletion of Greatwall,
however, abolished Plx activation and depletion of Plx abolished Greatwall activation.
They were also reported to directly interact via a Plx binding motif in the Greatwall N-
terminal and Plx was able to phosphorylate Greatwall in vitro. This implies that they may
act in a coordinative positive feedback manner to activate one another to drive recovery
and cell cycle re-entry after DNA damage repair. This was supported by the fact that pre-
phosphorylated Greatwall by Plx exhibited stronger activity in promoting checkpoint
recovery. Plx was not phosphorylated in vitro by Greatwall. However, Greatwall was
required for Aurora A activation during checkpoint recovery and the reconstitution of
wildtype Aurora A activity in Greatwall depleted extracts restored Plx activation. Thus it
is probable that Greatwall regulates Plx activation indirectly, through the activation of
Aurora A. This might represent a specific pathway required to allow proper mitotic entry
after a DNA damage provoked cell cycle arrest that is not as significant for unperturbed
normal cell cycle progression (Figure 1.6) (Macurek et al. 2008; Peng et al. 2011).
1.21 Greatwall in development
A novel role for Greatwall in development was proposed by Archambault et al.’s
(2007) work in Drosophila. They first identified Greatwall as a gain of function mutation
in an allele of Drosophila Greatwall (gwl) called Scant (Scott of the Antarctic). When this
was heterozygous with one wildtype and one mutant copy of polo (the Drosophila gene
for PLK1), Scant led to female production of embryos with greatly reduced viability. The
gene defined by the Scant mutation encodes an allele of gwl that carries a K97M point
mutation to produce a hyperactive form of Greatwall. The severity of the dominant Scant
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mutant phenotype was increased in direct proportion to the decrease in Polo (Drosophila
PLK1) function. The primary and only phenotype seen in these mutants was premature
centrosome detachment that led to spindle abnormalities and aberrant subsequent
mitoses. Thus the Polo-Greatwall balance is important to maintain centrosome-nuclear
proximity. The same effect was observed when a transgenic Scant Greatwall mutant was
expressed in females that were Polo deficient (Archambault et al. 2007).
These effects were only seen when the overexpression or hyperactivation (as in
Scant) of Greatwall was combined with reduced levels of Polo. In vitro kinase assays
with Myc-tagged Greatwall or Scant Greatwall expressed in Drosophila culture cells
showed that the Scant Greatwall had increased activity with altered specificity as
compared with wildtype activity in vivo. This suggests that Greatwall and Polo have
antagonistic activities in early developing Drosophila embryos (Archambault et al. 2007;
Boke et al. 2011).
Additionally, Scant Greatwall rescued the effects of Greatwall loss of function
identified by Yu et al. (2004), even when expressed at low levels (Archambault et al.
2007). Further study of loss of function mutants of Greatwall showed that it was required
for proper chromosome structure and segregation in mitosis as well as meiosis. One
mutant resulted in the loss of Greatwall in vitellogenesis (building up of the egg’s
contents) leading to the failure of meiosis I due to premature sister chromatid separation,
implicating Greatwall in the cohesion of sister chromatids in female meiosis I
(Archambault et al. 2007).
In Xenopus oocytes co-immunoprecipitation shows that Greatwall complexes
with PP2A-B55 in G2 (interphase) oocytes and dissociates in progesterone-treated M
phase (germinal vesicle breakdown; GVBD) oocytes (Yamamoto et al. 2011). A kinase
dead Greatwall could also associate with PP2A in interphase and release it in M phase so
the kinase activity of Greatwall is not required. A K71M mutant Greatwall, the Xenopus
equivalent of Drosophila Scant, showed very reduced but constitutive gain of activity
against Ensa. Kinase assays revealed that Scant Greatwall but not wildtype Greatwall had
interphase activity toward Ensa. It was able to promote M phase in oocytes but took
several hours longer than progesterone-mediated GVBD, suggesting its low activity
levels are limiting. Scant Greatwall in Xenopus displayed only a two-fold increase in
activity (at best) and it is likely that the increased activity seen in Drosophila Scant might
have resulted from the cell cycle arrest of the cultured cells leading to a high
concentration of protein in the preparation. That addition of proteasome inhibitor,
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MG132, led to increased levels and accelerated M phase entry suggests that Scant has
reduced stability (Yamano et al. 2004).
In 2011, two co-published reports investigated the functional relationship between
Greatwall and Polo in Drosophila further. Wang et al. (2011) carried out a genetic screen
that identified an inter-dependence between Polo and PP2A B-type subunit Twins.
Reducing both Polo and PP2A-Twins from the maternal contribution led to embryonic
lethality. PP2A-Twins collaborated with Polo to ensure centrosome attachment to the
nuclei. Polo was required for centrosome cohesion to the nuclei in prophase while PP2A-
Twins was required for centrosome attachment during mitotic exit. Therefore, proper
regulation of mitotic events by Polo and PP2A-Twins play an important role in
promoting mitotic entry and exit. Consistent with other studies they found that Greatwall
antagonised PP2A-Twins in metaphase of meiosis I and in early mitotic cycles,
suggesting an important pathway connecting Polo and Greatwall in control of M phase in
flies (Wang et al. 2011).
Another genetic screen carried out by Rangone et al. (2011) identified mutants in
a Drosophila protein Endos, the single Drosophila orthologue of Arpp19/Ensa. These
mutants potently suppressed the embryonic lethality that occurs with Scant Greatwall in
combination with reduced Polo function. That the loss of Greatwall and Endos function
in mitosis was very similar and reduced Endos function suppresses the phenotype seen in
Polo/Twins heterozygous double mutants suggests Endos is activated by Greatwall and
inhibits PP2A. This is further supported because the Endos depletion phenotype in
cultured cells is rescued by co-depletion of catalytic subunit of PP2A or the Twins
regulatory subunit (Rangone et al. 2011).
The mutation of the catalytic subunit of PP2A or the Twins subunit synergises
with Scant Greatwall when maternal dosage of Polo is low. This is suppressed by
reduction of Endos. This observation leads to a model for Greatwall and Polo genetic
interaction in which, during mitotic entry, Greatwall is active and inhibits PP2A-Twins
via Endos. This sustains CDK phosphorylations that enable Polo to bind to
phosphorylated partners mediating its functions in early mitosis. Once CDK activity is
decreased in anaphase, Polo then binds to partners via their dephosphorylated CDK sites.
These sites must be dephosphorylated by PP2A-B55/Twins. In this model the activating
Scant mutation of Greatwall would lead to inappropriate inhibition of PP2A in interphase
reducing the levels of Polo complexed to its dephosphorylated partners. One of these
partners would include a substrate required to maintain cohesion of the centrosome with
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the nuclear envelope. The mechanism of this cohesion still remains to be elucidated but,
as the other functions of Polo are normal, this would require the highest level of Polo
activity. Thus, if Polo activity is reduced in combination with increased Greatwall-
mediated PP2A inhibition in interphase, sufficient dephosphorylation of Polo interphase
partner(s) is prevented and their association is abolished (Rangone et al. 2011).
This suggests that sophisticated and precise control of mitotic entry and exit is
critical during embryonic cycles. It points to a conserved pathway in which Polo,
Greatwall and PP2A-Twins are key regulators. Overall this indicates that Greatwall
kinase potentially plays multiple roles in both mitotic and meiotic progression, fulfilling
crucial functions in different cell cycles of a developing animal (Archambault et al.
2007).
1.22 Aims of this dissertation
At the beginning of this project the human Greatwall homologue had not been
characterised and the aim was to investigate the role of this novel protein kinase in
human cells. The fact that this unusual kinase has such an important function in flies and
is conserved in mammals led us to believe that it might play an as yet unknown but
critical role in human cells. This project aimed to address this and to characterise
Greatwall in human cells.
This study of human Greatwall includes cloning the gene, analysis of Greatwall
depletion and overexpression phenotypes, using structural modelling to determine its
activation mechanisms, investigating its activation regulation within the cell cycle,
attempting a chemical genetics approach to specifically inhibit the kinase, and assessing
its potential as a key anti-cancer drug target and clinical biomarker. Overall this thesis
describes insights into the function and regulation of human Greatwall kinase.
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CHAPTER 2. Materials and methods
2.1 Materials
2.1.1 Chemicals and biochemicals
All chemicals were obtained from Fisher Scientific (Leicestershire, UK) or
Sigma-Aldrich (Missouri, USA) unless otherwise stated. Recombinant cyclin A-CDK2
was a kind gift from Tim Hunt (Clare Hall Laboratories, Hertfordshire, UK) and the
myelin basic protein (MBP; dephosphorylated) substrate was purchased from Merck
Millipore (Billerica, USA). Complete Protease Inhibitors and PhoSTOP Phosphatase
Inhibitor Cocktails were from Roche Diagnostics (West Sussex, UK). Prolong® Gold
mounting solution with DAPI was purchased from Invitrogen (Paisley, UK). Bio-Rad
Protein Assay Reagent was obtained from Bio-Rad (Hertfordshire, UK). The CDK
inhibitor, RO-3306, and phosphatase inhibitor, okadaic acid, were purchased from
Merck Chemicals (Nottingham, UK). The PLK inhibitor, BI2536, was purchased from
Axon Medchem (Gronigen, NL). The phosphatase inhibitor, Tautomycetin, and the Eg5
inhibitor, S-trityl-L-cysteine (STLC), were both purchased from Tocris Bioscience
(Bristol, UK). All restriction enzymes used were from New England Biolabs (Beverly,
USA). All buffers and chemicals were made up in double distilled water (ddH2O) unless
otherwise stated.
2.1.2 Cell culture
Transformed human cervical epithelial cancer HeLa cells, transformed human
colorectal epithelial carcinoma HCT116 cells, transformed Human Embryonic epithelial
Kidney (HEK) 293T cells, non-transformed human Telomerase Reverse Transcriptase
(hTERT) immortalised human Retinal Pigmented Epithelium (RPE) cells, and non-
transformed hTERT immortalised human fibroblast 1BRhTERT and 48BRhTERT cell
lines were used. Cells were obtained from laboratory stocks. The HeLa cell derivatives,
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HeLa Kyoto cells, were also used and were a kind gift from Dr Mark Petronczki (Clare
Hall Laboratories, Hertfordshire, UK). AAV-293 cells (Invitrogen) derived from HEK
293 were used for viral replication and packaging. Culture vessels and plates used were
from Corning (New York, USA).
2.1.3 Antibodies
Primary antibodies used for this study are listed in Table 2.1.1. Alexa-flour®-
conjugated secondary antibodies for immuunostaining; Alexa488 anti-rabbit, Alexa488
anti-mouse and Alexa594 anti-rabbit were purchased from Invitrogen. Horseradish
peroxidase- (HRP-) conjugated rabbit or mouse polyclonal secondary antibodies for
immunoblotting were from Dakocytomation (Cambridge, UK).
Table 2.1.1 Primary antibodies used in experiments
Optimal antibody concentrations were determined by titration. Dilutions used
for immunoblotting (IB) or for immunofluorescence (IF) are listed.
Primary Antibody RaisedIn
Dilution
for IB
Dilution
for IF Source
Anti-Greatwall Rabbit 1:200 1:100 GenScript (Piscataway,
USA)
Anti-pT194 Greatwall Rabbit 1:1,000 1:500 Eurogentec (Southampton,
UK)
 Anti-α Tubulin (DM1A)  Mouse 1:10,000 1:2,000  Abcam (Cambridge, UK) 
Anti-Flag M2 Mouse 1:250 N/A Sigma-Aldrich (Missouri,
USA)
Anti-Myc (9E10) Mouse 1:500 N/A Abcam (Cambridge, UK)
Anti-phospho-(Ser) CDK
substrates
Rabbit 1:5000 N/A Cell Signaling Technology
(Beverly, USA)
Anti-Ensa Rabbit 1:250 N/A Cell Signaling Technology
Anti-phospho-Ensa
(Ser67) Arpp19 (Ser62)
Rabbit 1:250 N/A Cell Signaling Technology
62
CHAPTER 2
2.1.4 Primers
DNA sequences were obtained from the National Centre for Biotechnology
Information website (NCBI; http://www.ncbi.nlm.nih.gov/) and primers were designed
according to requirements using Lasergene SequBuilder 10.1 DNASTAR (Madison,
USA). Primers were ordered from Eurofins MWG Operon (Ebersberg, Germany) or
GATC Biotech (London, UK). The primers used in this study are listed in Table 2.1.2.
Table 2.1.2 Primers used for this work
Primer Sequence (5'-3')
His-tag F+R
Primer pair to clone N-terminal 100
amino acids of Greatwall cDNA in
frame with a His-tag in pET28
ATT ACC ATG GAT CCC ACC GCG GGA A
AGA TCT CGA GCA GTG AAT AAT ACA AAT GGA CAA
TGA ATG GGC
GW F+R
Primer pair to clone full-length
Greatwall cDNA
ATG GAT CCC ACC GCG GGA AGC AAG AAG GAG
CTA CAG ACT AAA TCC AGA TAC GGT CAG GTG
GWEntry F+R
Primer pair to clone full-length
Greatwall cDNA into pDONR211
GGG GAC AAG TTT GTA CAA AAA AGC AGG CTT AAT GGA
TCC CAC CGC GGG AAG C
GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC CTA CAG ACT
AAA TCC AGA TAC GG
M110A
Mutagenesis primer pair
CAA TGT CTA CTT GGT AGC GGA ATA TCT TAT TGG GG
CCC CAA TAA GAT ATT CCG CTA CCA AGT AGA CAT TG
T193A
Mutagenesis primer pair
GGA TAT CCT TGC AAC ACC ATC AAT GGC
GCC ATT GAT GGT GTT GCA AGG ATA TCC
T194A
Mutagenesis primer pair
GGA TAT CCT TAC AGC ACC ATC AAT GGC
GCC ATT GAT GGT GCT GTA AGG ATA TCC
T193A/T194A
Mutagenesis primer pair
GAT GGA TAT CCT TGC AGC ACC ATC AAT GGC
GCC ATT GAT GGT GCT GCA AGG ATA TCC ATC
T740S
Mutagenesis primer pair
CGA ATT CTA GGA TCC CCA GAC TAC CTT G
CAA GGT AGT CTG GGG ATC CTA GAA TTC G
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T740A
Mutagenesis primer pair
CGA ATT CTA GGA GCC CCA GAC TAC CTT G
CAA GGT AGT CTG GGG CTC CTA GAA TTC G
S874A
Mutagenesis primer pair
CAG CAC CTG ACC GTA GCT GGA TTT AGT CTG TAG
CTA CAG ACT AAA TCC AGC TAC GGT CAG GTG CTG
S877A
Mutagenesis primer pair
CCG TAT CTG GAT TTG CTC TGT AGG ACC CAG
CTG GGT CCT ACA GAG CAA ATC CAG ATA CGG
S874A/S877A
Mutagenesis primer pair
CAG CAC CTG ACC GTA GCT GGA TTT GCT CTG TAG GAC CCA
GC
GCT GGG TCC TAC AGA GCA AAT CCA GCT ACG GTC AGG TGC
TG
S874T
Mutagenesis primer pair
CAG CAC CTG ACC GTA ACA GGA TTT AGT CTG TAG
CTA CAG ACT AAA TCC TGT TAC GGT CAG GTG CTG
T194D
Mutagenesis primer pair
GGA TAT CCT TAC AGA CCC ATC AAT GGC
GCC ATT GAT GGG TCT GTA AGG ATA TCC
S874D
Mutagenesis primer pair
CAG CAC CTG ACC GTA GAT GGA TTT AGT CTG TAG
CTA CAG ACT AAA TCC ATC TAC GGT CAG GTG CTG
T194E
Mutagenesis primer pair
GGA TAT CCT TAC AGA ACC ATC AAT GGC
GCC ATT GAT GGT TCT GTA AGG ATA TCC
S874E
Mutagenesis primer pair
CAG CAC CTG ACC GTA GAA GGA TTT AGT CTG TAG
CTA CAG ACT AAA TCC TTC TAC GGT CAG GTG CTG
S101D
Mutagenesis primer pair
GTA TTA TTC ACT GCA GGA TGC AAA CAA TGT CTA C
GTA GAC ATT GTT TGC ATC CTG CAG TGA ATA ATA C
T206E
Mutagenesis primer pair
CAA GAT TAT TCA AGA GAG CCA GGA CAA GTG TTA TCG C
GCG ATA ACA CTT GTC CTG GCT CTC TTG AAT AAT CTT G
S370A
Mutagenesis primer pair
GGA GTT AGC TCT TGC ACC CAT TCA TAA CAG C
GCT GTT ATG AAT GGG TGC AAG AGC TAA CTC C
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K72M
Mutagenesis primer pair
GCA GAC ATG ATC AAC ATG AAT ATG ACT CAT CAG G
CCT GAT GAG TCA TAT TCA TGT TGA TCA TGT CTG C
T194S
Mutagenesis primer pair
GGA TAT CCT TAC ATC ACC ATC AAT GGC
GCC ATT GAT GGT GAT GTA AGG ATA TCC
Left Arm_attB4 F
5' primer to amplify Greatwall genomic
DNA with the attB4 sequence for the
left recombination arm for gene
targeting
GGG GAC AAC TTT GTA TAG AAA AGT TGT GAG ACT CTG TCT
CAA AAT AAA ATA ACA TG
Left Arm_attB1_NdeI R
3' primer to amplify Greatwall genomic
DNA with the attB1 for the left
recombination arm to introduce an
additional NdeI site for gene targeting
GGG GAC TGC TTT TTT GTA CAA ACT TGC ATA TGA TTA CAG
TTA CAA TAT TTG GCA TGG CTC TG
Right Arm_attB2 F
5' primer to amplify Greatwall genomic
DNA with the attB2 sequence for the
right recombination arm introducing
the M110A mutation in exon 3 for gene
targeting
GGG GAC AGC TTT CTT GTA CAA AGT GGC TTT TTT GAA AGG
TAG CGG AAT ATC TTA TTG GGG G
Right Arm_attB3 R
3' primer to amplify Greatwall genomic
DNA with the attB3 sequence for the
right recombination arm for gene
targeting
GGG GAC AAC TTT GTA TAA TAA AGT TGC TGG TCT CAA ACT
CCC GAC CTC AGG TGA TC
Primer A
Forward primer situated at the
beginning of exon 3 of the Greatwall
allele used to detect wildtype
Greatwall alleles
GGG GAC AGC TTT CTT GTA CAA AGT GGC TTT TTT GAA
AGG TAG C
Primer B
Reverse primer situated in exon 4 of
the Greatwall allele used to detect
wildtype and targeted alleles
CTC ATT AGA AAT AAG CAT ATT GTC CGG TTT C
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Primer C
Forward primer situated in the
selection cassette and mutated
(M110A) region of exon 3 in targeted
Greatwall alleles used to detect the
presence of targeted alleles
CAC AAT ATT AAA TTC TTT TTT GAA AGG TAA T
Primer D
Forward primer situated in the
puromycin resistance gene of targeted
Greatwall alleles used to detect the
presence of the resistance gene
CTA ATT CCA TCA GAA GCT GGT CG
Southern Probe
Used for Southern blotting
CCA ATG ATA CCA AAG ATA ATC TAG
GTT GGA TGT TTT AAA AAA GTA CTT
Y59V
Mutagenesis primer pair
GAA AGG CGG CAA ATT GGT TGC AGT AAA GGT TG
CAA CCT TTA CTG CAA CCA ATT TGC CGC CTT TC
Y59T
Mutagenesis primer pair
GAA AGG CGG CAA ATT GAC TGC AGT AAA GGT TG
CAA CCT TTA CTG CAG TCA ATT TGC CGC CTT TC
V61I
Mutagenesis primer pair
GGC AGA AAG GCG GCA AAT TGT ATG CAA TAA AGG TTG
CAA CCT TTA TTG CAT ACA ATT TGC CGC CTT TCT GCC
Y107V
Mutagenesis primer pair
GCA GTC TGC AAA CAA TGT CGT CTT GGT AAT GG
CCA TTA CCA AGA CGA CAT TGT TTG CAG ACT GC
Y107T
Mutagenesis primer pair
GCA GTC TGC AAA CAA TGT CAC CTT GGT AAT GG
CCA TTA CCA AGG TGA CAT TGT TTG CAG ACT GC
2.1.5 Vectors
Vectors used in this work and their sources are listed in Table 2.1.3.
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Table 2.1.3 List of vectors used
Vector Source Notes
pET28a(+) Novagen (Merk KGaA,
Darmstadt, Germnay)
For expression of N-terminal His-tagged
100 amino acid Greatwall fragment.
pCR®II-TOPO Invitrogen (Paisley, UK) For cloning of Greatwall full-length
cDNA.
pDONR™221 Invitrogen For cloning of Greatwall full-length
cDNA and use with the Multisite
Gateway® system from Invitrogen.
deltaT-FLAG-DEST A kind gift from Stephan
Geley (Biocenter, Innsbruck
Medial University, Austria)
Expression vector for N-terminal flag-
tagged Greatwall and mutants.
deltaT-Myc-DEST A kind gift from Stephan
Geley
Expression vector for N-terminal myc-
tagged Greatwall and mutants.
pEGFP-C3 Clontech Laboratories
(Mountain View, USA)
Expression vector for GFP.
bML4(puroR) A kind gift from Shunichi
Takeda (Kyoto University,
Japan)
Used for co-transfection with flag-tagged
Greatwall to provide puromycin resistance
and indicate integration events.
SPI GenScript (Piscataway,
USA)
Minimal kinase construct containing
artificial splice transcript I in pUC57.
SPII GenScript Minimal kinase construct containing
artificial splice transcript II in pUC57.
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pDONRTM P4-P1R Invitrogen Left homology arm donor vector for gene
targeting using Gateway® technology
(Iiizumi et al. 2006).
pDONRTM P2R-P3 Invitrogen Right homology arm donor vector for
gene targeting using Gateway® technology
(Iiizumi et al. 2006).
pAAV-dest A kind gift from Professor
Alan Lehman (University of
Sussex, UK)
Destination vector with Gateway® att site-
containing cassette for recombination
inserted into the pAAV-MCS vector
(Invitrogen) using NotI restriction sites.
pHelper Invitrogen For production of infectious viral particles
containing the Greatwall gene targeting
vector in AAV-293 cells.
pAAV-RC Invitrogen For production of infectious viral particles
containing the Greatwall gene targeting
vector in AAV-293 cells.
Puro entry clone A kind gift from Shunichi
Takeda
Puromycin resistance gene subcloned into
the donor vector pDONR™221 (Iiizumi et
al. 2006).
Ad-CMV-Cre Vector BioLabs
(Philadelphia, USA)
For excision of puromycin resistance
gene.
pDEST™14 Invitrogen Destination vector used for in vitro
translation of Greatwall cDNA.
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2.2 Methods
2.2.1 Bacterial cultures and plasmid preparation
Individual colonies were picked from an LB (Luria Bertani medium; 0.5% yeast
extract, 1% tryptone and 171 mM sodium chloride (NaCl)) agar plate containing
appropriate selective antibiotics (kanamycin was used at 50 µg/ml and ampicillin was
used at 100 µg/ml). To prepare small amounts of plasmid deoxyribonucleic acid (DNA),
3 ml LB cultures containing the appropriate selective antibiotics were incubated
overnight at 225 revolutions per minute (r.p.m.) / 37˚C. Cells were harvested by 
centrifugation at 4000 r.p.m. for 5 minutes. The plasmid DNA was then purified from
the cells using the alkaline lysis method following the manufacturer’s protocol with the
QIAprep Spin Miniprep Kit using a microcentrifuge from QIAGEN (West Sussex, UK).
Plasmid DNA was eluted in 50 µl ddH2O and the concentration analysed by measuring
the absorbance at 260 nm on a spectrophotometer and confirmed by restriction digestion
and sequencing. Restriction digests were performed according to manufacturer's
instructions and as recommended by the New England Biolabs website
(https://www.neb.com/) and analysed by agarose gel electrophoresis. DNA was sent to
GATC Biotech for sequencing and then analysed using Lasergene SequBuilder 10.1
DNASTAR.
For preparation of larger quantities of plasmid DNA for transfection into human
cells, 5 ml starter cultures were grown for 8 hours at 225 r.p.m. / 37˚C. Then 100 µl of 
the starter cultures were used to inoculate 100 ml LB containing appropriate selective
antibiotics which were incubated at 225 r.p.m. / 37˚C overnight. Cells were harvested 
by centrifugation at 4000 r.p.m. / 4˚C for 20 minutes. The plasmid DNA was then 
purified from the pelletted cells again using the alkaline lysis method following the
manufacturer’s protocol with the QIAFilter Plasmid Midi Kit from QIAGEN. The
concentration of the purified plasmid DNA was then measured and the presence of the
expected plasmid DNA confirmed by restriction digestion and sequencing.
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2.2.2 Transformation of plasmid DNA in bacteria
 Competent DH5α Escherichia coli (E.coli) cells were thawed on ice and 50 µl
used per transformation. Between 50 to 100 ng of plasmid DNA was used and 50 µl
competent cells were added to the DNA and mixed gently, then incubated on ice for 20
minutes. The tubes were next incubated at 42˚C for 45 seconds to heat shock the cells 
before being returned to ice for 2 minutes. 1 ml of warmed LB was then added to the
cells and mixed gently. The tubes were incubated for a further hour in a water bath at
37˚C. After this 50 to 200 µl of the samples were plated onto LB agar plates with 
appropriate selection antibiotics and placed at 37˚C overnight. For transformations of 
mutagenesis PCR products the entire suspension was spun down and the supernatant
removed to leave a 50 µl concentrated suspension which was then plated onto LB agar
plates (LB medium and 15 g/L agar).
2.2.3 Cloning, PCR and RT-PCR
As mentioned previously, all DNA extractions were performed using QIAprep
Spin Miniprep from QIAGEN and all restriction digests were performed using enzymes
and buffers from New England Biolabs. All ribonucleic acid (RNA) extractions were
performed using the RNeasy Mini Kit from QIAGEN. Polymerase chain reactions
(PCRs) were performed using the Phusion High-Fidelity PCR Kit from Finnzymes
(Waltham, USA). Ligations were performed using the Ligation high Ver.2 from
TOYOBO (Osaka, Japan). Reverse-transcriptase PCRs (RT PCRs) were performed
using the SuperScript™ III One-Step RT-PCR System from Invitrogen. Greatwall
cDNA was amplified from HeLa cell messenger RNA (mRNA) using primers GW F+R
(detailed in section 2.1.4) and cloned into the pCR®II-TOPO cloning vector using the
TOPO-TA Cloning Kit from Invitrogen. In all cases the manufacturer’s recommended
protocols were followed and the presence of the expected DNA sequences confirmed by
restriction digestion and sequencing.
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2.2.4 Agarose gel electrophoresis and gel extraction
DNA was separated using 1% agarose gels by electrophoresis in TAE (40 mM
Tris base, 1 mM ethylene diamine tetraacetic acid (EDTA) and 20 mM acetic acid) and
visualised using the gel imaging system InGenius LHR from Syngene (Cambridge,
UK). The size of the DNA fragments was confirmed by parallel loading of 1Kb/+ DNA
ladder from New England Biolabs. When required, DNA was purified using the
QIAquick Gel Extraction Kit from QIAGEN following the manufacturer’s
recommended protocol and eluted in ddH2O.
2.2.5 Gateway cloning
In this work the MultiSite Gateway® technology from Invitrogen was used
instead of traditional cloning methods to manipulate the cDNA of Greatwall. This
technology takes advantage of the lambda phage recombination system to allow transfer
of cloned DNA between vectors via site specific att recombination sequences (Figure
2.2.1). Recombination is conservative and does not require any DNA synthesis. Once
DNA has been cloned in this system the DNA can then be transferred from an entry
clone into numerous other destination vectors, i.e. vectors for protein expression or to
tag the protein.
In order to create an entry clone containing the cDNA of Greatwall, the
appropriate att recombination sequences were added by PCR to either end of the cDNA
(that had been previously subcloned into the pCR®II-TOPO cloning vector) using the
primers GWEntry F+R (listed in section 2.1.4). A BP reaction was then performed
using the Gateway® BP Clonase II Enzyme Mix (Invitrogen) to move the cDNA into
the pDONR™221 vector (Invitrogen) following the manufacturer’s recommended
protocol, creating a Greatwall entry clone (Figure 2.2.1 A). This was then subsequently
used for a further cloning step by performing an LR reaction using the Gateway® LR
Clonase II Enzyme Mix (Invitrogen) following the manufacturer’s recommended
protocol with various destination vectors to yield the vectors detailed throughout this
work (Figure 2.2.1 B and C). Details of all reactions can be found in the Gateway®
Technology with Clonase II Manual available on the Invitrogen website
(www.invitrogen.com).
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Figure 2.2.1 Cloning using Gateway® technology
(A) In the BP reaction, BP Clonase facilitates recombination of the attB substrate (which can be an attB-
flanked PCR product, as was used for Greatwall, or a linearised attB expression clone) with the attP
substrate (the donor vector). This creates an attL entry clone that can then be used in the MultiSite
Gateway® system. (B) In the LR reaction, LR Clonase facilitates recombination of the attL substrate (the
entry clone) with an attR substrate (any destination vector). In this manner the cloned DNA can be
effectively transferred into multiple vectors, as was used for Greatwall cloning. (C) This technology
provides a rapid and efficient way to move a cloned DNA sequence into multiple vector systems.
Adapted from the Gateway® Technology with Clonase II Manual from Invitrogen (www.invitrogen.com).
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In this manner I created N-terminally flag- and myc-tagged Greatwall constructs
by performing LR reactions with the Greatwall entry clone and the destination vectors;
deltaT-FLAG-DEST and deltaT-Myc-DEST respectively. I also cloned Greatwall
cDNA into the Gateway® pDEST™14 expression vector. This allowed in vitro
expression of the cDNA in a rabbit reticulocyte lysate system using the TNT® Quick
Coupled Transcription/Translation System from Promega (Madison, USA) following
the manufacturer’s recommended protocol.
2.2.6 Site-directed mutagenesis
Primers were designed using Lasergene SequBuilder 10.1 DNASTAR and
properties checked using the Multifunctional Oligo Property Scan Tool provided by
Eurofins MWG Operon website (http://www.eurofinsgenomics.eu.). In general, the
codon that required the minimum base changes possible was chosen to mutate the target
amino acids. Primers were usually designed with the bases to be mutated in the centre
of the primer sequence with approximately 15 bases either side of the mutated bases
with a guanine (G) or cytosine (C) base at the termini of the primer.
The mutagenesis was carried out using the QuickChange® XL Site-Directed
Mutagenesis Kit from STRATAGENE (California, USA) following the manufacturer’s
protocol. The unmutated template DNA was removed by digestion with the restriction
enzyme DpnI as recommended and 5 µl of the reaction was taken for transformation
into DH5α E.coli cells.
2.2.7 Immunoblotting
Cells were lysed in SDS-sample buffer (0.01% (w/v) bromophenol blue, 62.5
mM Tris-hydrogen chloride (HCl) [pH6.8], 7% (w/v) sodium dodecyl sulphate (SDS),
5% β-mercaptoethanol and 20% (w/v) sucrose) and sonicated at high power with 0.5 
second intervals using a Bioruptor (Diagenode, Cambridge, UK) for 10 minutes in a
chilled ultrasonic bath at 4ºC. Samples were then boiled at 95ºC for 5 minutes and run
on SDS-polyacrylamide gels by electrophoresis using the Bio-Rad Mini Protean III
System from Bio-Rad, in Running buffer (25 mM Tris base, 192 mM glycine and 3.5
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mM SDS) along with a ColourPlus Prestained Protein Marker (Broad-range, New
England Biolabs). Stacking gels comprised 5% bisacrylamide, 125 mM Tris-HCl [pH
6.8], 0.1% SDS, 0.1% ammonium persulphate (APS) and 0.1% N,N,N',N'-
tetramethylethylenediamine (TEMED). Resolving gels comprised 10% bisacrylamide,
375 mM Tris-HCl [pH 8.8], 0.1 % SDS, 0.1% APS and 0.05% TEMED. Protein was
transferred by electro-blotting onto a HybondTM C+ membrane (Amersham Biosciences,
Piscataway, USA) using Trans-Blot Semi-Dry Transfer Cell (Bio-Rad) in Semi-dry
Transfer buffer (48 mM Tris base, 39 mM glycine, 0.04% SDS and 20% methanol).
Protein bands were then visualised using Ponceau S solution (0.1% (w/v) in 5% acetic
acid). The membranes were washed in PBS (137 mM NaCl, 0.3 mM potassium chloride
(KCl), 10 mM disodium hydrogen phosphate (Na2HPO4), 1.7 mM monopotassium
phosphate (KH2PO4) and pH to 7.4 with HCl) with 0.1% NP40 and blocked in 5% milk
(Marvel with PBS-0.1% NP40) for 1 hour at room temperature. Antibodies were diluted
in 5% milk or 5% bovine serum albumin (BSA; with PBS-0.1% NP40) and secondary
HRP-conjugated rabbit or mouse polyclonal secondary antibodies were used at
recommended concentrations. Proteins were visualised using the Enhanced
Chemiluminescence (ECL) Advance Western Blotting Detection Kit (Amersham)
following the manufacturer's protocol. The membrane was exposed to Hyperfilm ECL
(Amersham) and processed using an automatic X-ray film processor (Xograph,
Gloucestershire, UK).
2.2.8 Antibody generation
Antibodies against the Greatwall protein were produced by cloning the N-
terminal 100 amino acids (aa) of Greatwall into the pET28a(+) expression vector from
Novagen using XhoI and NcoI restriction enzymes. The N-terminal fragment was
expressed from this vector with a C-terminal 6 x His-tag from this vector in E.coli BL21
cells using 1 mM isopropylthio-β-galactoside (IPTG) and purified under denaturing 
conditions using nickel-nitrilotriacetic acid (Ni-NTA) agarose beads from QIAGEN in
an empty PD-10 Desalting Column from Amersham. This was carried out following the
batch purification protocol under denaturing conditions in 6 M Urea detailed in The
QIAexpressionist handbook available from QIAGEN. The purified recombinant protein
fragment was then sent to GenScript to raise antibodies in rabbit.
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The 4th immunisation sera was then purified by running out 4 x 5 μg of the 
purified recombinant protein fragment in SDS-sample buffer on a 15% SDS-
polyacrylamide gel by electrophoresis and transferred onto a Hybond C+ membrane (as
described in section 2.2.8). The protein bands were then visualised using Ponceau S
solution and individually cut out. These were then blocked in 5% milk for 1 hour at
room temperature and then washed briefly two times with PBS-0.1% NP40. After this
they were incubated at 4ºC for 72 hours with 0.5 ml 4th immunisation sera with end over
end rotation. The membranes were then washed five times with PBS-0.1% NP40 and
the antibodies eluted from the membrane in 150 μl freshly prepared chilled Elution 
buffer (0.5 M NaCl, 50 mM glycine, 0.5% Tween-20, 0.1 mg/ml BSA and pH to 2-3
with HCl) while vortexing for 20 seconds. Next 25 μl of 1 M Tris [pH 8.8] was added to 
neutralise the buffer and the elute removed and taken into a new tube. This was then
repeated. Next, the elute was then pooled and 10% Thimerosal added at 1:1000. Finally,
the elute was concentrated by centrifugation for 20 minutes through a Vivaspin 2 ml
column from Satorius Biotech (Gottingen, Germany) at 3000 r.p.m. / 4ºC. The purified
and concentrated 4th immunisation sera (anti-Greatwall) antibodies were then stored in
20 μl aliquots at - 80ºC. 
Phospho-specific antibodies against the phosphorylated threonine 194 of human
Greatwall were generated in rabbit by Eurogentec (antigen code: Greatwall-EP110355-
KLH-MBS) using the peptide sequence the peptide sequence
CMMDILTT(PO3H2)PSMAK (EP110355) and CMMDILTTPSMAK (EP110356). The
purified antibody sera was used for this work and stored at -20˚C. 
2.2.9 Cell culture and inhibitor treatments
Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 2 mM L-glutamine, 10% foetal calf serum (FCS) and 1% Penicillin
G (sodium salt)-Streptomycin in saline solution in a 37˚C, 5% carbon dioxide (CO2)
incubator. Trypsin-EDTA was used to passage cells. Frozen stocks were made in FCS
with 10% dimethyl sulfoxide.
Cells were treated with 1 mM of Thymidine, 10 µM RO-3306, or 10 µM of
BI2536 for 24 hours. Cells were treated with 75 ng/ml Nocodazole or 5 µM of STLC
for 16 hours. Cells were also treated with phosphatase inhibitors: 5 µM Tautomycetin
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and 1 µM okadaic acid (for further details see section 2.2.23). For these treatments the
media was aspirated and replaced with drug containing media, and mixed thoroughly by
pipetting.
2.2.10 Double Thymidine block and release
HeLa cells were seeded at 1 x 105 cells in a 6-well plate in 1 ml medium and
incubated at 37˚C overnight. The cells were then treated with 1 mM Thymidine for 24 
hours. Treatment was carried out by aspirating the medium and replacing it with drug-
containing medium, except for control cells for which the medium was replaced with
fresh (drug-free) medium. After 24 hours the Thymidine was washed away by the
addition of 5 ml of warmed PBS which was swirled and then removed for five repeats.
Finally, 1 ml of fresh medium was added and the cells allowed to recover for 12 hours
at 37˚C. The cells were then treated again with 1 mM Thymidine for a further 12 hours 
in the same manner as before. An initial sample (at time zero) was taken of the blocked
cells. The Thymidine was washed away, as above, for all the other cells and they were
released from their cell cycle block by the addition of 1 ml fresh drug-free medium.
Samples were then collected every hour for a 10 to 12 hour period. Samples were
collected by trypsiniation and resuspended in 1 ml PBS. 150 µl of the cell suspension
was then taken and the cells fixed in 70% ethanol for analysis by fluorescence assisted
cell sorting (FACS). The remaining cells were resuspended in 50 µl SDS-sample buffer
for analysis by immunoblot.
2.2.11 FACS analysis
Cells were fixed in 70% ethanol for at least 16 hours at 4oC. Cells were then
centrifuged at 1500 r.p.m. for 3 minutes and rinsed in 0.5 ml of 3% BSA-PBS. After
this they were re-centrifuged and resuspended in 3% BSA-PBS with 5 µg/ml propidium
iodide (PI) and 1 µg/ml RNase. These were analysed on a BD FACSCanto machine
from BD Biosciences (Oxford, UK) and FACS Diva software (BD Biosciences) was
used to plot PI area versus cell counts.
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2.2.12 Transfection
Cells were transfected with DNA at 60 to 80% confluency using FuGene® 6
Transfection Reagent (Roche Diagnostics) using the 3:2 ratio of reagent to DNA in
serum-free DMEM without antibiotics as per the manufacturer’s instructions. Cells
were then grown at 37oC for 48 to 72 hours before lysates were collected.
2.2.13 Generation of stable cell lines
HEK 293T cells were seeded at 1 x 105 cells in a 6-well plate and co-transfected
the next day with 5 µg of flag-tagged Greatwall cDNA in deltaT-FLAG-DEST and 1 µg
bML4(puroR) for selection of incorporation events using puromycin with FuGene® 6
Transfection Reagent as described in section 2.2.12. Cells were selected 48 hours later
with addition of medium containing 3 µg/ml puromycin. Selection pressure was
maintained over two weeks by the addition of fresh puromycin-containing medium
every 3 to 4 days. Surviving clones were trypsinised using 3 mm cloning disks and
expanded into 6-well plates in puromycin-containing medium. Once cells were 80% to
90% confluent half of the cells were frozen and the other half taken for analysis by
immunoblotting. Clones found to be expressing flag-Greatwall were then woken up and
expanded for experiments.
2.2.14 Growth curves
Flag-Greatwall expressing HEK 293T clones number 1 and 7 at passage 1 were
seeded at 5 x 104 cells in 1 ml medium in 24-well plates. Cells were then assessed and
data collected for growth curves using the IncuCyte system from Essen Biosciences
(Hertfordshire, UK). This phase-contrast compact microscope can be placed inside the
cell culture incubator to allow direct long-term monitoring and data collection of cell
growth. Nine different points from 6 wells of a 24-well plate were measured every 3
hours for 255 hours. Growth curves were then plotted using Microsoft® Office Excel
2003 from Microsoft (Reading, UK).
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2.2.15 siRNA transfection
Cells with 60% to 80% confluency were transfected with 6 µl HiPerFect
Transfection Reagent (QIAGEN) as per manufacturer's instructions, using 5 to 100 nM
RNA. Cells were then grown at 37oC for 48 to 72 hours before lysates were collected.
Control siRNA used was AllStars Negative Control siRNA from QIAGEN, control
siRNA against Eg5 was Hs_KIF11_8 FlexiTube siRNA from QIAGEN (target
sequence: CTCGGGAAGCTGGAAATATAA). Greatwall siRNA was Hs_MASTL_6
FlexiTube siRNA (target sequence: ACGCCTTATTCTAGCAAATTA) and
Hs_MASTL_7 FlexiTube siRNA (target sequence: CAGGACAAGTGTTATCGCTTA)
also from QIAGEN.
2.2.16 Immunoflourescent staining of cells
Prior to fixation, cells were seeded onto glass cover slips. Once cells had
reached 60% to 80% confluency, the media was aspirated and the cells washed briefly
with warmed PBS. The cells were then fixed in ice cold methanol at -20˚C for 10 
minutes. The fixed cells were next washed with PBS three times for 5 minutes and then
permeabilised using PBS-0.1% NP40 for 20 minutes. After this, the cells were blocked
for 30 minutes at room temperature in 5% BSA-PBS and incubated for 1 hour with
primary antibodies made up in 5% BSA-PBS. The cells were then washed with PBS
three times for 5 minutes and incubated with secondary antibodies diluted in 5% BSA-
PBS for 1 hour at room temperature. The cells were washed again with PBS before
being mounted onto standard laboratory slides face down with 10 µl of Prolong® Gold
mounting solution with DAPI and allowed to set for at least 16 hours at 4˚C. Images of 
cells were taken using a Delta Vision® microscope from Applied Precision
(Washington, USA) with a x100 or x60 oil immersion objective (Olympus, Essex, UK).
Z-series of 0.3 µm stacks were acquired using SoftWoRx software version 3.7.1 from
Applied Precision and deconvolution performed using Huygens Professional
Deconvolution Software Version 3.5 from Scientific Volume Imaging (Hilversum, NL).
Maximum intensity projections were obtained in Omero Version Beta 4.1.1 (The OME
Consortium, UK) and exported as Tiff files.
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2.2.17 Quantification of multinuclear cells
HeLa cells were treated with 25 nM control or Greatwall siRNA for 72 hours
after which cells were fixed and stained using anti-α Tubulin antibodies to visualise the 
cells and DAPI to visualise the nuclei. Z-series of 0.3 µm stacks were acquired and the
maximum intensity projections were obtained in Omero Version Beta 4.1.1. The
number of cells retaining a single nuclei or that had become multinucleate were
counted. For this 75 to 100 cells from three separate siRNA experiments were counted.
The data was then exported into Microsoft® Office Excel 2003 and plotted.
2.2.18 Transfection of flag-tagged Greatwall and mutants
Cells were seeded into 10 cm3 culture dishes at 1 x 106 in 10 ml medium. Cells
were transfected the next day using the calcium phosphate precipitation method. For
this 10 µg of plasmid DNA was added to 61 μl of 2 M calcium chloride (CaCl2) and
sterile water added to 500 μl. This solution was added drop wise to 500 μl of 2 × 
HEPES-Buffered Saline Solution (HBSS) (12 mM dextrose, 50 mM HEPES, 10 mM
KCl, 280 mM NaCl, 1.5 mM disodium hydrogen phosphate dihydrate
(Na2HPO4.2H2O), pH to 7 with HCl) while bubbling gently using a glass Pasteur pipette
and electronic pipette to mix. The 1 ml solution was then immediately added drop wise
to the cells and swirled to mix. The next day the precipitate-containing medium was
removed, the cells washed with PBS and fresh medium added back. Samples were
collected the following day.
2.2.19 Immunoprecipitation of flag-tagged Greatwall and mutants
HEK 293 cells were plated in 10 cm3 culture dishes at 1 x 106 cells in 10 ml
medium. Cells were transfected with plasmids using the calcium phosphate method as
described in section 2.2.19. The next day (16 hours later) the medium was removed, the
cells were washed once with 5 ml PBS and fresh medium or drug-containing medium
added and swirled to coat cells.
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The following day, after the appropriate incubation time with drug treatments if
required (see figure legends for details of individual experiments), cells were harvested
by trypsinisation (2 x plates per condition). The cells were resuspended in 500 µl of
chilled Lysis buffer (20 mM Tris-HCl [pH7.5], 137 mM NaCl, 10% glycerol, 0.5% NP-
40, 2 mM EDTA with one tablet of Complete Protease Inhibitors Cocktail and
PhoSTOP Phosphatase Inhibitor Cocktail per 50 ml) and incubated on ice for 20
minutes. The cell lysates were then spun down at 13000 r.p.m. / 4˚C for 15 minutes and 
the elute transferred to new tubes. Protein was equalised using the Bio-Rad Protein
Assay Reagent (Bio-Rad) and measuring absorbance at 600 nm. A 50 µl sample of the
equalised whole cell lysate was kept and SDS-sample buffer added for evaluation by
immunoblotting. The Anti-flag M2 Magnetic beads were prepared by washing two
times with Immunoprecipitation (IP) buffer (20 mM Tris-HCl [pH7.5], 137 mM NaCl,
10% glycerol, 0.5% NP-40, 2 mM EDTA, 10 mM sodium fluoride (NaF) and 1 mM
sodium orthovanadate (Na3VO4)) on a chilled magnetic stand. The equalised whole cell
lysates were then incubated with 20 µl of the beads resuspended in IP buffer for 1 hour
with end over end rotation at 4˚C to capture the flag-Greatwall protein. After this, the 
supernatant was removed from the beads using the chilled magnetic stand and the beads
were then washed two times in High Salt IP buffer (20 mM Tris-HCl [pH7.5], 500 mM
NaCl, 10% glycerol, 0.5% NP-40, 2 mM EDTA, 10 mM NaF and 1 mM Na3VO4).
Next, the beads were resuspended in 1 ml of chilled Kinase buffer (50 mM MOPS
[pH7.5], 5 mM magnesium chloride (MgCl2), 0.4 mM EDTA, 0.4 mM ethylene glycol
tetraacetic acid (EGTA) with one tablet of Complete Protease Inhibitors Cocktail and
PhoSTOP Phosphatase Inhibitor Cocktail per 50 ml with 1:1000 β-mercaptoethanol 
added as per use) and 100 µl (10%) of the beads removed and resuspended in 25 µl
SDS-sample buffer for analysis by immunoblotting. Beads resuspended in 0.9 ml
Kinase buffer were then prepared for kinase assays.
2.2.20 Kinase assays with immunoprecipitated flag-tagged proteins
Beads were split in half and each half then resuspended in 30 µl Kinase buffer or
Kinase buffer containing 20 µg of the Myelin Basic Protein (MBP) substrate. To start
reactions, 10 µl of 100 µM ATP including 0.1 MBq [γ-32P]ATP (made up in Kinase
buffer) from PerkinElmer (Massachusetts, USA) was added. Reactions were incubated
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at 37˚C for 20 minutes and were terminated by the addition of 25 µl SDS-sample buffer 
and boiling at 95˚C for 5 minutes. The phosphorylation was then analysed by running 
15 µl of each reaction out on a 15% SDS-polyacrylamide gel by electrophoresis (as
described in section 2.2.8). The gel was dried and transferred to a lead-lined cassette.
Based on the intensity of the radioactive signal, the blot was exposed on the Storm 840
PhosphorImager (Molecular Dynamics; California, USA) and the autoradiograph
exported as a Tiff file.
2.2.21 Quantification of kinase assays
The levels of flag-tagged Greatwall protein recovered in each immunoprecipitate
were measured using densitometry of the ECL film taken with ImageJ software (Wayne
Rasband, National Institutes of Health, USA). The corresponding phosphorylation of
the MBP induced by Greatwall in the kinase reaction were also measured using
densitometry of the autoradiograph using ImageJ software. Finally, the activity levels
were corrected by the amount of protein present in each immunoprecipitate and
represented as a percentage of the phosphorylation compared with that of the wildtype
form. This data was then exported into Microsoft® Office Excel 2003 and plotted. All
kinase assays were repeated twice unless otherwise stated.
2.2.22 Kinase assays with recombinant cyclin A-CDK2
Immunoprecipitations were performed as described in section 2.2.19. Beads
were split in half and each half resuspended in 30 µl Kinase buffer or Kinase buffer
containing 40 ng/µl recombinant cyclin A-CDK2. To start reactions 10 µl of 100 µM
ATP (made up in Kinase buffer) was added. Reactions were incubated at 37˚C for 20 
minutes and were terminated by the addition of 25 µl SDS-sample buffer and boiling at
95˚C for 5 minutes. Where required, instead of terminating the reaction, 1 µl of Lambda 
Protein Phosphatase with Protein MetalloPhosphatases buffer and manganese chloride
(MnCl2) from New England Biolabs were added to the tube as per the manufacturer’s
recommended protocol and incubated at 30˚C for 30 minutes. The reactions were then 
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stopped by addition of 15 µl SDS-sample buffer and boiling at 95˚C for 5 minutes. The 
phosphorylation was then analysed by immunoblotting (as described in section 2.2.8).
2.2.23 Phosphatase treatments
Cells that were 70 to 90% confluent in 125 cm3 culture flasks were treated with
the 5 µM of the Eg5 inhibitor, STLC, for 16 hours to arrest cells in mitosis. A mitotic
shake off was then performed and the cells collected and centrifuged at 1500 r.p.m. for
5 minutes before being resuspended in 5 µM STLC-containing medium alone or
medium that also contained 5 µM Tautomycetin or 1 µM okadaic acid. Cells were
incubated at 37˚C for one hour after which a time zero sample was taken. Samples were 
collected by centrifugation at 2000 r.p.m. for 2 minutes and immediately resuspended in
SDS-sample buffer. They were then transferred to ice before being sonicated and boiled
at 95˚C for 5 minutes at the end of the experiment. To the remaining cells 10 µM RO-
3306 was added to inhibit CDK1 (Vassilev et al. 2006) and the cells incubated again at
37˚C. Samples were then taken at different time points after the addition of RO-3306. 
2.2.24 Sequence alignments
All sequences alignments were carried out using CLUSTAL 2.1 multiple
sequence alignment (Larkin et al. 2007) using the Sequence Alignment Tool on the
European Bioinformatics Institute website (http://www.ebi.ac.uk/) (Goujon et al. 2010).
2.2.25 Structural modelling
The structural model of Greatwall was created in collaboration with Dr.
Anthony Oliver from the Genome Damage and Stability Centre (GDSC) at the
University of Sussex and was produced using the computational protein structure
prediction engine, the Protein Homology/analogY Recognition Engine (PHYRE)
(Kelley et al. 2009). This allowed generation of a 3-dimensional (3D) model based on
protein threading (or fold recognition). Structural prediction for proteins that have no
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homologues with known structures are made in this case by aligning, or ‘threading’,
amino acids from the target sequence onto a template structure and then evaluating how
well the target matches the template. In this manner a ‘best-fit’ template was selected
from known structures and a model of the target sequence structure was built. The
catalytic core of Greatwall was modeled in this manner using the α isoform of PKC, 
another AGC family kinase, as the best-fit template. All molecular graphics figures
were produced with the help of Dr. Anthony Oliver using the MacPyMOL Molecular
Graphics System from DeLano Scientific (www.delanoscientific.com/).
2.2.26 Phospho-site analysis
Phosphorylation site mapping analysis of Greatwall was performed using
PhosphoSitePlus® from Cell Signaling Technology (http://www.phosphosite.org). This
is an online systems biology resource for the study of protein post-translational
modifications (PTMs) that provides an extensive, manually curated database indicating
phosphorylation sites and other PTMs that have been identified from both high-
throughput and low-throughput articles and reports (Hornbeck et al. 2012). The output
of this analysis indicated likely modified (phosphorylated) residues of human Greatwall
and informed this study.
2.2.27 Gateway cloning to make an analogue sensitive Greatwall kinase
The MultiSite Gateway® technology from Invitrogen was used instead of
traditional cloning methods to create a gene targeting vector to introduce the M110A
mutation in the ATP-binding site of the Greatwall kinase. The targeting strategy
involved the generation of right and left homologous arms to target the Greatwall
genomic locus to introduce the mutation into exon 3 of the gene (Iiizumi et al. 2006).
This is described in detail in Chapter 6. The MultiSite Gateway® Three-Fragment
Vector Construction Kit from Invitrogen was used and manufacturer's protocols from
the MultiSite Gateway® Technology Manual Version E were followed.
83
CHAPTER 2
2.2.28 Adeno-associated viral (AAV) vectors and infection
The destination vector, pAAV-dest, used for Greatwall gene targeting contained
the Gateway att site-containing cassette for recombination inserted into the pAAV-MCS
vector using NotI restriction sites. Adeno-associated viruses are replication deficient
parvoviruses that require co-transfection with helper adenoviruses for productive
infection. The pAAV-MCS vector was co-transfected with the pHelper and pAAV-RC
vectors in AAV-293 cells using the calcium phosphate precipitation method (described
in section 2.2.18) to allow the production of infectious viral particles containing the
gene targeting vector. Viral particles were produced and HCT116 cells were infected as
described in the Stratagene AAV Helper-Free System Instruction Manual A.02 and in
Kohli et al. (2004). Selection was performed in complete DMEM with 2 µg/ml
puromycin.
2.2.29 Deletion of puromycin cassette in targeted clones
This was carried out using the Ad-CMV-Cre virus from Vector BioLabs
(Philadelphia, USA) at 100 multiplicity of infection (MOI) in 2 ml medium in a 6-well
culture plate for 24 hours. Cells were then diluted in DMEM in 96-well culture plates
and clones screened using double selection in medium with and without puromycin at 2
µg/ml.
2.2.30 Extraction of genomic DNA
Cells were trypsinised, pelleted and resuspended in Lysis buffer (200 mM NaCl,
20 mM EDTA, 40 mM EGTA, 40 mM Tris-HCl [pH8.0], 0.5% SDS, 0.5% 2-
Mercaptoethanol and 200 µg/ml Proteinase K), then incubated overnight at 55oC. The
next day 250 µl of 6 M NaCl was added and the samples vortexed for 10 seconds then
incubated on ice for 30 minutes. Next, these were then centrifuged at 13,000 r.p.m. for
30 minutes after which the supernatant was decanted and 1 volume of 100% ethanol
was added. These were then centrifuged again at 13,000 r.p.m. for 10 minutes. The
84
CHAPTER 2
DNA pellet was washed with 70% ethanol, air-dried and re-suspended in 20 µl of TE
(10 mM Tris-HCl [pH 8.0] and 1 mM EDTA [pH 8.0]).
2.2.31 Southern blotting
Once genomic DNA had been extracted, the concentration was measured and 30
µg was digested overnight using the NdeI restriction enzyme and then run on a 0.7%
agarose gel in TAE. The gel was depurinated using HCl solution (0.25 M HCl) for 15
minutes and placed in Denaturation buffer (1.5 M NaCl and 0.5 M sodium hydroxide
(NaOH)) for 30 minutes with gentle shaking. The gel was washed two times for 30
minutes in Neutralisation buffer (1.5 M NaCl and 0.5 M Tris-HCl [pH 7.5]). The DNA
was transferred overnight at room temperature using capillary blotting apparatus with
20 x Saline-Sodium Citrate (SSC) buffer (3 M NaCl and 300 mM trisodium citrate and
pH to 7 with HCl) onto a Hybond™ Nylon Membrane from Amersham. The DNA on
the membrane was then cross-linked using a UV-Stratalinker 2400 (Stratagene). The
371 bp probe was labelled using the Ready-to-go DNA labelling beads from Amersham.
For this 50 ng of DNA in 45 µl of TE was denatured by heating for 5 minutes at 95oC
and immediately placed on ice for 2 minutes. The denatured DNA was added to the tube
containing the reaction mix beads with 1.85 MBq of [α-32P]dCTP (PerkinElmer). The
tubes were incubated at 37oC for 1 hour and the labelled probe was purified using the
DyeEx 2.0 spin kit from QIAGEN following the manufacturer's protocol. Prior to use,
the labelled probe was again denatured at 95oC for 5 minutes. The membrane was pre-
hybridised using 10 ml of warmed ExpressHybTM Hybridisation Solution (BD
Biosciences) at 68oC for 30 minutes with continuous rotation. The denatured
radiolabeled probe was added to the hybridisation solution overnight at 68°C with
continuous rotation. The membrane was washed with 2 x SSC buffer for 15 minutes and
2 x SDS-SSC buffer (2 x SSC with 0.1% SDS) for 30 minutes. The blot was transferred
to a lead-lined cassette and, based on the intensity of the radioactive signal, the blot was
exposed on the Storm 840 PhosphorImager. The autoradiograph was then exported as a
Tiff file.
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2.2.32 Human lung and breast cancer cell lines
Samples were prepared by collection of 1 x 105 cells in 100 µl SDS-sample
buffer by Dr. Victoria Haley from the Trafford Centre at the Brighton and Sussex
Medical School. These were then sonicated and boiled at 95˚C for 5 minutes, and run 
out on an SDS-polyacrylamide gel. They were then analysed by immunoblotting and the
levels of the Greatwall protein present in each cell line sample was measured using
densitometry of the ECL film taken with ImageJ software. These levels were
normalised against the levels of the α tubulin protein present in each cell line sample, 
also measured using densitometry of the ECL film again taken with ImageJ software.
The data was then exported into Microsoft® Office Excel 2003 and plotted. This
quantification was carried out by Dr. Victoria Haley (Trafford Centre, Brighton and
Sussex Medical School, Sussex, UK).
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CHAPTER 3. Making tools to investigate and characterise Greatwall in
human cells
3.1 Introduction
The gene encoding the human homologue of Greatwall was first identified by
Gandhi et al. in 2003. This gene, called FLJ14813, was within the region of
chromosome 10p that in 2000 Drachman et al. had mapped to autosomal dominant
nonsyndromic thrombocytopenia, also known as thrombocytopenia-2 (Drachman et al.
2000). A novel missense mutation in this gene segregated perfectly with
thrombocytopenia in their cohort of 51 family members. All the thrombocytopenic
family members carried a substitution of guanidine to cytosine at position 565 of this
gene that predicted a substitution of glutamic acid to aspartic acid (E167D) in exon four.
This disorder is characterised by decreased numbers of normal platelets that results in a
mild bleeding tendency (Gandhi et al. 2003). Platelet function and morphology is
normal in these patients suggesting it results from defective platelet production or
release. They described the gene product as a putative kinase similar to a novel gene
described in Drosophila called Greatwall (Yu et al. 2004) and postulated that this
mutation, although subtle, might be responsible for the disorder in these patients. A
follow up study in 2009 in zebrafish linked the disorder to a reduction in expression
levels of the gene (Johnson et al. 2009). It is unclear how this defect could fit with the
emerging model of Greatwall function but suggests a role for Greatwall in the
development of megakaryocytes in humans that could be similar to the defect seen in
Xenopus oocytes.
In 2002 Manning et al. catalogued the protein kinase complement of the human
genome; the human kinome (Manning et al. 2002). In this study they identified the
same gene but categorised it as Microtubule Associated Serine/Threonine-Like
(MASTL) kinase, as a distantly related family member of the Microtubule Associated
Serine/Threonine kinases (MAST kinases) (Walden et al. 1993; Garland et al. 2008).
This family of AGC kinases comprise MAST1 to 4 and MASTL. They are characterised
by the presence of a kinase domain, a Domain of Unknown Function 1908 (DUF1908)
and a PDZ scaffolding/membrane-targeting domain (Manning et al. 2002; Pearce et al.
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2010). MAST 1 and 2 are found expressed in multiple tissues in the rodent brain.
MAST3 and 4 are expressed more selectively in the brain and are found in the striatum
and oligodendrocytes respectively (Garland et al. 2008). MAST1 to 3 have been
reported to bind to the tumour suppressor protein PTEN to mediate its signalling
(Valiente et al. 2005) and missense mutations in MAST3 have been linked to increased
risk of inflammatory bowel disease, due to its loss promoting aberrant signalling from
nuclear factor-kappa B (NF-κB) (Labbe et al. 2008). Although relatively little is
currently known about their biological functions, this family of proteins are proposed to
play a structural role that facilitates signal transduction and plasticity throughout the
central nervous system (Valiente et al. 2005; Garland et al. 2008; Labbe et al. 2008).
Recently the identification of functional gene fusions in several breast cancers that
result in MAST1 and 2 overexpression and increased proliferation have also been
described (Robinson et al. 2011).
In contrast to the other members of the MAST family, MASTL was not found
expressed in the rodent brain (Garland et al. 2008). Its expression appeared to be
exclusive to the heart and testis in the rat tissues examined. Moreover, it bears little
homology to the other MAST kinase family members. MASTL lacks a DUF1908 or
PDZ domain and is far shorter than the other MAST family kinases (Figure 3.1 A)
(Pearce et al. 2010). Human MAST1 to 4 are large enzymes of 1,309 to 2,444 amino
acids with conventional small T-loops (31 amino acids in length for MAST1), while
human MASTL is 879 amino acids and the kinase domain is split by a large region of
~540 amino acids. The exact function of this large insertion between the two halves of
the kinase domain has yet to be determined but could represent an as yet
uncharacterised large T-loop (discussed further in the next Chapter). This large insertion
of amino acids separating the kinase domain N- and C-termini is replicated in the
Drosophila and Xenopus Greatwall kinases and these proteins share 50.2% and 65.7%
sequence homology respectively with human MASTL, while its homology with
MAST1 is only 10.4% (Figure 3.1 B) (Burgess et al. 2010). This evident lack of
similarity to any of the other MAST family kinases, supported by recent studies of
human MASTL described later in this chapter, led to the conclusion that MASTL is not
a true member of the MAST family, and that it is instead the functional human
orthologue of Drosophila and Xenopus Greatwall kinase. This was subsequently
confirmed by Burgess et al. in 2010 when they cloned and expressed human MASTL
complimentary DNA (cDNA) in Xenopus CSF egg extracts (Burgess et al. 2010). Using
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Figure 3.1 MASTL is the human homologue of Greatwall
(A) Schematic drawing of the domain structures of the human MAST kinase family. Copied from Pearce
et al. (2010). Human MASTL does not contain either a DUF1908 or PDZ domain and is far shorter than
the other MAST family members. (B) Schematic drawing to show sequence homology between Xenopus
Greatwall (xGwl), Drosophila Greatwall (dGwl), human MASTL (hMASTL) and human MAST1
(hMAST1). Copied from Burgess et al. (2010). The kinase domains of xGwl, dGwl and hMASTL are
separated by long inserted regions of >500 amino acids, while hMAST1 has a conventional T-loop of ~30
amino acids. Neither xGwl, dGwl nor hMASTL contains a PDZ domain and hMASTL shows much
higher sequence homology with xGwl and dGwl than when compared with hMAST1 (see table).
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extracts that had been depleted of their endogenous Greatwall the expression of MASTL
cDNA, at endogenous levels, rescued the mitotic state while expression of a kinase dead
MASTL did not. For the purpose of this study this MATSL gene product will be
referred to as Greatwall kinase from this point onward.
3.2 Making tools to investigate human Greatwall
At the onset of my work on this thesis little was known about the functions of
human Greatwall kinase and no tools existed to allow detection or analysis of Greatwall
in human cells. Thus, in order to begin to research this novel kinase I needed to develop
tools to allow me to undertake its analysis. During this investigation of human Greatwall
other studies, now published, also described the important role of this kinase in the cell
cycle in human cells and these will be discussed in detail at the end of this chapter and
where relevant.
3.2.1 Antibody generation
To initiate this study of human Greatwall kinase I first raised antibodies against
an N-terminal fragment of the protein cDNA encoding the N-terminal 1 to 100 amino
acids (aa). This was obtained by PCR amplification from HeLa cell mRNA in a two
step RT-PCR Figure 3.2 A). This was carried out with primers that introduced XhoI
and NcoI restriction sites at the N- and C-termini respectively, allowing it to be
directionally cloned into the pET28 bacterial expression vector. Using this strategy, I
expressed the Greatwall N-terminus with a C-terminal His-tag of six histidine residues
in E.coli BL21 cells and purified it under denaturing conditions in 6M urea using
nickel-nitrilotriacetic acid (Ni-NTA) beads. The purified recombinant protein fragment
was then used to raise antibodies in rabbit using a commercial service.
Antibodies were raised in two rabbits (A and B) and the 4th immunisation sera
from both rabbits were tested by immunoblotting. I expressed the human Greatwall
protein (from cloned full-length cDNA) in a rabbit reticulocyte system in a T7
expression vector (pDEST14). This in vitro translated Greatwall was run out on an
SDS-PAGE gel with HeLa cell lysates from asynchronous and mitotically arrested cells
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Figure 3.2 Making tools to investigate Greatwall in human cells
(A) Schematic representation of the Greatwall protein. The N-terminal 100 aa indicated were used to
create an antigen peptide subsequently used for antibody generation in rabbit. (B) SDS-PAGE analysis of
the 4th immunisation sera from rabbit (rabbits A and B). Loaded in the first lanes are in vitro translations
in a rabbit reticulocyte system alone (-) or in the presence of Greatwall cDNA expressed from pDEST14
(+). Loaded in the next lanes are HeLa cell lysates from asynchronous cells (Asyn) or cells that have been
treated with Nocodazole (+ Noc). The in vitro translated human Greatwall kinase and HeLa endogenous
Greatwall kinase is seen at its predicted size of ~110 kDa (indicated by the arrow), other bands are non-
specific background signal. (C) The same SDS-PAGE analysis was performed using the concentrated and
purified antibody sera (anti-GW). Far fewer non-specific bands are observed. The in vitro translated and
endogenous Greatwall kinase is seen as a band at ~110 kDa (indicated by the arrow). An anti-α Tubulin 
antibody (anti-α T) was used as a loading control here. 
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(D) SDS-PAGE analysis of flag- and myc-tagged Greatwall constructs expressed in HEK 293T cells.
Loaded in the first lane is asynchronous (Asyn) HEK 293T cell lysate and subsequent lanes contain
lysates from HEK 293T cells transfected with myc- (Myc-) or flag-tagged Greatwall (Flag-GW) or a
Greatwall mutant (Flag-GW-M110A), as indicated. Anti-Flag or anti-Myc antibodies were used to detect
the expressed tagged constructs and an anti-α Tubulin (anti-α T) antibody was used as a loading control. 
The cell cycle (FACS/PI) profiles for these HEK 293T cell samples transfected with the constructs (myc-
or flag-tagged Greatwall or Greatwall M110A) as indicated are shown beneath.
using the spindle poison Nocodazole (Figure 3.2 B). These were then transferred to a
nitrocellulose membrane and probed with the rabbit anti-Greatwall antibodies. Both
antibodies clearly detected the in vitro translated Greatwall in the rabbit reticulocyte
lysates, but high background signal was seen on the resulting immunoblots, especially
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in the whole cell lysates. To remove this high non-specific background signal the
antibodies were further purified by incubation with the His-tagged N-terminal Greatwall
protein fragment run out on an SDS-PAGE gel and transferred to a nitrocellulose
membrane. Specific antibodies were then eluted from the membrane and concentrated.
The concentrated purified antibody sera was then used to probe fresh immunoblots for
Greatwall. This resulted in much cleaner blots showing a single specific band at ~110
kDa, corresponding to the predicted size of the human Greatwall protein. This band was
identified at the same position in the in vitro translation reaction in which the cloned
Greatwall cDNA was expressed but not in the translation sample without any Greatwall
cDNA. This indicates that the band detected by these antibodies is human Greatwall
kinase and this protein is present in human (HeLa) cell lysates.
3.2.2 Tagging Greatwall
I cloned the cDNA of human Greatwall for use as a tool to investigate
Greatwall, principally to allow tagged versions of the protein to be produced. In order to
clone Greatwall, I prepared mRNA from HeLa cells and carried out a two step RT-PCR
to amplify the cDNA of the Greatwall (MASTL) gene product. A DNA fragment of the
expected 2367 bp size was obtained and was subsequently purified from an agarose gel
and cloned into a TOPO cloning vector. This was confirmed by sequence analysis
(Appendix A contains a full alignment of the cloned sequence with human Greatwall
cDNA sequence) and used for subsequent cloning using Gateway® Technology from
Invitrogen (Hartley et al. 2000). This is a universal cloning system that is based on the
site-specific recombination properties of bacteriophage lambda that provides an
efficient way in which to move DNA sequences into multiple vector systems (for a
detailed explanation of this technology see Chapter 6 section 6.3).
Tagging of human Greatwall cDNA to create fluorescently tagged proteins
proved unsuccessful. Constructs created with green fluorescent protein (GFP), red
fluorescent protein (RFP) or mCherry at the C-terminus or at the N-terminus of
Greatwall failed to express. The addition of multiple myc-tags at the N-terminus also
failed to be expressed. It is likely that these results can be explained because the
Greatwall kinase domain is bifurcated and must fold correctly to bring the two sections
of its kinase domain together to form a fully active kinase. The presence of a tag at
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either the N-terminus or C-terminus of the protein thus might interfere with this folding
and result in an unfolded protein that is subsequently degraded by the cell. For this
reason the size and/or nature of the attached tag is therefore critical and the GFP, RFP,
mCherry and multiple myc-tags were likely incompatible with the correct folding of the
protein to produce a tagged and functional kinase. Finally, the expression of N-terminal
flag-tagged Greatwall cDNA was achieved in HEK 293T cells (Figure 3.2 D). Of all
tags tested only this small flag-tag on the N-terminus was amenable to permitting
correct protein folding, preventing any adverse effects from the tag on the tertiary
structure of the protein, and allowing the functional kinase to be expressed.
In addition to the flag-tagged wildtype cDNA, I introduced a methionine to
alanine substitution at position 110 (M110A) into this flag-tagged cDNA (Greatwall
M110A) that should render the protein ATP-analogue sensitive (discussed in more
detail in Chapter 6). This Greatwall M110A mutant was also successfully expressed by
transient transfection in HEK 293T cells. The cell cycle (FACS) profiles for HEK 293T
cells transfected with either the wildtype or Greatwall M110A appeared normal. This
implies that these cells were capable of growing and proceeded to cycle normally
despite the presence of the ectopically expressed Greatwall proteins (Figure 3.2 D).
3.3 Characterisation in human cell lines
Expression of Greatwall kinase was detected in several human cell lines. The
protein was detected by immunoblotting in human HeLa, HCT116, HEK 293T and RPE
cells (Figure 3.3 A). I compared Greatwall levels in different cell cycle states including
asynchronous cells, early S phase (treated with Thymidine), G2 phase (treated with the
CDK1 inhibitor RO-3306, ), and in mitotic cells (treated with the microtubule poison
Nocodazole). Greatwall protein levels were slightly increased in S phase in the HeLa
cells, something that was repeatedly seen after a Thymidine block in these cells. The
reason for this is not clear but is possibly as a result of the DNA replication block
causing cells with significant levels of Greatwall to build up in this cell cycle phase.
The RPE cells were not evaluated for Greatwall in S phase as they did not arrest in
response to Thymidine treatment. In the other cell lines Greatwall levels appeared
unchanged in S phase, while Greatwall levels seemed to be decreased in late G2 and
mitosis. This may be due to post-translational modifications (PTMs) of the protein in
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Figure 3.3 Greatwall characterisation in human cells
(A) SDS-PAGE analysis of HeLa, HEK 293T, HCT116 and RPE cell lysates from asynchronous (A) cells
or cells that had been treated with Thymidine (T), RO-3306 (R) or Nocodazole (N). The anti-Greatwall
antibody (the purified 4th immunisation sera from rabbit A; anti-GW) was used to probe for human
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Greatwall protein levels and an anti-α Tubulin antibody (anti-α Tub) was used as a loading control. The 
cell cycle (FACS/PI) profiles for HeLa, HEK 293T, HCT116 and RPE cells from asynchronous (Asn)
cells, cells that had been treated with Thymidine (+ Thy), RO3306 (+ RO) or Nocodazole (+ Noc) are
shown beneath. (B) SDS-PAGE analysis of HeLa cells synchronised by a double Thymidine block and
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then released for 10 hours. Samples were analysed using the anti-Greatwall antibody to probe for human
Greatwall protein levels and an anti-α Tubulin antibody was used as a loading control. The cell cycle 
(FACS/PI) profile of these cells at each hour time point are shown in the lower panel. Asynchronous (A)
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cells were analysed as well for comparison. (C) Flag-tagged Greatwall was expressed and
immunoprecipitated from HEK 293T asynchronous cells (Asyn) or cells that had been treated with
Thymidine (Thy), RO-3306 (RO), or with Nocodazole (Noc). Asynchronous cell lysates transfected with
GFP (GFP) were analysed as well for comparison. The top panel shows the immunoblot indicating the
expression of the flag-tagged protein from the cell lysates (L) or the immunoprecipitation (IP) detected
using the anti-Greatwall antibody. An in vitro kinase assay was performed and the autoradiograph is
shown in the second panel. The cell cycle (FACS/PI) profiles for all the cell lysates and untransfected
cells are shown in the bottom panel.
late G2 (at the G2/M transition) and mitosis, resulting in a poor transfer and a smear of
shifted bands with lower electrophoretic mobility. Therefore, Greatwall levels are likely
not decreased in late G2 or mitosis but the presence of activating PTMs prevented its
detection. In the G2 cells this could alternatively be a result of Greatwall protein levels
being kept at a low level until activation of CDK1 allows the cells to activate and
increase (or stabilise) Greatwall levels to allow progression into mitosis.
How Greatwall protein levels alter throughout the cell cycle was further
analysed using synchronised cells. HeLa cells were synchronised by a double
Thymidine block, then released and subsequently followed through their cell cycle for
10 hours. During this time samples were taken every hour and analysed for Greatwall
levels by immunoblotting (Figure 3.3 B). Greatwall expression levels remained
relatively stable, indicating that during the cell cycle Greatwall kinase levels largely
remain constant and that its predominant mode of regulation might be via PTMs
controlling the initiation and inhibition of its activity. These observations are supported
by work carried out by Burgess et al. (2010) and Voets et al. (2010) who also observed
that Greatwall protein levels were stable during the cell cycle and that it became
phosphorylated upon mitotic entry.
The transient overexpression of flag-tagged Greatwall in human HEK 293T cells
allowed analysis of the activity of Greatwall in different cell cycle phases. Flag-
Greatwall was transfected into HEK 293T cells and allowed to express for 24 hours.
The media was then replaced with fresh media or drug-containing media and the cells
incubated for 24 hours or overnight and then harvested. Flag-Greatwall was
immunoprecipitated using magnetic beads coated with an anti-flag antibody and the
purified kinase was then taken into an in vitro kinase assay using recombinant Myelin
Basic Protein (MBP) as a substrate. The lysates and immunoprecipitates were assessed
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for flag-Greatwall expression by immunoblotting and Greatwall kinase activity against
MBP was visualised on an autoradiograph (Figure 3.3 C). Interestingly, the levels of
exogenous protein again appeared reduced in G2 cells arrested using the CDK1
inhibitor RO-3306 as I previously also observed for the endogenous protein. The lysates
of the mitotically arrested cells exhibited an additional shifted band of higher molecular
weight Greatwall, confirming that Greatwall is modified in mitosis and the
overexpression of the flag construct allowed it to be detected here. The activity of
Greatwall was low overall in the asynchronous population and in S phase cells but was
increased in mitotically arrested cells, as judged by the autoradiographs shown in
Figure 3.3 C. Greatwall’s overall low activity from an asynchronous cell population is
likely due to the small percentage of mitotic cells present. It has little or no activity in S
phase arrested cells. It is difficult to conclude if Greatwall is active in the late G2 RO-
3306-mediated block as it was always only immunoprecipitated at very low levels. This
indicates that it might be unstable or modified so it cannot be assessed well by
immunoprecipitation in G2 in the absence of CDK1 activity. In the mitotic cells it was
shown to have high activity. That Greatwall is maximally active only in mitosis was
also reported by Voets et al. (2010). They observed a mitotic mobility shift that was
concomitant with the phosphorylation of APC/C subunit APC3 and was diminished by
treatment with λ phosphatase. This was also enhanced by treatment with okadaic acid. 
This suggests that Greatwall is subject to an activating phosphorylation event in mitosis
similar to that seen for Xenopus Greatwall.
3.4 Greatwall depletion leads to G2/M delay, mitotic defects and cytokinesis failure
Short interfering (si) RNA was used to target Greatwall mRNA to the RNA-
induced silencing complex (RISC) to achieve post-transcriptional gene silencing. HeLa
cells were transfected with Greatwall siRNA at 5 nM to 100 nM concentration. These
cells were then analysed 72 hours later by SDS-PAGE and FACS (Figure 3.4 A).
The immunoblot indicates that Greatwall levels had decreased below detectable
levels in cell lysates that had been treated with Greatwall siRNA as compared with
asynchronous untreated cell lysates. In lysates from cells treated with control non-
coding siRNA, Greatwall levels remained comparable with those seen in the untreated
cells ruling out this being a non-specific effect of the siRNA treatment. The
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Figure 3.4 Greatwall depletion in human cells
(A) SDS-PAGE analysis of HeLa cells that had been treated with Greatwall siRNA. Lysate from
asynchronous (Asyn) cells is loaded in the first lane followed by lysates from cells that had been treated
with 5, 10, 20, 50 and 100 nM Greatwall siRNA for 72 hours. Loaded in the final lane is lysate from cells
that were treated with 100 nM control (scrambled) siRNA (Cont) for 72 hours. The anti-Greatwall
antibody (anti-Greatwall) was used to probe for human Greatwall protein levels and an anti-α Tubulin 
antibody was used as a loading control. The cell cycle (FACS/PI) profiles for the asynchronous, control
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or Greatwall siRNA treated cells are shown beneath. (B) Images showing HeLa cells depleted of
Greatwall. Cells were treated with 25 nM Greatwall or control siRNA for 72 hours. HeLa cells were
probed with an anti-α Tubulin antibody (red) and the DNA stained with DAPI (pale blue). The maximum
projection from 0.3μm Z-sections are shown with scale bars of 50 μm. Quantification of the number of 
cells retaining single nuclei or that had become multinucleate is shown beneath. For this 75-100 cells
from three separate siRNA experiments were counted. (C) Representative images showing defects in
HeLa cells depleted of Greatwall. Cells were treated with 25 nM Greatwall or control siRNA for 72
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hours. HeLa cells were probed with an anti-α Tubulin antibody (green) and the DNA stained with DAPI 
(blue). The maximum projection from 0.3μm Z-sections are shown with scale bars of 10 μm. The inserts 
are magnified images of the DNA bridges seen.
corresponding cell cycle (FACS) profiles indicated that depletion of Greatwall resulted
in accumulation of the G2/M population of the cells, suggesting that human Greatwall,
similar to its Xenopus and Drosophila counterparts, is required for cell cycle
progression through mitosis.
Immunofluorescence analysis of the Greatwall depleted HeLa cells indicated
numerous defects (Figure 3.4 B and C). The images shown are from cells that had been
treated with Greatwall siRNA for 72 hours. At this time many of the cells had already
died and were subsequently washed away during the fixation treatment. A large
proportion of the cells that survived fixation appeared to have become multinucleate,
while cells treated with control siRNA exhibited few multinucleate cells (Figure 3.4 B).
Control siRNA treated cells showed only 5.7% polyploid cells while 39.3% of the
Greatwall depleted population had a 4n DNA content or greater. A similar accumulation
(40%) of cells with ≥4n DNA content and an increased cell death after Greatwall 
depletion were also reported by both Burgess et al. (2010) and Voets et al. (2010). It is
therefore conceivable that the accumulation of cells with 4n DNA content 72 hours after
Greatwall depletion was not only a result of an increased population of cells arrested at
G2/M and an increased mitotic index, but also the result of the accumulation of
multinuclear cells in which cytokinesis has failed. We also observed signs of abnormal
and aborted mitoses in the Greatwall depleted cells as well as DNA bridges between
daughter cells, further indicating a failure to complete mitosis and carry out efficient
cytokinesis (Figure 3.4 C). These observations have been subsequently supported by the
work of Burgess et al. (2010) and Voets et al. (2010) who carried out in depth
investigations, which are discussed in detail at the end of this chapter.
3.5 Greatwall overexpression
As a tool for Greatwall analysis stable HEK 293T cell lines overexpressing flag-
tagged Greatwall were generated. The presence of flag-Greatwall in two cell lines,
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Clone 1 (C1) and Clone 7 (C7), was confirmed by immunoblotting (Figure 3.5 A) and
by immunoprecipitation using anti-flag magnetic beads (Figure 3.5 B).
Both cell lines expressed Greatwall at much higher levels than the endogenous
protein. C1 had 6-fold overexpression and C7 had 13-fold overexpression as compared
to endogenous Greatwall levels in HEK 293T cells. These cell lines were assessed for
any cell cycle perturbation that might result from this increase in Greatwall expression.
The cell cycle (FACS) profiles for both cell lines were normal and growth curves for the
cell lines showed that they grew at the same rate (Figure 3.5 B and C). A single factor
analysis of variance (ANOVA) was performed on the growth data (shown in Appendix
B) which showed no significant main effect (F(2, 255) = 0.14, p = 0.87), indicating that
there is no significant difference between the growth of the wildtype HEK 293T cells
and the two cell lines’ growth. Thus, no adverse effects of Greatwall overexpression
were observed in either cell line, even at these elevated expression levels. Greatwall
overexpression from our observations with these stable cell lines and from transient
overexpression by transfection seems well tolerated in human cells. Its activity here is
likely highly regulated and, as such, simply overexpressing Greatwall might not have a
relevant effect on the cell cycle. A more detailed investigation, perhaps using additional
cell lines and with Greatwall mutants with aberrant activity that cannot be regulated,
could be more informative as to possible phenotypes associated with inappropriate
(high) Greatwall activity.
The C7 cell line was used to assess Greatwall activity in an in vitro kinase assay.
The cells were treated with the CDK1 inhibitor RO-3306 to arrest them in G2, the
PLK1 inhibitor BI2536 to arrest them in mitosis or with both drugs for 24 hours. Flag-
Greatwall was then immunoprecipitated and taken into an in vitro kinase assay with
recombinant MBP as a substrate (Figure 3.5 D). Greatwall had high activity in the
mitotic BI2536-treated lysates and was phospho-shifted on the immunoblot. These data
supports findings in Xenopus (Yu et al. 2006) that Greatwall is phosphorylated and
active in mitosis. The activation of Greatwall in mitosis appears independent of PLK1
activity. Where the cells were treated with RO-3306 and BI2536 together the FACS
profile indicates that the cells arrested in G2 and therefore Greatwall was likely not
active, although its levels again appear lower in the immunoprecipitate upon RO-3306
treatment as previously discussed. The high overexpression of Greatwall in these cells
did not effect its activation, further supporting the hypothesis that Greatwall activation
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Figure 3.5 Greatwall overexpression in human cells
(A) SDS-PAGE analysis of HEK 293T (HEK) and stable cell lines, C1, C6 and C7 indicating their
expression of flag-Greatwall at passage 1. The anti-Greatwall antibody (anti-Greatwall) and an anti-Flag
antibody was used to probe for flag-Greatwall protein levels in these clones and an anti-α Tubulin 
antibody was used as a loading control. C1 and C7 highly overexpress flag-Greatwall while C6 was not
targeted (B) Flag-tagged Greatwall immunoprecipitated from HEK 293T (HEK) and stable cell line
clones, C1, C6 and C7. The immunoblot indicates the expression of the flag-tagged protein from the cell
lysates (L) or the immunoprecipitation (IP) detected using the anti-Greatwall antibody (anti-Greatwall),
and an anti-α Tubulin antibody (anti-α Tub) was used as a loading control. The cell cycle (FACS/PI) 
profiles for the HEK 293T and stable cell lines are shown beneath. (C) Growth curves of HEK 293T and
stable cell lines C1 and C7. These were generated using an IncuCyte (ESSEN Biosciences). Nine
different points from 6 wells of a 24-well plate were measured every 3 hours for 255 hours. (D) Stable
cell line C7 was used to investigate Greatwall activity. Flag-tagged Greatwall was immunoprecipitated
from asynchronous (Asyn) cells or cells that had been treated with RO-3306 (RO) or BI2536 (BI) or both
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drugs (RO+BI). Asynchronous cell lysates transfected with GFP (GFP) were analysed as well for
comparison. The top panel shows the immunoblot indicating the expression of the flag-tagged protein
from the cell lysates (L) or the immunoprecipitation (IP) detected using the anti-Greatwall antibody. An
in vitro kinase assay was performed using MBP as a substrate. The autoradiograph is shown in the second
panel. The cell cycle (FACS/PI) profiles for all the cell lysates are shown in the bottom panel.
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is highly regulated by PTMs and that this restricts its activity specifically to mitosis in
human cells.
3.6 Conclusions and discussion
Here I generated tools that allowed the characterisation of Greatwall in human
cells. Rabbit polyclonal antibodies were produced that detected human Greatwall at
~110 kDa on immunoblots of human cell lysates. Human Greatwall cDNA was cloned,
flag-tagged and expressed in human cell lines, and in vitro kinase assays to analyse
Greatwall activity were developed. These tools allowed the investigation of human
Greatwall expression and activity.
I found that Greatwall protein levels remain relatively constant throughout the
cell cycle. It is instead tightly regulated by post-translational modifications that activate
it at the G2/M transition in the presence of CDK1 activity. Depletion of Greatwall in
human cells causes a delay or arrest in G2. Cells that do enter mitosis exhibit multiple
defects and either die due to mitotic catastrophe or exhibit chromosomal alignment
defects, segregation defects, cytokinesis defects and aberrant mitotic exit that leads to
multinucleate cells. Conversely Greatwall overexpression is well tolerated in human
HEK 293T cells and points to the regulation of Greatwall activity by PTMs as key for
its function.
While work on this thesis was underway Burgess et al. (2010) and Voets et al.
(2010) published detailed characterisations of Greatwall localisation and its depletion
phenotypes in human cells, that are in agreement with my findings. These studies
characterised Greatwall localisation and described the effects of Greatwall depletion in
human cells in greater depth than is explored here. The publication of these reports led
to a decision to investigate other aspects of human Greatwall biology in this work.
Briefly, as reported from work in Drosophila, their investigations of human
Greatwall found that the kinase is predominantly present in the nucleus of interphase
cells (Yu et al. 2004; Burgess et al. 2010; Voets et al. 2010). Although they additionally
observed persistent partial cytoplasmic localisation as well as localisation at the
centrosomes of G1, S and G2 phase cells (Burgess et al. 2010; Voets et al. 2010).
Mitotic cells display an enhanced signal that spreads diffusely throughout the cell upon
nuclear envelope breakdown but is excluded from the chromosomes. Greatwall is also
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concentrated at spindle poles in early mitosis and Burgess et al. (2010) also observed
that Greatwall emanated out along the spindle fibers as the cells entered mitosis. Once
cells are in anaphase Greatwall leaves the spindle becoming increasingly diffuse
throughout the cell. During telophase and cytokinesis it localises in the nucleus as the
nuclear envelope reforms, although a small proportion localises to the cleavage furrow
and midzone microtubules where it is also occasionally detected at the midbody
(Burgess et al. 2010; Voets et al. 2010).
These studies also confirmed that Greatwall depleted cells released from an S
phase block induced using Thymidine showed delayed entry into mitosis and then
further delayed progression into anaphase (Burgess et al. 2010; Voets et al. 2010). In
mitosis, cells depleted of Greatwall showed significant chromosome abnormalities. In
metaphase cells displayed under-condensed chromatin scattered along the spindle or, in
cases where they had managed to condense their chromosomes, they failed to correctly
align them on the metaphase plate. Many cells arrested in metaphase for long periods
after which they died or performed an aberrant anaphase. This delay was likely due to
activation of the SAC as the checkpoint proteins (BubR1 and Aurora B) were localised
to the kinetochores in these cells (Burgess et al. 2010). Few cells were observed in
anaphase, but those that were had lagging chromosomes and displayed chromosome
bridges. The spindles appearance was relatively normal in these cells, although in some
cases the spindles were slightly elongated with lower numbers of microtubules and were
observed by live cell imaging to rotate dynamically several times within the cell. The
defects seen in cells that had exited mitosis are indicative of a cytokinesis failure. DNA
bridges trapped in the cleavage furrow suggest problems with abscission that ultimately
lead to retraction of the cleavage furrow and formation of 4n cells, suggesting a role for
Greatwall in sister chromatid separation (Burgess et al. 2010; Voets et al. 2010).
The severity of the depletion phenotype observed correlated with the level of
depletion achieved. As the level of Greatwall knockdown increased the ability of cells
to remain in and perform efficient mitosis decreased. In synchronised cells depleted of
Greatwall, progression through S phase occurred with normal kinetics but showed
delayed entry into mitosis that corresponded to the level of Greatwall depletion. In the
most severe cases, in which Greatwall knockdown was greatest, the delay in entry into
mitosis was greatest, indicating that increasing Greatwall depletion results in an
increased G2 arrest (Burgess et al. 2010; Voets et al. 2010).
Immunoblotting revealed that Greatwall depletion did not prevent the loss of
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inhibitory phosphorylation on CDK1 in mitotic cells but did enhance mitotic
phosphatase activity. This was shown by the diminished presence of mitotic phospho-
epitopes in Greatwall depleted mitotic cells (Voets et al. 2010). The double depletion by
siRNA of Greatwall and PP2A resulted in rescue of mitotic phospho-epitopes. Also the
addition of okadaic acid to Greatwall depleted synchronised cells rescued the delayed
mitotic entry defect and allowed depleted cells to enter mitosis with normal kinetics
(Burgess et al. 2010). Thus indicating that increased PP2A phosphatase activity
mediates the Greatwall knockdown phenotype.
Taken together, these data indicates that Greatwall is required in human cells to
regulate PP2A activity to promote and maintain mitosis. This role for human Greatwall
fits well with the current understanding of Drosophila and Xenopus Greatwall function
and indicates that human Greatwall is their functional homologue.
Greatwall interacts with PP2A via its substrates Arpp19 and Ensa in Xenopus
(Gharbi-Ayachi et al. 2010; Mochida et al. 2010). Accordingly, Arpp19 knockdown
using siRNA in HeLa cells released from a Thymidine block into Nocodazole showed a
50% decrease in the number of mitotic cells compared with controls (Gharbi-Ayachi et
al. 2010). This suggests that this pathway is highly conserved and that Greatwall
regulates mitotic entry by Arpp19/Ensa mediated inhibition of PP2A.
Historically, entry into mitosis has been thought to be regulated exclusively by
CDK1 activation and positive feedback loops. The emergence of the role of Greatwall
in mitotic entry has highlighted that in fact it is the balance of CDK activation and
phosphatase inhibition that coordinate to allow timely and proficient mitotic entry. The
data and studies cited here indicate that Greatwall is a highly evolutionary conserved
regulator of mitosis in higher eukaryotes including humans.
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CHAPTER 4. Understanding the mechanisms of activation of Greatwall
4.1 Introduction
Protein kinases are key signalling enzymes that make up two percent of the
proteins encoded in eukaryotic genomes and represent the third most common protein
domain in the human genome (Hunter et al. 1997; Plowman et al. 1999; Morrison et al.
2000; Manning et al. 2002). In order to classify and distinguish between kinases they
are grouped into distinct families based on their catalytic domain amino acid sequences
(Hanks et al. 1991).
Greatwall is a member of the AGC kinase family (Hanks et al. 1995; Yu et al.
2004). An alignment of its N- and C- lobes with other AGC kinases is shown in Table
4.1. This is a diverse family of serine/threonine kinases that phosphorylate target amino
acids C-terminal to basic amino acids (Hanks et al. 1995). These were first described in
1995 as a family of kinases that are related to cAMP-dependant protein kinase 1 (PKA),
cGMP-dependant protein kinase (PKG) and protein kinase C (PKC). There are at least
60 AGC kinases and in many cases multiple isoforms and splice variants exist that add
to the complexity in this family (Hanks et al. 1995; Manning et al. 2002; Pearce et al.
2010). The AGC kinase family phosphorylate a vast array of cellular substrates and
regulate numerous cellular processes including cell division, survival, metabolism,
transmembrane ion flux, migrative behaviour and differentiation (Sturgill et al. 1988;
Kobayashi et al. 1999; Park et al. 1999; Flynn et al. 2000; Williams et al. 2000).
Intricate and diverse mechanisms control their activity. These are often mediated by key
functional domains outside of the catalytic core. These are critical to facilitate AGC
kinases localisation and association with their activators and substrates (Frodin et al.
2000; Williams et al. 2000; Frodin et al. 2002). The phosphorylated targets of these
kinases are often distinct as well as overlapping. The AGC kinases are further divided
into 21 subfamilies based on their homology outside of the kinase domain (Pearce et al.
2010). One of these is the MAST kinase family that includes Greatwall (as described in
Chapter 3).
The vast array of important cellular functions that these kinases are involved in
means that, conversely, deregulation of these enzymes can lead to human diseases such
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Table 4.1 Multiple sequence alignment
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as diabetes and cancer (Cho et al. 2001; Sano et al. 2003; Carpten et al. 2007; Maurer et
al. 2009). Protein kinases have recently emerged as major targets for drug development
and comprise almost a third of newly validated targets by the pharmaceutical industry
(Cohen 2002). This makes the AGC family of kinases important potential new targets of
great relevance to our understanding of health and disease.
That Greatwall has been implicated in human disease and seemingly has critical
importance in control of entry into and progression through mitosis, makes it an
attractive target. Key to understanding how it functions is to unlock the mechanisms
controlling its activity. In this chapter I use structural modeling, phosphorylation site
mapping and mutagenic analysis to gain insight into the mechanisms that regulate
Greatwall.
4.2 The structure of AGC kinases
The kinase core of AGC kinases is a bilobal kinase fold that comprises a small
amino-terminal lobe (N-lobe) and a larger carboxy-terminal lobe (C-lobe). This gives
the catalytic core of these kinases a characteristic ‘bean-like’ structure. The kinase
domain can be further split into 12 subdomains that are defined by possessing
characteristic patterns of conserved residues that are not interrupted by large amino acid
insertions. The N-lobe is comprised of kinase subdomains I-IV and has a predominantly
anti-parallel β-sheet structure. It serves primarily to anchor and orientate the nucleotide. 
The C-lobe contains subdomains VIA-XI and has a predominantly α-helical structure. 
This lobe is responsible mainly for binding the substrate and initiating phospho-transfer.
Subdomain V residues span the lobes (Hanks et al. 1995; Pearce et al. 2010).
The two lobes sandwich a molecule of ATP in the cleft between them. ATP
binds via the glycine rich loop in the N-lobe (Hirai et al. 2000). The ATP molecule then
serves as the phosphate donor. Its adenine ring lies deep in the cleft directing the γ-
phosphate outward which is transferred to the acceptor hydroxyl group of a specific
serine or threonine residue of the substrate protein (Figure 4.1). It is common for
protein kinases to posses N-terminal and C-terminal extensions from the catalytic core
that can fold back into the core forming important and specific interactions. The AGC
kinases possess such extensions that serve to promote both their activation and their
stability (Hanks et al. 1995; Huse et al. 2002; Pearce et al. 2010).
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Figure 4.1 Phosphorylation by protein kinases
A protein kinase transfers the terminal phosphate of ATP to a hydroxyl group on a substrate protein.
Many AGC kinases have two common activation mechanisms mediated by
highly conserved regulatory motifs (Figure 4.2). One is a key phosphorylation within
their activation segment, known as the activation or T-loop, on a serine or threonine.
The other is a phosphorylation in the conserved tail region C-terminal to the kinase
domain, known as the hydrophobic motif. The activation loop is located adjacent to the
ATP-binding site, usually in the C-lobe. It contains critical elements for catalytic
activity including the DFG (Asp-Phe-Gly) motif that, with the glycine rich loop,
positions the ATP for phospho-transfer. The aspartic acid of the DFG motif binds
magnesium (Mg2+) ions which in turn coordinate the β- and γ-phosphates of ATP while 
the glycine rich loop forms the ceiling of the active site (Johnson et al. 1996; Pearce et
al. 2010). The activation loop is linked to the N-lobe through the αC helix that 
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Figure 4.2 Modelling Greatwall kinase domain structure
(A) Structural model of PKCβII displaying the key structural features of AGC kinases. Here the small N-
lobe (aqua), large C-lobe (orange), αC helix, activation loop (grey), C-terminal extension containing the 
turn motif and hydrophobic motif (pink), substrate binding grove and αG helix, are indicated. The three 
important regulatory phosphorylations are shown in ball-and-stick representation (red) and a competitive
inhibitor of ATP is shown in the ATP-binding site in green. This and all other molecular graphics figures
were produced with the help of Dr. Anthony Oliver using MacPyMOL (DeLano Scientific). (B)
Structural model of Greatwall kinase. This model was generated using the modelling software PHYRE
and coloured as for (A). The C-terminal extension leading up to the hydrophobic motif could only be
partially modelled and is shown in pink. One molecule of ADP is shown in the ATP-binding site in green.
The activation loop is coloured grey, with the unmodelled region between the lobes where the large
middle insertion of amino acids are likely looped out is indicated by the dashed lines and grey
parenthesis. The active site magnesium ion is shown as a magenta sphere and the side chains for the
conserved lysine and glutamic acid (K62 and E81) that position the γ-phosphate of ATP for phospho-
transfer are indicated by ball-and-stick representation.
undergoes conformational changes upon phosphorylation for the activation loop. This
allows a key glutamic acid residue in the αC helix to form an ion pair with a conserved 
lysine residue in the N-lobe. This creates a network of hydrogen bonds that are critical
for catalytic activity and to allow positioning of the ATP γ-phosphate for phospho-
Hydrophobic
motif in pocket
Turn motif
phosphorylation
Activation loop
Substrate binding
grove
ATP binding
site
C-lobe
N-lobe
αG helix, substrate  
interaction
αC helix 
C-lobe
N-lobe
ATP binding
site
Activation
loop
Inserted amino
acids
K62 E81
B GreatwallA PKC
114
CHAPTER 4
transfer. A hydrophobic pocket in the N-lobe, part of which is formed by the αC helix, 
mediates important regulatory interactions with the hydrophobic motif. The
hydrophobic motif is formed by an extension from the C-lobe, in the C-terminal tail. In
the active kinase this wraps around the N-lobe and stabilises the active conformation of
the αC helix by inserting two aromatic residues into the hydrophobic motif pocket. In 
this manner the activation loop and the hydrophobic motif act together to help position
the αC helix in the active conformation. In most AGC kinases a turn motif precedes the 
hydrophobic motif in the C-terminal tail. This assists the positioning of the C-terminal
tail allowing it to correctly fold around the whole of the N-lobe and increases the local
concentration of the hydrophobic motif at the hydrophobic motif pocket. For this reason
phosphorylation of the turn motif and presence of the corresponding positively charged
patch of the N-lobe are required for full kinase activity. AGC kinases can interact with
their substrates in different ways but a grove close to the active site is known to be
involved in binding the substrate. The residues forming this grove likely determine
sequence specificity of the kinase. In addition, an αG helix that protrudes from the C-
lobe has been implicated in substrate interactions (Knighton et al. 1991; Hanks et al.
1995; Biondi et al. 2002; Frodin et al. 2002; Yang et al. 2002; Biondi et al. 2003; Sano
et al. 2003; Komander et al. 2005; Pearce et al. 2010).
Many AGC kinases have two common activation mechanisms mediated by
highly conserved regulatory motifs. One is a key phosphorylation within their activation
segment, known as the activation or T-loop, on a serine or threonine. The other is a
phosphorylation in the conserved tail region C-terminal to the kinase domain, known as
the hydrophobic motif. The activation loop is located adjacent to the ATP-binding site,
usually in the C-lobe. It contains critical elements for catalytic activity including the
DFG (Asp-Phe-Gly) motif that, with the glycine rich loop, positions the ATP for
phospho-transfer. The aspartic acid of the DFG motif binds magnesium (Mg2+) ions
which in turn coordinate the β- and γ-phosphates of ATP while the glycine rich loop 
forms the ceiling of the active site (Johnson et al. 1996; Pearce et al. 2010). The
activation loop is linked to the N-lobe through the αC helix that undergoes 
conformational changes upon phosphorylation for the activation loop. This allows a key
glutamic acid residue in the αC helix to form an ion pair with a conserved lysine residue 
in the N-lobe. This creates a network of hydrogen bonds that are critical for catalytic
activity and to allow positioning of the ATP γ-phosphate for phospho-transfer. A 
hydrophobic pocket in the N-lobe, part of which is formed by the αC helix, mediates 
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important regulatory interactions with the hydrophobic motif. The hydrophobic motif is
formed by an extension from the C-lobe, in the C-terminal tail. In the active kinase this
wraps around the N-lobe and stabilises the active conformation of the αC helix by 
inserting two aromatic residues into the hydrophobic motif pocket. In this manner the
activation loop and the hydrophobic motif act together to help position the αC helix in 
the active conformation. In most AGC kinases a turn motif precedes the hydrophobic
motif in the C-terminal tail. This assists the positioning of the C-terminal tail allowing it
to correctly fold around the whole of the N-lobe and increases the local concentration of
the hydrophobic motif at the hydrophobic motif pocket. For this reason phosphorylation
of the turn motif and presence of the corresponding positively charged patch of the N-
lobe are required for full kinase activity. AGC kinases can interact with their substrates
in different ways but a grove close to the active site is known to be involved in binding
the substrate. The residues forming this grove likely determine sequence specificity of
the kinase. In addition, an αG helix that protrudes from the C-lobe has been implicated 
in substrate interactions (Knighton et al. 1991; Hanks et al. 1995; Biondi et al. 2002;
Frodin et al. 2002; Yang et al. 2002; Biondi et al. 2003; Sano et al. 2003; Komander et
al. 2005; Pearce et al. 2010).
The importance of the phosphorylation-dependant interactions in allowing
kinase integrity and activity has been highlighted by the inactive conformations of these
kinases. Once active, the kinase fold forms an ordered and conserved catalytic core unit.
When the kinases are inactive, however, their conformations can be highly diverse. In
the inactive state the hydrophobic motif pocket, the αC helix and most of the activation 
segment can be highly flexible and disordered. These differing inactive conformations
allow individual AGC kinases to mediate interactions with various different cellular
compartments, activators and substrates (Huse et al. 2002; Yang et al. 2002; Pearce et
al. 2010).
4.3 Modelling Greatwall kinase
Little was known about the mechanisms promoting Greatwall activation when
this work began. What was known was based on work in Xenopus that indicated that
Greatwall was activated by phosphorylation in mitosis (Yu et al. 2006; Zhao et al.
2008). To build on this and increase our understanding of Greatwall’s regulation a
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structural model of human Greatwall was generated. All positions of amino acid
residues refer to human Greatwall kinase and relate to this model, unless otherwise
stated.
This model was created in collaboration with Dr Anthony Oliver at the Genome
Damage and Stability Center (GDSC), University of Sussex. This was produced using
the computational protein structure prediction engine, the Protein Homology/analogY
Recognition Engine (PHYRE) (Kelley et al. 2009). This generates a 3-dimensional (3D)
model based on protein threading (or fold recognition) and can be used to generate
models for proteins that have no homologues with known structure. Structural
prediction is made in this case by aligning, or ‘threading’, amino acids from the target
sequence onto a template structure and then evaluating how well the target matches the
template. In this manner a ‘best-fit’ template is selected from known structures and a
model of the target sequences structure is built based on its alignment with this chosen
template (Kelley et al. 2009). The catalytic core of Greatwall was modeled in this
manner using the α isoform of PKC, another AGC family kinase, as the ‘best-fit’ 
template (Figure 4.2 B).
The amino acid sequence alignment revealed that active kinase core likely
comprises the first 36 to 195 amino acid residues (N-lobe) and the last amino acid
residues 737 to 849 (C-lobe) (Figure 4.3). These regions are highly conserved between
human, Drosophila and Xenopus Greatwall kinases (for full alignment of these proteins
see Appendix C). The two lobes then fold together effectively looping out the middle
amino acids (residues 196 to 736). These residues between the N- and C-lobes represent
a large insertion between the lobes of 540 amino acids with as yet unknown function. In
this model the glycine rich loop (ISRGAFGKV) is formed by amino acids 41 to 49 and
the DFG motif is formed by amino acids 174 to 176. The ion pair required to coordinate
the Mg2+ ion and position the ATP γ-phosphate for phospho-transfer is formed by lysine 
62 (K62) in the N-lobe and glutamic acid 81 (E81) from the αC helix. At the end of the 
C-lobe amino acids 854 to 878 form an AGC kinase C-terminal tail that contains the
hydrophobic motif (residues 853 to 875).
Greatwall is not a conventional AGC kinase due to its large region of inserted
amino acids between the two lobes of the kinase domain , between kinase subdomains
VII and VIII (Burgess et al. 2010) where the activation loop is typically located. Our
model indicates that part of this region forms the activation loop but much of this
insertion could not be modelled. Structural prediction software indicates that it has no
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Figure 4.3 Mapped features of Greatwall
The kinase domain lobes and hydrophobic motif are coloured as in Figure 4.2 B. The glycine rich loop,
DFG motif, ion pair (K62 and E81) are indicated. Residues mutated in this investigation are indicated by
diamond parentheses.
sequence similarity with any known protein folds and it is poorly conserved between
human, Drosophila and Xenopus Greatwall kinases (see Appendix C). It is interesting
1 MDPTAGSKKEPGGGAATEEGVNRIAVPKPPSIEEFSIVKPISRGAFGKVY
51 LGQKGGKLYAVKVVKKADMINKNMTHQVQAERDALALSKSPFIVHLYYSL
101 QSANNVYLVMEYLIGGDVKSLLHIYGYFDEEMAVKYISEVALALDYLHRH
151 GIIHRDLKPDNMLISNEGHIKLTDFGLSKVTLNRDINMMDILTTPSMAKP
201 RQDYSRTPGQVLSLISSLGFNTPIAEKNQDPANILSACLSETSQLSQGLV
251 CPMSVDQKDTTPYSSKLLKSCLETVASNPGMPVKCLTSNLLQSRKRLATS
301 SASSQSHTFISSVESECHSSPKWEKDCQESDEALGPTMMSWNAVEKLCAK
351 SANAIETKGFNKKDLELALSPIHNSSALPTTGRSCVNLAKKCFSGEVSWE
401 AVELDVNNINMDTDTSQLGFHQSNQWAVDSGGISEEHLGKRSLKRNFELV
451 DSSPCKKIIQNKKTCVEYKHNEMTNCYTNQNTGLTVEVQDLKLSVHKSQQ
501 NDCANKENIVNSFTDKQQTPEKLPIPMIAKNLMCELDEDCEKNSKRDYLS
551 SSFLCSDDDRASKNISMNSDSSFPGISIMESPLESQPLDSDRSIKESSFE
601 ESNIEDPLIVTPDCQEKTSPKGVENPAVQESNQKMLGPPLEVLKTLASKR
651 NAVAFRSFNSHINASNNSEPSRMNMTSLDAMDISCAYSGSYPMAITPTQK
701 RRSCMPHQTPNQIKSGTPYRTPKSVRRGVAPVDDGRILGTPDYLAPELLL
751 GRAHGPAVDWWALGVCLFEFLTGIPPFNDETPQQVFQNILKRDIPWPEGE
801 EKLSDNAQSAVEILLTIDDTKRAGMKELKRHPLFSDVDWENLQHQTMPFI
851 PQPDDETDTSYFEARNTAQHLTVSGFSL
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to note that a large majority (70%) of the insertion is encoded by a single large exon in
the Greatwall (MASTL) gene (exon 8, residues 329 to 708, Appendix D). This leads us
to postulate that it could represent a gene fusion event. The resulting protein, Greatwall,
would therefore represent a hybrid gene product, although searches for sequences
homologous to this exon sequence return no results. At present the origin of this unique
type of bifurcated kinase structure and the functions of the large insertion remain
obscure.
4.4 Identification of the activation loop
The structural model of Greatwall kinase allowed the identification of the
activation loop and positioning of the DFG motif. Any threonine or serine after this
motif might represent the phosphorylation of the activation loop critical for kinase
activity. This phosphorylation is mediated by upstream kinases and begins AGC kinase
activation. It serves to promote conformational changes that are critical for kinase
activity as discussed in section 4.2 (Johnson et al. 1996; Pearce et al. 2010). A threonine
at position 194 (T194) was identified that might represent the candidate phosphorylated
residue. This was guided in part by phosphorylation site mapping analysis of Greatwall
using PhosphoSitePlus (http://www.phosphosite.org). This is an online systems biology
resource for the study of protein PTMs. It provides an extensive, manually curated
database indicating phosphorylation sites and other PTMs that have been identified
from both high-throughput and low-throughput articles and reports (Hornbeck et al.
2012). The output of this analysis is shown in Figure 4.4. This indicated that the first
residue that is likely to be phosphorylated after the DFG motif is T194. This informed
our prediction that T194 would be phosphorylated in the activation loop and therefore
be critical for kinase activity.
In order to test this prediction, I mutated T194 to an alanine (T194A) by site-
directed mutagenesis. The chemically inert methyl functional group of the alanine
residue cannot be phosphorylated and allows the significance of the phosphorylation of
this residue on the activity of the kinase to be assessed. T194 lies adjacent to another
threonine residue, T193, that might also be phosphorylated and contribute to kinase
activation. This was also mutated to alanine (T193A) and a double mutant in which both
of these residues were mutated to alanines (T193/4A) was also generated. The non-
119
CHAPTER 4
Figure 4.4 Phosphorylation site mapping of Greatwall
Phosphorylation site mapping analysis of Greatwall using PhosphoSitePlus. Sites with only one mass
spectrometry (MS)/high-throughput (HTP) reference are shown in black. Sites with more than one
MS/HTP reference are shown in blue and a site with more than five MS/HTP references is indicated in
pink. The kinase domain lobes and hydrophobic motif are indicated coloured as in Figure 4.2 B.
phosphorylatable mutants T193A, T194A and T193/4A were flag-tagged and
transfected into human HEK 293 cells. Wildtype flag-Greatwall (WT Greatwall) was
also transfected into these cells to provide a bench mark for full kinase activity. The
cells were then allowed to express the tagged proteins for 24 hours. After this, the media
was then replaced with media containing the spindle poison Nocodazole and the cells
incubated for a further 16 hours. This served to arrest the cells in mitosis at the time
when Greatwall is maximally active as determined in Chapter 3 (Figure 3.3). The cells
were harvested and the flag-tagged active protein immunoprecipitated using magnetic
beads coated with an anti-flag antibody. The purified kinase was then taken into an in
vitro kinase assay using recombinant MBP as an arbitrary substrate. The lysates and
immunoprecipitates were assessed for flag-Greatwall expression by immunoblotting
and Greatwall kinase activity against MBP was visualised on an autoradiograph (Figure
4.5 A). No band-shift of active Greatwall is observed on the resulting immunoblots as
the exposure shown is relatively short and indicates the main bands of Greatwall only.
In longer (but overexposed) images a band-shift can be seen. This suggests that only a
proportion of Greatwall is in the highly active (up-shifted) state at any one time while in
mitosis. The T194A mutant had severely reduced activity with only 32% of WT
Greatwall’s kinase activity (normalised for protein amount) while T193A had around
70% activity (that varied up to 95% of WT activity). The double mutant had 27% of
WT kinase activity and is not significantly different to that of T194A. These results
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Figure 4.5 Determination of the phosphorylation events that begin Greatwall kinase activation
(A) Flag-tagged Greatwall or non-phosphorylatable mutants T193A, T194A and T193/4A were expressed
in human HEK 293T cells. Cells transfected with a GFP control were analysed as well. After 24 hours the
cells were treated with Nocodazole. The flag-tagged proteins were then immunoprecipitated using anti-
B
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flag magnetic beads. An in vitro kinase assay was then performed using MBP as a substrate for the
kinase. The top panel shows the results of SDS-PAGE analysis indicating the expression of the flag-
tagged protein in the cell lysates (L) and the immunoprecipitate (IP) detected using the anti-Greatwall
antibody. The autoradiograph is shown in the second panel. Quantification of the kinase activity of the
mutant kinases relative to the wildtype is shown in the graph beneath. This represents results averaged
from three independent experiments and the standard deviation is represented by the error bars. (B) Flag-
tagged Greatwall or mutants T741S and T741A were expressed in HEK 293T cells, immunoprecipitated
and taken into a kinase assay as described for (A).
imply that T193 does not significantly contribute to kinase activation and its mutation
does not synergise with the loss of activity seen when T194 is mutated in combination
with this residue. This indicates that T194 is a phosphorylated residue that is important
for Greatwall kinase activity and is likely part of the kinase activation loop as predicted.
This was further supported by a recent publication in which this residue, T194,
was also found to be essential for Greatwall kinase activation (Blake-Hodek et al.
2012). Here they carried out mutagenesis of Xenopus Greatwall. They also concluded
that T194 (T193 in Xenopus) formed part of the kinase activation loop of Greatwall.
The authors reported the same result as obtained here, that mutation of T194 to an A
severely disrupted kinase activity and furthermore its function. In Xenopus CSF extracts
expression of the A mutant led to failure to sustain M phase when endogenous
Greatwall had been depleted (Blake-Hodek et al. 2012). Together, this provides
evidence that T194 is an important phosphorylated residue of the Greatwall kinase
activation loop and is required for kinase activity in mitosis.
4.5 Identification of a second site important for Greatwall activity
Threonine 740 (T740) was identified by phospho-site mapping and structural
analysis to also be a potentially significant residue that requires phosphorylation for full
activation of Greatwall (Figure 4.4). In order to test this proposal, I mutated T740 to an
A, expressed it with a flag-tag and immunoprecipitated the protein from human cells
arrested in mitosis. A kinase assay was then performed to assess its activity as described
previously (in section 4.4). The mutant, T740A, again severely disrupted Greatwall
kinase activity and displayed only 44% of WT kinase activity (Figure 4.5 B). This was
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not rescued by mutation of this site to another phosphorylatable residue, in this case to a
serine (S). The T740S mutant displayed a similar reduction in kinase activity (39%) as
T740A when compared to WT Greatwall. The failure of this phosphorylatable mutation
to restore kinase activity might reflect a specific structural requirement of the kinase for
a T at this position rather than a direct requirement for this site to be phosphorylated.
T740 was identified as an important phospho-residue in Greatwall in three
studies published during the course of this work. Each of these found that mutation of
this residue to an A disrupted kinase activity to a similar degree as reported here and
that this led to failure to support M phase in Xenopus egg extracts after endogenous
Greatwall depletion (Yu et al. 2006; Vigneron et al. 2011; Blake-Hodek et al. 2012).
This implies that this residue is necessary for Greatwall function and might represent a
critical element of the P+1 loop rather than forming part of the activation loop itself.
The P+1 loop is a small motif that usually resides immediately downstream of the
activation loop. It is implicated in substrate sequence recognition and is thought to bind
a substrate residue C-terminal of the residue to be phosphorylated. A phospho-mimetic
mutant of this residue, T740E, in Xenopus displayed no function, further supporting the
proposal that this site does not represent an important activation loop phosphorylation
(Blake-Hodek et al. 2012). It indicates an intolerance of Greatwall activity for amino
acid substitutions at this position. This is therefore likely to be because it is an important
residue in the P+1 loop and represents a site critical for substrate interaction (Nolen et
al. 2004; Hauge et al. 2007; Vigneron et al. 2011; Blake-Hodek et al. 2012).
4.6 Other structural features of Greatwall kinase
The primary aim of this work was to understand the mechanisms involved in
Greatwall activation and we began our investigation by attempting to determine key
activating phosphorylations of the kinase, based on those described for other AGC
kinases. As mentioned earlier, as this work was coming to fruition, another paper was
published by Vigneron et al. (2011) also detailing Greatwall’s activation mechanisms.
In this paper they investigated human Greatwall kinase by mutating residues that are
highly conserved in other eukaryotic serine/threonine kinases to assess if Greatwall
could function as a typical AGC kinase. Initially they mutated a conserved glycine
residue (G44) found in the glycine rich loop (Figure 4.3) to a serine and analysed the
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mutant for kinase activity. The glycine rich loop covers and anchors the nontransfered
α- and β-phosphates of the ATP leaving the γ-phosphate exposed and positioned 
appropriately for phospho-transfer (Hanks et al. 1995; Pearce et al. 2010). In their study
they over expressed HA-tagged human Greatwall or mutant Greatwall in Xenopus CSF
extracts and carried out in vitro kinase assays using MBP as a substrate (Vigneron et al.
2011). They also performed rescue experiments, in which they introduced the HA-
tagged mutant Greatwall into Xenopus CSF extracts that had been depleted of
endogenous Greatwall. They then assessed the ability of the mutants to sustain the
mitotic phenotype in these extracts. Analysis of the G44S mutant showed that it
exhibited only 5% of WT Greatwall activity and was incapable of maintaining M phase
in CSF extracts, indicating that the glycine rich loop is critical for Greatwall kinase
activity. They also mutated lysine 62 (K62) that forms the ion pair with the glutamic
acid in the αC helix to coordinate a network of hydrogen bonds required for catalytic 
activity (Figure 4.2 and 4.3) (Hanks et al. 1995; Pearce et al. 2010). Mutation of this
residue to an alanine resulted in only 8% of kinase activity remaining as compared with
WT Greatwall. The mutant was not able to support the mitotic state in CSF extracts and
thus rendered the kinase non-functional (Hanks et al. 1995; Pearce et al. 2010;
Vigneron et al. 2011). The importance of these two key residues for Greatwall activity
indicate the conservation of key AGC kinase structural features in Greatwall kinase, in
agreement with the results presented already in this work.
4.7 Identification of the hydrophobic motif
The hydrophobic motif is characterised by three aromatic residues surrounding a
phosphorylated serine or threonine residue. This can be phosphorylated by another
kinase or result from autophosphorylation by the kinase itself. Once phosphorylated, in
addition to contributing to kinase activity itself, it can serve as a docking site for other
kinases that when bound, enhance or mediate the catalytic activity of the kinase (Frodin
et al. 2002; Pearce et al. 2010).
The AGC C-terminal tail of Greatwall is somewhat unconventional and seems to
lack elements seen in other AGC kinases. Despite this, sequence alignments with the
tail regions of the other MAST kinases and the AGC kinase PKC (Figure 4.6 A)
combined with phospho-site mapping (Figure 4.4) of this region highlighted two
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Figure 4.6 Identifying the hydrophobic motif of Greatwall
(A) Sequence alignments of Greatwall C-terminal tail region with those of the other AGC kinases.
Alignments with the MAST kinases and PKC are shown. Serine 874 (S874) and serine 877 (S877) are
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highlighted with pink parentheses. These residues might represent important phospho-sites for Greatwall
activation as they are well conserved in the tail region of these kinases. (B) Flag-tagged Greatwall or non-
phosphorylatable mutants S874A, S877A and S874/7A were expressed in HEK 293T cells,
immunoprecipitated and taken into a kinase assay as described for Figure 4.5. (C) Flag-tagged Greatwall
or the phosphorylatable mutant T874S were assessed as described for (B).
residues that might represent important phospho-sites for Greatwall activation. These
residues that might represent important phospho-sites for Greatwall activation. These
sites, serine 874 (S874) and serine 877 (S877), are well conserved in the tail region of
these AGC kinases. We hypothesised that one of these residues might represent the
hydrophobic motif phosphorylation of the C-terminal tail of Greatwall. Once this site is
phosphorylated on the last serine (or threonine) it then wraps around the N-lobe and
anchors the two aromatic residues in the hydrophobic motif pocket. This allows the
phosphate of the serine or threonine to bind an arginine residue of the αC helix, 
stabilising it and enhancing phospho-transferase activity. Thus, phosphorylation of the
hydrophobic motif acts in concert with the activation loop to stabilise the active form of
the kinase and is required for full activity of AGC kinases (Yang et al. 2002; Pearce et
al. 2010).
In order to determine which, if either, of these residues were phosphorylated and
important for Greatwall kinase activity, I mutated these residues to alanines separately
or in combination. I then analysed these mutants for kinase activity as described
previously (Figure 4.6 B). The S874A mutant displayed much reduced activity with
only 24% of WT kinase activity. This was the same for the double mutant, while the
S877A mutant showed less disruption of kinase activity with 65% of WT kinase activity
remaining. We concluded from this data that the key phosphorylated residue of the
hydrophobic motif is S874, and that S877 does not contribute to kinase activity.
At the time of analysis of these results Vigneron et al. (2011) published their
analysis of the same sites. They also found that S874 when mutated to an A resulted in
reduction of kinase activity to only 31% of WT activity. When tested in Xenopus CSF
extracts this mutation resulted in complete loss of functionality, as judged by its
inability to sustain M phase in these depleted extracts. In contrast, and in keeping with
my conclusions, they found that mutation of S877 did not affect kinase activity (with
85% activity remaining) nor did its mutation affect Greatwall functionality (Vigneron et
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al. 2011). These results were subsequently further confirmed by Blake-Hodek et al.
(2012) who also reported the same effects when S874 was mutated in Xenopus
Greatwall (S883 in Xenopus).
Conclusion that this residue therefore represented the key activating
phosphorylated residue of the hydrophobic motif, however, proved premature. Vigneron
et al. (2009; 2011) reported that sequence alignment of AGC kinase C-terminal tails
with that of the Greatwall kinase indicated that the C-terminal tail is truncated in
Greatwall (something also noted here) (Figure 4.6 A). This, they hypothesised,
represented a lack of a true hydrophobic motif in this kinase. Instead they found that
addition of a synthetic peptide encompassing the carboxy-terminal hydrophobic motif
of another AGC kinase, Rsk2, stimulated kinase activity of Greatwall that was
dependant on prior phosphorylation of S784. This led them to propose that S874 in fact
represents phosphorylation of what would be more similar to the typical turn motif of
AGC kinases. The turn motif precedes the hydrophobic motif and allows the correct
orienting of the C-terminal tail to allow it to fold around the N-lobe and thus increases
the local concentration of the hydrophobic motif in hydrophobic motif pocket. For this
reason, phosphorylation of the turn motif is required for full kinase activity (Hauge et
al. 2007; Kannan et al. 2007; Vigneron et al. 2011).
Seemingly in contradiction to this, however, they also confirmed that Greatwall
does posses a functional hydrophobic motif binding pocket (Vigneron et al. 2011).
When they mutated arginine 82 (R82) and tyrosine 98 (Y98) to alanines, both Greatwall
kinase activity and functionality were lost with only 13% and 7% kinase activity
remaining respectively. These residues are conserved with the hydrophobic motif
binding pockets of other AGC kinases. The first residue binds the phosphorylated
residue of the hydrophobic motif and the second binds the last phenylalanine of the
motif to mediate the stabilisation of the active catalytic core (Biondi et al. 2003; Kannan
et al. 2007; Pearce et al. 2010). It is strange that Greatwall should require a hydrophobic
motif binding pocket while not actually possessing a true hydrophobic motif. It is
known that membrane-localised 3-phosphoinositide-dependant kinase 1 (PDK1),
another unconventional AGC kinase, binds via its hydrophobic motif binding pocket to
the phosphorylated hydrophobic motifs of its substrates (Biondi et al. 2000; Biondi et
al. 2002; Biondi et al. 2003; Kannan et al. 2007). This binding facilitates
conformational changes in its catalytic core that increase its activity. Thus, the authors
proposed a model in which Greatwall kinase activation is completed via the interaction
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of another AGC kinase inserting its phosphorylated hydrophobic motif into the
hydrophobic motif binding pocket of Greatwall (Vigneron et al. 2011). In this model the
phosphorylation of S874 would act as the turn motif and would be predicted to act by
mediating the interaction of the hydrophobic motif with the pocket. This seems a logical
conclusion, but in a final twist, Blake-Hodek et al. (2012) suggest that the C-terminal
tail of Greatwall is insufficiently long to promote such an interaction. Thus, the true
nature of the mechanism of S874 phosphorylation in mediating Greatwall kinase
activity still remains to be fully elucidated.
This also leads to speculation on the reason that mutation of this site to another
phosphorylatable residue (to a threonine, S874T) failed to even partially rescue
Greatwall activity (with the T mutant displaying 24% of WT kinase activity, as was the
same for the A mutant) (Figure 4.6 C). Indicating that, rather than this representing an
important phosphorylation event, it is a structural requirement of the catalytic core to
have a serine residue at this position. This result was considered anomalous in the face
of the report by Vigneron et al. (2011) until recently (when the report by Blake-Hodek
et al. (2012) was published as this was being written up) and further analysis is required
to clarify these issues.
4.8 Making a constitutively active kinase
The important T194 and S874 sites were also altered to an aspartic acid (D),
both separately and in combination, to mimic a phosphorylated T or S. The purpose of
making these phospho-mimetic mutants was primarily to make a Greatwall kinase that
was constitutively active. Unfortunately none of these mutant kinases exhibited
constitutive activity; rather they all showed reduced activity as compared to the WT
kinase whether the cells were in mitosis or not (Figure 4.7 A and B). T194D had only
26% activity in asynchronous cells and only 28% of WT activity in mitotic cells
arrested with Nocodazole. S874D had only 30% and 26% activity in asynchronous and
mitotic cells respectively. In both cases the reduction in activity is similar to that seen
for the original A mutants. The double mutant displayed very similar reductions in
kinase activity, with 24% activity in asynchronous cells and 16% activity in mitotic
cells. This suggests that these phospho-mimetic mutants were not sufficient to restore
kinase activity. I also tried mutating these sites to glutamic acid, E, in case this should
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Figure 4.7 Making a constitutively active Greatwall
(A) Flag-tagged Greatwall or phospho-mimetic mutants T194D, S874D and double mutant
T914D/S874D (T/SD) were expressed in HEK 293T cells, immunoprecipitated and taken into a kinase
assay as described for Figure 4.5. Here only one lot of cells transfected with the wildtype kinase were
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treated with Nocodazole (+N). (B) Flag-tagged Greatwall or phospho-mimetic mutants T194D, S874D
and double mutant T914D/S874D (T/SD) were expressed in HEK 293T cells, immunoprecipitated and
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taken into a kinase assay as described for (A). All cells were treated with Nocodazole (+Noc) as
indicated. (C) Flag-tagged Greatwall or phospho-mimetic mutants T194E and S874E were expressed in
HEK 293T cells, immunoprecipitated and taken into a kinase assay as described for (A). Where indicated
cells were treated with Nocodazole (+Noc). (D) Flag-tagged Greatwall or the triple mutant
S102D/T194E/T207E (STT) were expressed in HEK 293T cells, immunoprecipitated and taken into a
kinase assay as described for (A). Where indicated cells were treated with Nocodazole (+N).
prove more successful (Figure 4.7 C). The results were again disappointing with both
the T194E and S874E mutant displaying reduced activity as compared to the WT
kinase. Both displayed only 31% activity in asynchronous cells. The activity shown by
these mutants was slightly increased by the addition of Nocodazole to arrest the cells in
mitosis. This still did not increase the activity of the mutants to that of the mitotic WT
kinase; T194E had only 45% activity and S874E had only 40% activity. This suggested
that mutation of these sites to an E was slightly less disruptive to kinase activity but was
insufficient to produce a fully active or constitutively active kinase.
Vigneron et al. (2011), however, reported that in their experiments when S874 is
mutated to a D it showed only a 38% decrease in activity when compared to mitotic WT
kinase activity. This mutant was also able to completely rescue the mitotic exit
phenotype in Xenopus egg extracts. This supported their conclusion that this is an
important phospho-site. Recently, Blake-Hodek et al. (2012) reported the same result.
In their experiments the mutation of S874 to a D resulted in less than 50% activity as
compared with the WT kinase but again was functional in Xenopus egg extracts.
Further, they reported that mutation of T194 to an E resulted in a reduction in kinase
activity to below 50% of that of WT kinase activity but that this mutant was fully
functional in egg extracts. This is in conflict with the results discussed here that neither
mutation of these residues to a phospho-mimetic (D or E) nor another phosphorylatable
mutant (T/S) could induce kinase activity. However, in human cells we have so far been
unable to test the mutant kinases for functionality and must defer to these analyses.
Taking into account the reports described here it seems that although mutation of these
sites to phospho-mimetic residues reduces kinase activity, they do restore Greatwall
functionality.
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4.9 A novel mechanism for Greatwall activation
A novel mechanism for Greatwall activation was proposed recently in the work
published by Blake-Hodek et al. (2012). Here they found that more than 20 tryptic
phospho-peptides result after Greatwall activation and hyperphosphorylation in M phase
of Xenopus egg extracts. At least 15 were found to result from autophosphorylation by
Greatwall itself. They found that 32P was almost exclusively incorporated into active
Greatwall with first-order kinetics typical of unimolecular reactions, indicating that
Greatwall autophosphorylation is intramolecular (Blake-Hodek et al. 2012).
To investigate how Greatwall is activated by phosphorylation in mitosis they
mutated all conserved T and S residues outside of the non-conserved middle region
(NCMR) of inserted amino acid residues. In this manner they identified five phospho-
sites by mass spectral analysis that were conserved between Xenopus and human
Greatwall. Mutation of these residues to an A severely compromised Greatwall
function. Three of these sites were T194, T740 and S874 (that were also identified in
this work). The two further sites identified in this study were T207 (T206 in Xenopus)
and S213 (S212 in Xenopus). Phospho-mimetic mutations of T194E, T207E and S874D
rescue Greatwall activity in extracts while T740E and S212D do not. This implies a
structural role for the residues S212 and T470 in Greatwall activation but that residues
T194, T207 and S874 represent important phosphorylated residues (Blake-Hodek et al.
2012).
Blake-Hodek et al. (2012) found that a peptide containing S874 was
phosphorylated in vitro by active Greatwall. They proposed a mechanism for activation
of Greatwall based on the activation mechanism of PKA. Previous studies have shown
that activation of PKA occurs via a two-step mechanism. Activation is begun by a
priming phosphorylation of the activation loop on T197 by PDK1. It then
autophosphorylates S338 in the turn motif of its C-terminal tail to mediate full
activation (Frodin et al. 2002; Iyer et al. 2005). Blake-Hodek et al. (2012) suggest that
Greatwall might be activated by a similar mechanism. In this model, residues T194 and
T207 are initially phosphorylated in the presumptive activation loop by an upstream
activating kinase. These two residues are found in a position analogous to that of the
activating phosphorylation of PKAs activation loop on T197. This then allows the
primed Greatwall to autophosphorylate on residue S874. As mentioned previously, this
phosphorylation of the turn motif would possibly then allow it to mediate interaction
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with/or the binding of an exogenous hydrophobic motif to complete Greatwall
activation.
4.10 Other mutagenesis
Another residue, S102 (S101 in Xenopus), was reported by Blake-Hodek et al.
(2012) to severely disrupt Greatwall function when mutated to an A, while its mutation
to a D conferred limited constitutive activity. They found no evidence for the
phosphorylation of this site and concluded that the mutation of this residue to a D must
instead stabilise a partially active conformation of Greatwall by as yet unknown
structural interactions. This constitutive activity synergises when combined with T207E
and T194E mutations (Blake-Hodek et al. 2012). Correspondence from the authors prior
to publication of this paper had informed us that this was the case for Xenopus
Greatwall and the same mutagenesis was performed to try to produce a constitutively
active human Greatwall kinase (Figure 4.7 B). Expression of the triple human
Greatwall mutant, S102D, T194E and T207E (STT), did not restore kinase activity. The
activity of the mutant remained far below that of WT kinase activity, with only 20%
activity in asynchronous cells that increased to only 30% in mitotically arrested cells.
The disruption to kinase activity is equivalent to that seen for the individual A mutants
and suggests no constitutive activation. It is important to point out that it is possible that
Greatwall function has been preserved or increased in this mutant. It has not been
possible to test this, although the very low activity seen for the STT mutant Greatwall
suggests that this is unlikely.
In addition, S370 was of interest early on in this study. Its possible involvement
in Greatwall activation was suggested by phospho-site mapping of Greatwall (Figure
4.4). It was thought that this residue could potentially form an important interaction
with T194. Both these residues were initially mutated to an A. The results of this are
shown in Figure 4.8 A. While T194 mutation severely disrupted Greatwall kinase
activity, S370 mutation had no effect. It was therefore concluded that this residue was
not significant for Greatwall activity.
Another mutant was made in which lysine at position 72 (K72) was mutated to a
methionine (M). This K72M mutant (K71M in Xenopus) is equivalent to the Drosophila
Scant mutation (Archambault et al. 2007) and was reported to show reduced but
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Figure 4.8 Other Greatwall mutants
(A) Flag-tagged Greatwall or non-phosphorylatable mutants T194A and S370A were expressed in HEK
293T cells, immunoprecipitated and taken into a kinase assay as described for Figure 4.5. (B) Flag-
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tagged Greatwall or mutant K72M were expressed in HEK 293T cells, immunoprecipitated and taken into
a kinase assay as described for (A). The cells were treated with Nocodazole (+Noc) as indicated.
constitutive gain of activity against Ensa in Xenopus (Yamamoto et al. 2011). Kinases
assays revealed that Scant Greatwall but not WT Greatwall showed interphase activity
toward Ensa. It was able to promote M phase in oocytes but only with a significant
delay, suggesting its low level of activity is limiting. In Xenopus only a two-fold
increase in activity (at best) was reported and the authors suggested that the increased
activity seen in Drosophila Scant might have resulted from the cell cycle arrest of the
cultured cells leading to a high concentration of protein in the preparation (Yamamoto
et al. 2011). They reported that the addition of a proteasome inhibitor (MG132) caused
increased protein levels and accelerated M phase entry. This suggested that Scant
Greatwall has partial constitutive activity but with reduced stability. We were interested
to see what effects this mutation might have on the activity of human Greatwall. The
results of the kinase assay are shown in Figure 4.8 B. The K72M mutant appears to
have slightly increased activity in both interphase and mitosis (with 123% activity in
asynchronous cells and 108% in mitotic cells as compared to that of WT). The
functionality of this mutant in human cells has not yet been tested but it seems
promising that this might also have increased activity.
4.11 Making a minimal kinase
An obvious question when looking at the structure of Greatwall kinase is what is
the function, if any, of the large non-conserved middle region (NCMR) of inserted
amino acids? Is it dispensable for kinase activity? In order to address these questions we
created two different minimal kinases or artificially spliced variants of Greatwall;
artificial splice transcript I (SPI) and artificial splice transcript II (SPII). To determine
where the kinase domain boundaries might fall we aligned the kinase domain sequences
of other AGC kinases PKC isoforms and MAST1, 2, and 3 kinases with that of
Greatwall (Figure 4.9 A). Greatwall showed homology and aligned with the kinase
domains of PKC and in particular with the α isoform. Based on this we created the 
artificially spliced variants of Greatwall in which the kinase domain sequence that
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1 43
PKCalpha DFGMCKEHMM D--------- ------GVTT RTFCGTPDYI APE
PKCbeta DFGMCKENIW D--------- ------GVTT KTFCGTPDYI APE
PKCgamma DFGMCKENVF P--------- ------GTTT RTFCGTPDYI APE
PKCepsilon DFGMCKEGIL N--------- ------GVTT TTFCGTPDYI APE
PKCdelta DFGMCKENIF G--------- ------ESRA STFCGTPDYI APE
MAST1 DFGLSKMGLM SLTTNLYEGH IEKDAREFLD KQVCGTPEYI APE
MAST2 DFGLSKIGLM SLTTNLYEGH IEKDAREFLD KQVCGTPEYI APE
MAST3 DFGLSKIGLM SMATNLYEGH IEKDAREFID KQVCGTPEYI APE
Greatwall DFGLSKVTL- NRDINMMD-- ------ILTT PXILGTPDYL APE
Consensus DFG$cKe... .......... ........tt .tfcGTP#Yi APE
1 34
PKCalpha DFGMCKE--- ---HMMDGVT TRTFCGTPDY IAPE
PKCbeta DFGMCKE--- ---NIWDGVT TKTFCGTPDY IAPE
PKCgamma DFGMCKE--- ---NVFPGTT TRTFCGTPDY IAPE
PKCepsilon DFGMCKE--- ---GILNGVT TTTFCGTPDY IAPE
PKCdelta DFGMCKE--- ---NIFGESR ASTFCGTPDY IAPE
Greatwall DFGLSKVTLN RDINMMDILT TPXILGTPDY LAPE
Consensus DFG$cKe... ...n..d..t t.tfcGTPDY iAPE
1 43
MAST1 DFGLSKMGLM SLTTNLYEGH IEKDAREFLD KQVCGTPEYI APE
MAST2 DFGLSKIGLM SLTTNLYEGH IEKDAREFLD KQVCGTPEYI APE
MAST3 DFGLSKIGLM SMATNLYEGH IEKDAREFID KQVCGTPEYI APE
Greatwall DFGLSKVTL- NRDINMMD-- ------ILTT PXILGTPDYL APE
Consensus DFGLSK.gLm s..tN$y#gh iekdaref.d kq!cGTP#Yi APE
1 * 34
PKCalpha DFGMCKE--- ---HMMDGVT TRTFCGTPDY IAPE
Greatwall DFGLSKVTLN RDINMMDILT TPXILGTPDY LAPE
Consensus DFG$cKe... ...nMMDglT TrticGTPDY iAPE
* *
Greatwall
1 MDPTAGSKKEPGGGAATEEGVNRIAVPKPPSIEEFSIVKPISRGAFGKVY
51 LGQKGGKLYAVKVVKKADMINKNMTHQVQAERDALALSKSPFIVHLYYSL
101 QSANNVYLVMEYLIGGDVKSLLHIYGYFDEEMAVKYISEVALALDYLHRH
151 GIIHRDLKPDNMLISNEGHIKLTDFGLSKVTLNRDINMMDILTTPSMAKP
201 RQDYSRTPGQVLSLISSLGFNTPIAEKNQDPANILSACLSETSQLSQGLV
251 CPMSVDQKDTTPYSSKLLKSCLETVASNPGMPVKCLTSNLLQSRKRLATS
301 SASSQSHTFISSVESECHSSPKWEKDCQESDEALGPTMMSWNAVEKLCAK
351 SANAIETKGFNKKDLELALSPIHNSSALPTTGRSCVNLAKKCFSGEVSWE
401 AVELDVNNINMDTDTSQLGFHQSNQWAVDSGGISEEHLGKRSLKRNFELV
451 DSSPCKKIIQNKKTCVEYKHNEMTNCYTNQNTGLTVEVQDLKLSVHKSQQ
501 NDCANKENIVNSFTDKQQTPEKLPIPMIAKNLMCELDEDCEKNSKRDYLS
551 SSFLCSDDDRASKNISMNSDSSFPGISIMESPLESQPLDSDRSIKESSFE
601 ESNIEDPLIVTPDCQEKTSPKGVENPAVQESNQKMLGPPLEVLKTLASKR
651 NAVAFRSFNSHINASNNSEPSRMNMTSLDAMDISCAYSGSYPMAITPTQK
701 RRSCMPHQTPNQIKSGTPYRTPKSVRRGVAPVDDGRILGTPDYLAPELLL
751 GRAHGPAVDWWALGVCLFEFLTGIPPFNDETPQQVFQNILKRDIPWPEGE
801 EKLSDNAQSAVEILLTIDDTKRAGMKELKRHPLFSDVDWENLQHQTMPFI
851 PQPDDETDTSYFEARNTAQHLTVSGFSL
Figure 4.9 Making a minimal Greatwall kinase
(A) Alignment of the kinase domains and bridging activation loop sequences from the DFG motif of PKC
isoforms and MAST1-3 with that of Greatwall (with the insertion between the N- and C-lobes removed).
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Greatwall SPI
1 MDPTAGSKKEPGGGAATEEGVNRIAVPKPPSIEEFSIVKPISRGAFGKVY
51 LGQKGGKLYAVKVVKKADMINKNMTHQVQAERDALALSKSPFIVHLYYSL
101 QSANNVYLVMEYLIGGDVKSLLHIYGYFDEEMAVKYISEVALALDYLHRH
151 GIIHRDLKPDNMLISNEGHIKLTDFGLSKVTLNRDINMMDILTTPTILGT
201 PDYLAPELLLGRAHGPAVDWWALGVCLFEFLTGIPPFNDETPQQVFQNIL
251 KRDIPWPEGEEKLSDNAQSAVEILLTIDDTKRAGMKELKRHPLFSDVDWE
301 NLQHQTMPFIPQPDDETDTSYFEARNTAQHLTVSGFSL
Greatwall SPII
1 MDPTAGSKKEPGGGAATEEGVNRIAVPKPPSIEEFSIVKPISRGAFGKVY
51 LGQKGGKLYAVKVVKKADMINKNMTHQVQAERDALALSKSPFIVHLYYSL
101 QSANNVYLVMEYLIGGDVKSLLHIYGYFDEEMAVKYISEVALALDYLHRH
151 GIIHRDLKPDNMLISNEGHIKLTDFGLSKVTLNRDINMMDILTTPRTFCI
201 LGTPDYLAPELLLGRAHGPAVDWWALGVCLFEFLTGIPPFNDETPQQVFQ
251 NILKRDIPWPEGEEKLSDNAQSAVEILLTIDDTKRAGMKELKRHPLFSDV
301 DWENLQHQTMPFIPQPDDETDTSYFEARNTAQHLTVSGFSL
The sequence alignment was created using Multalin version 5.4. The N- and C-lobes of the Greatwall
kinase domain are indicated coloured in Figure 4.2 B. The alignment of Greatwall with the kinase
domain of PKCα is shown in the bottom alignment. (B) Mapped Greatwall. The two halves of the kinase
domain are shown coloured as in (A). The purple font indicates the NCMR. (C) Artificial splice variants
of Greatwall. The two different variants, SPI and SPII, are shown. The two halves of the kinase domain
are coloured as in (A). The purple font indicates residues introduced between the two halves of the kinase
catalytic core. (D) Flag-tagged Greatwall or mutants SPI and SPII were expressed in HEK 293T cells,
immunoprecipitated and taken into a kinase assay as described for Figure 4.5. The phosphorylation of
MBP and autophosphorylation of the WT and mutant kinases are indicated by arrows.
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aligned with PKCα was preserved with the intervening NCMR removed. These variants 
contained amino acid residues 1-195 and 737-878 which encompasses the presumptive
N- and C-lobes of the kinase domain as well as any important N- or C-terminal
extensions (Figure 4.9 B and C). Between the two halves of the kinase domain a single
T was inserted to form the first variant, SPI. The second variant, SPII, contained the
short sequence RTFC between the two halves of the kinase domain making the
sequence between the halves equivalent to that of PKCα. These two variants were then 
expressed with a flag-tag in human cells and immunoprecipitation and subsequent
kinase assays performed to assess their activity (Figure 4.9 D). Disappointingly they
seemed to be relatively inactive, retaining only 28% and 22% of mitotic WT kinase
activity for SPI and SPII respectively. We did, however, see some evidence of
autophosphorylation of the Greatwall SPI and SPII proteins themselves (Figure 4.9 D).
This is perhaps surprising in light of the proposed mechanism of Greatwall activation
discussed in section 4.9 here. It might suggest that phosphorylation of T194, in the
absence of T207 is sufficient to induce autophosphorylation of the C-terminal tail motif
and activate Greatwall, even if only weakly. This could mean that these variants are at
least partially functionally active. Further investigation is required to establish if these
variants have functional activity and this work is currently ongoing.
Two groups that recently mechanistically investigated Greatwall performed
similar deletions. Vigneron et al. (2011) deleted residues 195-735 (without inserting any
bridging sequence) and found the resulting minimal kinase had a 95% decrease in
activity as compared to the WT kinase and a complete loss of functionality. A shorter
deletion of residues 254-640 produced the same results. However, by performing a
series of shorter deletions within this region they established that no specific sequence
between residues 254-640 were required for activity. Moreover, the point mutation or
deletion of all phospho-residues within the region did not perturb the kinase activity or
functionality. Instead they suggest that this might represent a requirement of a minimal
length of sequence to allow structural rearrangements required for kinase activity. By
deleting various regions of the NCMR in Xenopus Greatwall the same conclusion was
reached by Blake-Hodek et al. (2012). They also found that the Drosophila Greatwall
NCMR, despite having no sequence homology to that of Xenopus, could functionally
substitute for the Xenopus enzyme in CSF extracts, further supporting the conclusion
that its presence is required for kinase functionality but that the NCMR sequence is
nonessential.
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4.12 Conclusions and discussion
Greatwall is an atypical AGC kinase. The two lobes of its kinase domain are
separated by a large insertion of non-conserved amino acids of unknown function. The
predicted structural model produced was validated and the activation loop, P+1 loop,
and turn motif were identified here. These findings determine that Greatwall conserves
many of the basic structural features of other eukaryotic serine/threonine kinases.
Although, it appears to be regulated by unique mechanisms that do not conform to those
seen for other AGC kinases. The production of a constitutive kinase, however, has not
been successful so far.
The use of structural modeling, phosphorylation site mapping and mutagenic
analysis has allowed an insight into the mechanisms that regulate human Greatwall.
This, in combination with the investigations carried out in two other studies, has led to
the emergence of a novel three-step mechanism for its activation (Vigneron et al. 2011;
Blake-Hodek et al. 2012). In this model, Greatwall’s activation begins with the priming
phosphorylations of its activation loop on two threonines, T194 and T207. It then
becomes partially active and autophosphorylates its turn motif in the C-terminal tail, on
S874. Finally, this then likely mediates the docking and/or interaction of the
hydrophobic motif binding pocket with a phosphorylated hydrophobic motif of another
AGC kinase. Once bound the kinase is fully active. This mechanism of activation best
suits the data available and represents the culmination of work from all three studies.
This surprising mechanism of activation is in keeping with the highly intricate
mechanisms that control AGC kinase activities (Pearce et al. 2010). These are often
aided by specific domains located in associated proteins. Moreover, Greatwall itself has
been found to be an unconventional kinase from the start, when it was found not to
phosphorylate and initiate mitosis but to counteract a phosphatase that otherwise
prevents mitotic entry (Yu et al. 2004; Haccard et al. 2011). There are still more
questions that arise from this model. The identity of the activating kinase that
phosphorylates the activation loop and primes Greatwall activation will be discussed in
the next chapter. Additionally, the identity of the hydrophobic motif-donating protein
that is required for full activity remains unknown, as does the exact mechanism by
which this interaction is mediated. It is likely that additional, non-essential
phosphorylations elsewhere in the kinase fine tune this mechanism. The NCMR is likely
to contribute to this despite the finding that no specific sequences within this region are
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absolutely required for kinase activity.
The structural study presented, unfortunately, has several limitations. Primarily,
the inability to test the functionality of the mutants in vivo. This is being addressed by
the establishment of an siRNA resistant form of Greatwall that can subsequently be
mutated and used to perform rescue experiments in human cells after Greatwall
knockdown. At the time of writing this thesis, this system was still being established
and will hopefully answer some of the outstanding questions regarding these mutants
functionality in due course. Fortunately, many of the mutants discussed here were also
analysed by other groups in Xenopus egg extracts (Yu et al. 2006; Vigneron et al. 2011;
Blake-Hodek et al. 2012). These were mentioned where relevant and in many cases
their reported data lent support to the results I presented here and the conclusions that
were drawn. Another limitation is the lack of a true substrate with which to test
Greatwall activity. The cellular substrates of Greatwall, Arpp19 and Ensa, were only
established relatively late on in this project and it was felt that there was insufficient
time remaining to try and express these in vitro and go back and repeat each kinase
assay. Reassuringly this was addressed by the work of Blake-Hodek et al. (2012) who
found that there was no difference in vitro between Greatwalls ability to phosphorylate
Ensa or the MBP. In all cases they found that the levels of phosphorylation seen when
either Ensa or MBP were used as a substrate for their kinase assays were the same
(Blake-Hodek et al. 2012). This suggests that the activity of Greatwall can be
reasonably assessed in vitro using MBP as a substrate. Although its in vivo activity
could still differ and the functionality of the enzyme cannot be assumed to correlate
with the in vitro activity seen. Additionally, in future work, it would also be informative
to assess PP2A binding in all the phosphorylation site mutants to gain further insight to
how they might be effecting Greatwall regulation and functionality.
Overall, an interesting mechanism for Greatwall activation has been uncovered
that warrants further investigation to unravel the complexities of Greatwall in vivo
activation mechanisms.
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CHAPTER 5. Investigating Greatwall activation
5.1 Introduction
The mechanisms of Greatwall activity still remain to be fully elucidated and will
likely require structural insight. Moreover, the precise dynamics of Greatwall activation
and inactivation as well as characterisation of the upstream kinases and phosphatases
that regulate this kinase also remain enigmatic. The work presented in this chapter
focuses on gaining deeper understanding of this aspect of Greatwall regulation.
There is strong evidence from the studies carried out in frog egg extracts that
Xenopus Greatwall is activated by MPF in mitosis. The MPF (the cyclin B-CDK1
complex) is an obvious candidate for the upstream activating kinase of Greatwall. Once
MPF becomes active at the end of G2 it is known to phosphorylate and activate kinases
(Wee1) and phosphatases (Cdc25) that then in turn propagate its own activation and
mediate changes to promote mitotic entry. Conceivably, CDK1 also acts upstream of
Greatwall, integrating it in the general MPF activation feedback loop (Figure 5.1 A). In
this way, activation of Greatwall by MPF phosphorylation would then mediate
inhibition of PP2A, via phosphorylation of Arpp19/Ensa, allowing CDK
phosphorylations to persist promoting further activation of MPF and mitotic entry. It
has been shown that Greatwall becomes hyperphosphorylated and active at the same
point in the cell cycle at which the MPF becomes active, at the G2/M transition. It then
remains active in mitosis until mitotic exit, also the time in which MPF becomes
inactive (Zhao et al. 2008). Thus, the cyclic rise and fall of Greatwall activation follows
closely with that of MPF and corresponds inversely to that of PP2A activity (Mochida
et al. 2009). The addition of purified MPF to Greatwall immunoprecipitated from
interphase egg extracts leads to phosphorylation of Greatwall. Moreover, when
recombinant Greatwall was pre-treated with MPF it exhibited autophosphorylation and
phosphorylated MBP in vitro. The addition of the MPF pre-treated Greatwall into
Greatwall depleted CSF extracts rescued the loss of M phase while a non-treated
(unphosphorylated) or kinase dead Greatwall could not (Yu et al. 2006).
Greatwall has numerous potential CDK phosphorylated sites (S/TP). Yu et al.
(2006) found that mass spectral analysis of Xenopus Greatwall revealed seven sites
phosphorylated in recombinant Greatwall that had been treated with MPF, and five of
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Figure 5.1 Is human Greatwall activated by CDK1?
(A) Schematic representation of the Greatwall pathway. Once Greatwall is active in late G2 it then
phosphorylates its targets, Ensa and/or Arpp19, inactivating PP2A-B55δ. This allows CDK1 mitotic 
phosphorylations to accumulate on targets, including Cdc25, and activation of the CDK positive feedback
loop to drive cells into mitosis. Activating modifications are shown as purple arrows and all inhibitory
modifications are shown in orange. The potential activation of human Greatwall by CDK1 is indicated by a
question mark and dashed arrow. (B) Flag-tagged WT Greatwall (WT) or phosphorylatable mutant T194S
(T194S) were expressed in human HEK 293T cells. Cells transfected with a GFP control were analysed as
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well. After 24 hours the cells were treated with Nocodazole. The flag-tagged proteins were then
immunoprecipitated using anti-flag magnetic beads. An in vitro kinase assay was then performed using
MBP as a substrate for the kinase. The top panel shows the results of SDS-PAGE analysis indicating the
expression of the flag-tagged protein in the cell lysates (L) and the immunoprecipitate (IP) detected using
the anti-Greatwall antibody. The autoradiograph is shown in the second panel. Quantification of the kinase
activity of the mutant kinase relative to the wildtype is shown in the graph beneath.
these were conserved. Sequential mutation of these five residues (from a serine or
threonine to alanine) revealed only one mutation, T748A that was unable to rescue the
CSF extracts to M phase. This is not that surprising in light of later studies, discussed in
Chapter 4, as the other residues they identified were all in the NCMR. They did not
investigate this residue further but concluded that there is likely at least one CDK1
phosphorylation site in Greatwall that is important for its activation. Additionally,
Blake-Hodek et al. (2012) found that one or more phospho-sites of M phase Greatwall
were epitopes recognised by the Mitotic Protein Monoclonal 2 (MPM-2) antibody that
reacts with mitotic phospho-proteins phosphorylated on serine or threonine residues
followed by a proline. As mentioned, these sites are often phosphorylated by CDKs
(Wu et al. 2010). Further proof that Greatwall activation in Xenopus might depend on
the prior activation and subsequent phosphorylation by MPF came from a later report by
Zhao et al. (2008). They found that microinjection of CDK inhibitor, p21, into oocytes
or treatment of cycling extracts with the CDK inhibitor Roscovitine prevented
Greatwall phosphorylation. This leads to the conclusion that MPF is an important
activator of Xenopus Greatwall.
There is also data that supports the activation of human Greatwall by cyclin B-
CDK1. Human Greatwall localises to centrosomes during G2 where cyclin B-CDK1 is
also first activated (Burgess et al. 2010). There are 18 potential CDK phospho-sites
(T/SP) in human Greatwall, although the majority of these (all but five) lie inside the
NCMR (Appendix C). Human Greatwall is also maximally active only in mitosis, as
reported here and by Voets et al. (2010). This group observed a mitotic mobility shift
that was concomitant with the phosphorylation of APC/C subunit APC3, was
diminished by treatment with λ phosphatase and was enhanced by treatment with 
okadaic acid. Correspondingly, they found that the addition of okadaic acid at any other
stage of the cell cycle did not elicit this mobility shift. This suggests that Greatwall is
subject to an activating phosphorylation event in mitosis similar to that seen for
Xenopus Greatwall. Moreover, CDK inhibition (using Flavopiridol), but not Aurora B
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inhibition (using AZD1152), reverted Greatwall phosphorylation in cells released from
a Nocodazole arrest but held in mitosis by MG132-mediated proteasome inhibition.
Thus, suggesting that mitotic phosphorylation of Greatwall requires CDK activity
(Voets et al. 2010).
Despite this body of evidence, the precise activating residues that are
phosphorylated by CDK1 have not yet been identified and the dynamics of Greatwall
activation at the G2/M transition have yet to be established. Additionally, the
inactivating phosphatase(s) that act on Greatwall and its substrates, and on CDK
substrates in general, at mitotic exit have still to be determined. Without a clear
understanding of these pathways, that play critical roles in cell cycle progression, an
adequate model of cell cycle control cannot be compiled. Throughout this chapter these
questions will be addressed.
5.2 Creating a phospho-specific antibody to monitor Greatwall kinase activation
The threonine at position 194 (T194) was identified in Chapter 4 as a key
phosphorylated site required for human Greatwall activation. To confirm this as a
phosphorylation event that allows Greatwall activity, this residue was mutated to
another phosphorylatable residue, a serine. Its mutation to a serine should allow this site
to still be phosphorylated and propagate Greatwall activation. The results are shown in
Figure 5.1 B. The mutant T194S was clearly still a functional kinase and displayed full
activity (96%) in mitotic cells as compared to WT Greatwall. This finding supports the
importance of phosphorylation of this residue for Greatwall activation.
A phospho-specific antibody was generated in rabbit by Eurogentec to target this
phosphorylation site in human Greatwall using the peptide sequence
CMMDILTT(PO3H2)PSMAK. The purified antibody sera was tested using human HEK
293T cell lysates produced from cells that were transiently overexpressing a flag-tagged
WT Greatwall and the nonphosphorylatable T194A Greatwall mutant (Figure 5.2 A).
The phospho-specific anti-pT194 Greatwall antibody detected the presence of T194
phosphorylated Greatwall in Nocodazole arrested mitotic cells lysates and
immunoprecipitate. Despite the clear presence of the T194A mutant Greatwall in the
mitotic cell lysates and immunoprecipitate (detected using the total anti-Greatwall
antibody), none was detected by the phospho-specific anti-pT194 Greatwall antibody. It
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Figure 5.2 Investigating Greatwall activation by CDK in human cells
(A) Immunoprecipitation of flag-tagged WT Greatwall or the non-phosphorylatable mutant Greatwall
T194A from HEK 293T cells. Cells were untreated (Asyn) or treated with RO-3306 (+RO-3306) or
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Nocodazole (+ Noc). The top panel shows the results of SDS-PAGE analysis indicating the expression of
the flag-tagged protein in the cell lysates (L) and the immunoprecipitate (IP) detected using the anti-
Greatwall antibody to probe for total human Greatwall protein levels (top panel) and the anti-pT194
antibody was used to probe for the presence of Greatwall phosphorylated on T194 (middle panel) in these
different conditions, while an anti-α Tubulin antibody (bottom panel) was used as a loading control. (B)
Kinase assay of flag-tagged WT Greatwall (WT) or the non-phosphorylatable mutant Greatwall T194A
(T194A) from HEK 293T cells. Cells transfected with a GFP control (GFP) were analysed as well. The in
vitro kinase assay was performed using recombinant cyclin A-CDK2 (CYCA/CDK2) in which the
immunoprecipitated Greatwall was the substrate. A sample of cyclin A-CDK2-treated WT Greatwall was
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then subsequently treated with λ phosphatase (+ λ). The top panel shows the results of SDS-PAGE
analysis indicating the expression of the flag-tagged protein in the cell lysates (L) and the
immunoprecipitate (IP) detected using the anti-Greatwall antibody to probe for total human Greatwall
protein levels. The in vitro kinase assays were also analysed by SDS-PAGE analysis using the anti-
Greatwall antibody to probe for total human Greatwall protein levels (middle panel) and the anti-pT194
antibody to probe for the presence of Greatwall phosphorylated on T194 (bottom panel). (C) Flag-tagged
WT Greatwall (WT) or the non-phosphorylatable mutant Greatwall T194A (T194A) were expressed in
HEK 293T cells. Cells transfected with a GFP control (GFP) were analysed as well. Cells were treated
with Nocodazole (+ Noc) and the flag-tagged proteins then immunoprecipitated. These were then taken
into an in vitro kinase assay with recombinant cyclin A-CDK2 (CYCA/CDK2) using the
immunoprecipitated Greatwall as a substrate. All samples were then washed to remove cyclin A-CDK2
and taken into an in vitro kinase assay with MBP as a substrate for Greatwall. The top panel shows the
results of SDS-PAGE analysis indicating the expression of the flag-tagged protein in the cell lysates (L)
and the immunoprecipitate (IP) detected using the anti-Greatwall antibody to probe for total human
Greatwall protein levels (top panel). The cyclin A-CDK2 in vitro kinase assays were analysed by SDS-
PAGE analysis using the anti-Greatwall antibody to probe for total human Greatwall protein levels
(second panel) and the anti-pT194 antibody to probe for the presence of Greatwall phosphorylated on
T194 (third panel). Finally the autoradiograph from the in vitro kinase assays using MBP as a substrate
for Greatwall is shown in the bottom panel with or without pre-treatment with cyclin A-CDK2 (+ CDK).
Quantification of the kinase activities from the autoradiograph is shown relative to the untreated WT
Greatwall kinase activity in the graph beneath.
can be concluded that in this mutant the site could not be phosphorylated and was
therefore not detected. This indicates that the anti-pT194 Greatwall antibody generated
is highly specific for the phosphorylation of this residue in human Greatwall.
Furthermore, this site is phosphorylated when Greatwall is known to be active in
mitosis.
5.3 Confirmation of CDK as an activator of Greatwall kinase
T194 is found in a CDK phosphorylation consensus motif (T/SP). Its potential as
a proline-directed CDK phospho-site was supported by the lack of signal detected by
the anti-pT194 Greatwall antibody from WT Greatwall in HEK 293T cells that had been
treated with the CDK1 inhibitor, RO-3306 (Figure 5.2 A). Although, once again, the
levels of the Greatwall protein expressed in the presence of this inhibitor appeared
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lower than for the other lysates. This was the case despite the tubulin loading control
indicating that total protein levels in all lysates were equal.
To test if human Greatwall can be phosphorylated in vitro on T194 by CDK,
WT and T194A mutant Greatwall were purified from asynchronous HEK 293T cells
and incubated with recombinant cyclin A-CDK2. The results are shown in Figure 5.2
B. WT Greatwall that was not incubated with cyclin A-CDK2 shows no
phosphorylation of T194 while Greatwall incubated with cyclin A-CDK2 is clearly
phosphorylated at this site. Moreover, the signal seen from WT Greatwall incubated
with cyclin A-CDK2 is severely diminished after treatment with λ phosphatase. This 
indicates that the signal seen from the anti-pT194 Greatwall antibody is a result of
phosphorylation of this site in Greatwall by cyclin A-CDK2. This conclusion is further
supported by the lack of any detectable signal seen from the incubation of the mutant
T194A Greatwall with cyclin A-CDK2. However, only a small proportion of the
phosphorylated WT Greatwall is shifted up in the gel after incubation with cyclin A-
CDK2. This suggests that phosphorylation of Greatwall by cyclin A-CDK2 does not
trigger phosphorylation of the kinase to mediate the modifications of the protein to the
extent noted for Greatwall from mitotic extracts. Therefore, CDK phosphorylation of
Greatwall might not fully activate Greatwall or other phosphorylations/PTMs might
occur to correctly activate and localise it allowing it to promote proper mitotic entry.
To address if the phosphorylation of Greatwall by cyclin A-CDK2 on T194 can
activate Greatwall, immunoprecipitated WT and T194A Greatwall were incubated with
or without cyclin A-CDK2. The beads were then washed to remove the cyclin A-CDK2
(if present) and the CDK pre-treated (or not) Greatwall was then incubated in a kinase
assay with MBP (Figure 5.2 C). The incubation of Greatwall with cyclin A-CDK2
activated the kinase, as judged by the phosphorylation of MBP. The high level of
Greatwall kinase activity produced after incubation with cyclin A-CDK2 exceeded that
of the WT Greatwall immunoprecipitated from Nocodazole-arrested mitotic cells, with
159% kinase activity comparatively. This large increase in kinase activity is likely a
result of incomplete removal of the cyclin A-CDK2 from the sample. This is probable
as the phosphorylation of MBP was also increased in the negative GFP control sample
after cyclin A-CDK2 incubation. However, the increases in the controls are relatively
minor and it is conceivable that CDK is sufficient to fully activate Greatwall in vitro to
levels comparable to, or even exceeding, those of Greatwall purified from mitotic cells.
These assays will have to be repeated in the presence of a CDK inhibitor, such as the
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Roscovitine, to rule out contamination of CDK activity in the observed MBP
phosphorylation.
The significance of the activity of the CDK pre-treated T194A mutant may also
be a result of incomplete removal of cyclin A-CDK2. If this result were shown to be
robust however, it might suggest that upon incubation with cyclin A-CDK2
phosphorylations elsewhere in the kinase are sufficient to render it partially active, at
least in vitro. This is possible given that Xenopus Greatwall can be phosphorylated on
its T-loop at two predicted CDK phospho-sites, T194 and T207 (Blake-Hodek et al.
2012). As discussed in Chapter 4 in section 4.11 it is possible that a minimal Greatwall
kinase lacking the T-loop phosphorylation site, T207, has some activity. This might
mean that only one of these sites need be phosphorylated for partial kinase activity, at
least in vitro. Further experiments with additional mutants and CDK inhibitors added to
the reaction should serve to clarify these points.
These results clearly demonstrate that cyclin A-CDK2 can phosphorylate T194
in human Greatwall in vitro. It is relatively well established that in vitro all CDKs will
phosphorylate target sites and exhibit similar substrate specificity (Hochegger et al.
2008). Moreover, when interphase recombinant Xenopus Greatwall was treated with
MPF, cyclin A-CDK2 or cyclin E-CDK2 they were all equally efficient at activating
Greatwall (Blake-Hodek et al. 2012). But which CDK activates human Greatwall in
vivo? The fact that T194 is not phosphorylated in RO-3306-treated G2 arrested cells
suggests that this site is a true mitotic CDK1 target. At the concentration (10 µM) used
here, RO-3306 does not inhibit CDK2 and blocks cells at the end of G2 phase just prior
to CDK1 activation (Vassilev et al. 2006). This observation is in agreement with work
from other studies in Xenopus (Yu et al. 2006; Zhao et al. 2008) and allows the
conclusion that human Greatwall is phosphorylated at the G2/M transition by CDK1 on
T194.
5.4 Investigating Greatwall activation by CDK phosphorylation of T194 in vivo
The dynamics of Greatwall activation throughout the cell cycle in human cells
was assessed using synchronised HeLa cells. These were synchronised by a double
Thymidine block and then released and subsequently followed through their cell cycle
for 12 hours. During this time, samples were taken every hour and analysed for
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Greatwall levels by immunoblotting using the total anti-Greatwall antibody and the anti-
pT194 Greatwall antibody (Figure 5.3 A). Greatwall expression remained relatively
constant throughout the cell cycle as previously observed. However, Greatwall
phosphorylation on T194, and thus its activation, fluctuated. No signal (activation) was
seen in the cells until mitotic entry, as judged by the corresponding FACS analysis, at
which point it peaked and remained high until the cell population began to return to G1
phase after mitotic exit when it decreased again. This pattern of Greatwall activation
agrees with the reports from other studies and coincides with cyclin B-CDK1 activity,
suggesting that Greatwall is activated by cyclin B-CDK1 phosphorylation at the G2/M
transition. In addition, an unexpected peak of Greatwall activity was detected at the two
hour time point once the cells had been released. This might correspond to a serge of
Greatwall activity to restart the cell cycle in a similar manner as described after DNA
damage (see Chapter 1, section 1.11) (Peng et al. 2010; Peng et al. 2011) or hint at an
as yet unknown function for Greatwall in S phase. This potentially interesting result
falls outside the scope of this thesis but warrants further investigation to clarify.
Greatwall activation at different stages throughout the cell cycle was also
assessed by immunoblotting in human HeLa, HCT116, HEK 293T and RPE cells
(Figure 5.3 B). Lysates of asynchronous cells, S phase cells arrested using Thymidine,
G2 phase cells arrested using RO-3306, and mitotic cells arrested using Nocodazole
were analysed. RPE cells were not assessed in S phase as they do not exhibit a
Thymidine-mediated cell cycle arrest, as previously discussed. For all cell lines
Greatwall is not phosphorylated on T194 in the asynchronous cells or in the cells
arrested in S phase. This supports the idea that Greatwall activity is required to restart
the cell cycle after the Thymidine block is removed, rather than it being active in S
phase blocked cells. Cells treated with RO-3306 all show apparently reduced expression
of Greatwall, in keeping with results obtained previously. Greatwall activation by T194
phosphorylation in the RO-3306 arrested cells is not detected. A small amount of
Greatwall is detected in the HEK 293T cells and is likely a result of slippage into
mitosis during the G2 arrest in these cells. A strong signal is detected in all mitotic
lysates and confirms that Greatwall is phosphorylated and active in these cells in
mitosis. The strong signal of T194-phosphorylated Greatwall seen in the mitotic cells
indicates that Greatwall is present despite it not being detected, or being detected only
poorly, by the total anti-Greatwall antibody. This further supports the hypothesis that
the activating phosphorylations/PTMs modifications of Greatwall in mitosis serve to
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Figure 5.3 Investigating Greatwall activation by CDK in vivo in human cells
(A) SDS-PAGE analysis of HeLa cells synchronised by double Thymidine block and then released for 12
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hours. Samples were taken every hour for a 12 hour period and analysed using the anti-Greatwall
antibody to probe for total human Greatwall protein levels (top panel) and the anti-pT194 antibody to
probe for the presence of Greatwall phosphorylated on T194 (middle panel). An anti-α Tubulin antibody 
(bottom panel) was used as a loading control. The cell cycle (FACS/PI) profiles for all the cell lysates are
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shown beneath. Asynchronous (A) cell lysates were analysed as well for comparison. (B) SDS-PAGE
analysis of HeLa, HEK 293T, HCT116 and RPE cell lysates from asynchronous (A) cells or cells that had
been treated with Thymidine (T), RO-3306 (R), or Nocodazole (N). The anti-Greatwall antibody was
used to probe for total human Greatwall protein levels (top panel) and the anti-pT194 antibody was used
to probe for the presence of Greatwall phosphorylated on T194 (middle panel) in these different
conditions, while an anti-α Tubulin antibody (bottom panel) was used as a loading control. (C) Flag-
tagged WT Greatwall was expressed and immunoprecipitated from HEK 293T asynchronous (Asyn) cells
or cells that had been treated with Thymidine (Thy), RO-3306 (RO) or Nocodazole (Noc). Asynchronous
cell lysates transfected with GFP (GFP) were analysed as well for comparison. The top panel shows the
immunoblot indicating the expression of the flag-tagged protein from the cell lysates (L) or the
immunoprecipitate (IP) detected using the anti-Greatwall antibody. The middle panel shows the presence
of Greatwall phosphorylated on T194 in these different conditions probed using the anti-pT194 antibody.
In vitro kinase assays were performed using MBP as a substrate for the kinase. The autoradiograph is
shown in the bottom panel. The cell cycle (FACS/PI) profiles for all the cell lysates are shown below. (D)
Representative images of HeLa cells stained for T194 phosphorylated Greatwall in interphase and in
different stages of mitosis. Fixed cells from an asynchronous population HeLa cells were stained with the
anti-pT194 Greatwall antibody (cherry), an anti-α Tubulin antibody (green) and DAPI (blue). The 
maximum projection from 0.3μm Z-sections are shown with scale bars of 10 μm. 
mask the protein from detection by the total anti-Greatwall antibody. Therefore,
Greatwall levels are not decreased in mitosis but the presence of activating PTMs
prevent its detection and the anti-pT194 Greatwall antibody indicates that high levels of
active Greatwall are present in all cell lines in mitosis.
These findings are supported by results shown in Figure 5.3 C. Transient
overexpression of flag-tagged Greatwall in human HEK 293T cells was used to analyse
of the activity of Greatwall in different cell cycle phases. Some phosphorylated
Greatwall was detected in the asynchronous cells, none was detected in S phase cells, a
small amount was detected in the RO-3306 treated cells likely due to mitotic slippage,
and a strong signal was detected in the mitotically arrested cells. The analysis of
Greatwall activity in these cell cycle phases was also assessed using in vitro kinase
assays. The results confirm the immunoblot analysis and indicate that in S phase
Greatwall is not active while in the mitotic cells Greatwall had high activity. This
further validates a model in which Greatwall is activated by CDK1 at mitosis. It is again
difficult to conclude about Greatwall activity in late G2 because it is detected by the
total anti-Greatwall antibody only at much reduced levels despite careful equalisation of
total protein levels in the lysates.
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Immunofluorescent staining using the anti-pT194 Greatwall antibody (Figure
5.3 D) revealed very little signal in interphase cells. G2 cells with separated
centrosomes showed weak nuclear staining. At the end of G2 and in early prophase
active Greatwall accumulated in the nucleus. It then moved to the spindle and emanated
across the spindle microtubules and was concentrated at the poles. This signal peaked in
metaphase and the progressively diminished until in telophase it had returned to
background levels and was considered extinguished.
5.5 Investigating mitotic exit and Greatwall inactivation
Once active in mitosis, another key question regarding Greatwall regulation is
how it is inactivated during mitotic exit? The current understanding of phosphatase
regulation and activity during mitotic exit is relatively rudimentary. A recent study in
Drosophila using siRNA screening found that ~ 20% of all phosphatases are required
for proper cell cycle progression and/or mitosis (Chen et al. 2007). As entry into mitosis
depends on the phosphorylation of numerous cyclin B-CDK1 substrates, to allow
subsequent mitotic exit, these mitotic phospho-proteins must be dephosphorylated or
degraded by the activity of phosphatases to return them to their interphase
dephosphorylated forms (Wurzenberger et al. 2011). Consistent with this, persistent
CDK activity prevents mitotic exit and CDK substrate dephosphorylation is considered
a hallmark of mitotic exit (Queralt et al. 2008). The results of studies in Xenopus have
been conflicting as to which phosphatase is the dominant CDK-antagonising
phosphatase at mitotic exit. In Xenopus, PP2A complexed with the B55δ isoform was 
shown to prevent mitotic exit when depleted from cycling egg extracts but both PP1 and
PP2A have been implicated in facilitating mitotic exit via the removal of these mitotic
phosphorylations (Forester et al. 2007; Mochida et al. 2009; Wu et al. 2009). The
precise mechanisms controlling mitotic exit are far from clear at present.
A recent study in Cdc20 null primary mouse embryonic fibroblasts found that
Greatwall must be inactivated to promote cyclin B-CDK1 substrate dephosphorylation
and mitotic exit (induced via CDK1 inhibition) (Manchado et al. 2010). They also
determined that mitotic exit in these cells was mediated by activation of PP2A
complexed with B55α and δ isoforms specifically, while siRNA depletion of the B55β 
isoform did not affect mitotic exit. However, the identity of the inactivating phosphatase
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of Greatwall in human cells is still unknown.
In order to examine mitotic exit mechanisms in human cells, HeLa cells were
arrested in mitosis using the Eg5 inhibitor, S-trityl-L-cysteine (STLC). A mitotic shake
off was then performed and the mitotic cells incubated for 30 minutes with the CDK1
inhibitor, RO-3306, in the presence of STLC to induce mitotic exit. Samples were then
taken at 0, 5, 10, 20 and 30 minutes after RO-3306 addition and analysed for their
general CDK substrate phosphorylation state using immunoblotting and an antibody
directed against phosphorylated serines of the CDK consensus motif. The results seen in
Figure 5.4 A, show a strong signal, corresponding to phosphorylated CDK substrates,
was present in the STLC-treated extracts before RO-3306 addition. This indicates that
they were arrested in mitosis with high CDK activity. This signal decreased markedly
following the addition of RO-3306 and was almost completely diminished after 30
minutes incubation with the CDK1 inhibitor. Thus, once CDK1 is inhibited, mitotic
phosphatases rapidly dominate and dephosphorylate its substrates. These samples were
also analysed for Greatwall levels and the presence of T194-phosphorylated Greatwall.
Concurrent with the induction of mitotic exit Greatwall becomes rapidly
dephosphorylated. The phosphorylation of T194 is diminished after only 5 minutes and
is totally absent after 20 minutes of RO-3306 treatment. The protein itself is seen to
shift down in the gel at each increasing time point as its mitotic modifications that retard
its electrophoretic mobility are lost. The total protein levels of Greatwall do not appear
to decrease suggesting that in these conditions it is not degraded, merely inactivated, as
judged by the loss of the phosphorylation of T194 in its T-loop that is required for its
kinase activity.
A key aspect of understanding Greatwall regulation is determination of the
phosphatase(s) responsible for removing its mitotic activating phosphorylations during
mitotic exit. Manchado et al. (2010) proposed that mitotic exit in mammalian cells
required Greatwall inhibition and the activation of PP2A. They also found that the
siRNA-mediated depletion of the PP1 inhibitor, Inhibitor 1, and resulting PP1 activation
led to partial exit from mitosis when CDK activity was inhibited by Roscovitine. They
suggested that PP1 could potentially have a role upstream of PP2A in inactivating
Greatwall. This indicates a potential role for both PP1 and PP2A in promoting exit from
mitosis as has been previously suggested in Xenopus (Mochida et al. 2009; Wu et al.
2009), although the precise mechanisms involved are still to be elucidated.
In order to address this, two phosphatase inhibitors were used: okadaic acid and
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Figure 5.4 Investigating Greatwall inactivation in human cells
(A) Investigating Greatwall inactivation during mitotic exit. SDS-PAGE analysis of HeLa cells that were
treated with STLC to arrest them in mitosis. A mitotic shake-off was performed and the cells treated with
RO-3306 in the presence of STLC to induce mitotic exit. Samples were then taken at 0, 5, 10, 20 and 30
minutes after RO-3306 addition and analysed by immunoblot. The phosphorylation pattern of cyclin B-
CDK1 substrates was assessed using an anti-phosphorylated serine CDK motif antibody (anti-phos(Ser)
CDK substrates) (top panel). The anti-Greatwall antibody was used to probe for total human Greatwall
protein levels (second panel) and the anti-pT194 antibody was used to probe for the presence of Greatwall
phosphorylated on T194 (third panel) in these different conditions, while an anti-α Tubulin antibody 
(bottom panel) was used as a loading control.
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(B) Investigating Greatwall inactivation by phosphatases during mitotic exit. HeLa cells were treated with
STLC to arrest them in mitosis. The cells were then treated for one hour with (+) or without (-)
phosphatase inhibitors; okadaic acid (OA), Tautomycetin (TC), or both (OA/TC). A mitotic shake-off
was performed and the cells treated with RO-3306 in the presence of STLC to induce mitotic exit.
Samples were then taken at 0, 15 and 30 minutes after RO-3306 addition and analysed by immunoblot.
The protein and phosphorylation status of the lysates were analysed as for (A) and additionally an anti-
Ensa antibody was used to probe for total human Ensa protein levels and an anti-pS67 Ensa antibody was
used to probe for the presence of Arpp19/Ensa phosphorylated on S67 in these different conditions.
Tautomycetin. At the concentrations used here okadaic acid is a potent inhibitor of
PP2A but has little effect on PP1 (Felix et al. 1990), while Tautomycetin inhibits PP1
specifically (Cheng et al. 1989; Favre et al. 1997). The phosphatase inhibitors were
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added to the STLC-treated cells separately or together for one hour prior to RO-3306
addition to allow the mitotic drug-targeted phosphatase(s) to be fully inhibited at the
time of RO-3306-induced mitotic exit. Samples were then taken at 0, 15 and 30 minutes
after RO-3306 addition and analysed as before (Figure 5.4 B).
A strong signal of CDK substrate phosphorylation was again seen before
addition of RO-3306 which was severely diminished after 15 minutes and gone after 30
minutes in the absence of any phosphatase inhibitors. In the presence of okadaic acid,
the initial amount of CDK phosphorylation was increased and the removal of CDK
substrate phosphorylations was delayed but the majority of the signal was still gone
after 30 minutes. In the presence of Tautomycetin, although the initial amount of CDK
substrate phosphorylation was again increased, the signal was gone after 30 minutes the
same as in the absence of any phosphatase inhibitors. The results of addition of both of
the phosphatase inhibitors together were the same as for okadaic acid alone suggesting
that PP2A could serve to initiate activity of the CDK counteracting phosphatases, but
neither PP2A nor PP1 are required for removal of the majority of mitotic
phosphorylations during mitotic exit in human cells. That the removal of CDK substrate
phosphorylations is not blocked by inhibition of PP1 and PP2A indicates that other
unknown phosphatases contribute to the removal of mitotic phosphorylations during
mitotic exit to return cells to interphase.
Total Greatwall levels detected using the anti-Greatwall antibody tends towards
an increased signal at later time points. This fits with the observation reported
previously that the total anti-Greatwall antibody is unable to efficiently detect the
presence of mitotically modified active Greatwall. Only once the protein has been
dephosphorylated/its mitotic modifications have been removed as the cells exit mitosis,
is the antibody able to detect the presence of the protein once more in these samples.
The presence of T194-phosphorylated, and thus active, Greatwall is rapidly decreased
after 15 minutes of RO-3306 treatment in the absence of phosphatase inhibitors or if
PP1 only is inhibited (using Tautomycetin). In the presence of okadaic acid (when
PP2A is inhibited), T194 phosphorylation of Greatwall persists and is still detected even
after 30 minutes of incubation with the CDK1 inhibitor (Figure 5.4 B). This indicates
that PP2A activity is required to dephosphorylate Greatwall at mitotic exit and that PP1
does not contribute to this. Interestingly, treatment with the PP2A inhibitor alone
seemed to cause a decreased mobility shift of Greatwall on the immunoblot prior to
CDK inhibition, suggesting that some of the mitotic modifications or phosphorylations
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of Greatwall were removed in the absence of PP2A activity. The association of
Greatwall directly with PP2A subunits, which could potentially serve to facilitate its
PTMs required for full kinase activity, have been reported (Vigneron et al. 2009). This
loss of electrophoretic mobility of Greatwall was not seen if both PP2A and PP1 were
both inhibited. Further investigations by Dr. Nadia Hégarat in our laboratory have
shown that Greatwall kinase activity levels are maintained up to 60% relative to WT
mitotic Greatwall in in vitro kinases assays when PP2A is inhibited with okadaic acid in
CDK1-inhibited mitotic cells. Therefore suggesting that PP2A contributes to the
majority of Greatwall inactivation during mitotic exit but that the removal of other
PTMs or phosphorylations (by other phosphatases, such as PP4 and PP6) likely also
occur.
The total levels of the Ensa protein remained constant in the lysates indicating
that it is not degraded, merely inactivated by dephosphorylation at mitotic exit. A
phospho-specific anti-pS67 Ensa antibody was used to assess Greatwall substrate
phosphorylation. However, the Greatwall phosphorylation motif recognised by this
antibody (FDSGDY) is identical in both Arpp19 and Ensa and thus both are detectable
with this antibody. Here I will refer to Arpp19/Ensa for simplicity because it is not
possible to distinguish between the phosphorylation of the two proteins with specific
antibodies. Greatwall phosphorylation of Arpp19/Ensa on serine 67 (S67) (Gharbi-
Ayachi et al. 2010; Mochida et al. 2010) was detected in the mitotically arrested lysates
prior to forced mitotic exit via CDK inhibition. This phosphorylation persisted 15
minutes after CDK inhibition but was gone after 30 minutes in the absence of a
phosphatase inhibitor or in the presence of either okadaic acid or Tautomycetin alone.
Only when both of these inhibitors were added together was Arpp19/Ensa
dephosphorylation blocked. This indicates that to dephosphorylate Arpp19/Ensa and
relieve its inhibition of PP2A at mitotic exit both PP2A and PP1 must be inhibited or
that a separate phosphatase targets Arpp19/Ensa that is only sufficiently inhibited in the
presence of both drugs. Further work by Dr. Nadia Hégarat in our laboratory has
demonstrated that this phosphatase is the RNA polymerase II C-terminal domain
phosphatase Fcp1 (a personal communication by Dr. Nadia Hégarat). SiRNA depletion
of Fcp1 blocked Arpp19/Ensa dephosphorylation following CDK inhibition in STLC-
synchronised mitotic HeLa cells. Fcp1 has been recently reported to be required in
human cells at the end of mitosis for timely cyclin B-CDK1 inactivation (Visconti et al.
2012). Its crucial targets include Cdc20 and Wee1, and as a result of this work we now
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add Arpp19/Ensa to this list.
5.6 Conclusions and discussion
The activation status of Greatwall has been implicated to play a critical role in
mitotic entry, maintenance of the mitotic state, as well as in mitotic exit. Throughout
this chapter the control of Greatwall activity has been examined.
A phospho-specific antibody that is highly specific for phosphorylation of
human Greatwall at T194 was used to confirm that Greatwall is phosphorylated by
CDK1 on T194 to activate it at the G2/M transition. Greatwall then remains
phosphorylated and active in mitosis until mitotic exit. It is likely that activating
phosphorylations of the T-loop by CDK1 are not the whole story of Greatwall
regulation and it is probable that other PTMs/phosphorylations occur during mitosis.
The work presented suggests that it is likely that CDK1 and not CDK2 activates
Greatwall in vivo. This may be because of the activity of the Greatwall
dephosphorylating phosphatase that counteracts Greatwall activation in interphase. This
phosphatase may require the cyclin B-CDK1 activation loop for its inactivation, thereby
integrating Greatwall activation in the larger G2/M feedback system. This chapter
describes work that initiated characterisation of the phosphatase(s) that regulate
Greatwall and its substrates.
Interestingly, the majority of WT Greatwall activated by cyclin A-CDK2 was
not hyper-shifted in the gel while the mitotic WT Greatwall was (Figure 5.2 C). This
has also been observed by other groups (Yu et al. 2006; Zhao et al. 2008). This can be
interpreted to mean that Greatwall that has been activated is further modified in mitosis.
This might point to a complex mechanism of activation to ensure Greatwall activity
with correct timing and dynamics to promote and sustain mitosis.
Phosphorylation site mapping using PhosphoSitePlus (Figure 5.5) indicates that
human Greatwall might be phosphorylated on as many as 33 different residues. Five of
these sites lie outside of the NCMR (Y59, T194, T740, S874 and S877) the rest are all
contained within it. Within the NCMR only one site is a tyrosine (Y720). The others are
all serine or threonine residues and could therefore potentially be autophosphorylated by
Greatwall itself after priming phosphorylation by CDK. Six of the indicated sites are
also potential CDK phospho-sites (S/TP) and could be alternatively phosphorylated by
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Figure 5.5 Phosphorylation/PTM site mapping of Greatwall
Phosphorylation/PTM site mapping analysis of Greatwall using PhosphoSitePlus. Sites with only one
MS/HTP reference are shown in black. Sites with more than one MS/HTP reference are shown in blue
and a site with more than five MS/HTP references is indicated in pink. The kinase domain lobes and
hydrophobic motif are indicated coloured as in Figure 4.2 B. In addition, the sites that are potentially
ubiquitinated are indicated in purple and the site, K644, which is potentially both ubiquitinated and
acetylated is indicated in orange.
CDK itself (Appendix C). It has been speculated that both of these occur upon mitotic
entry; CDKs phosphorylate Greatwall at multiple sites and Greatwall can in turn
autophosphorylate itself at multiple sites (Blake-Hodek et al. 2012). PhosphoSitePlus
analysis of Greatwall also revels that, in addition to multiple potential phosphorylated
sites, there are six sites that might be ubiquitinated; lysines (K) 39, 66, 158, 179, 199,
and 644. One of these sites, K644, is also potentially acetylated (Figure 5.5). The
massive electrophoretic retardation of mitotic Greatwall in Xenopus was reduced by
treatment with λ phosphatase (Yu et al. 2006) but in human Greatwall it was only
partially diminished (Burgess et al. 2010). Also, Greatwall was reported to be
ubiquitinated and excluded from the nucleus prior to NEBD in Drosophila, despite
being enriched in the nucleus during interphase (Archambault et al. 2007). Here, human
Greatwall pre-treated with recombinant cyclin A-CDK2 was fully active and
phosphorylated in the T-loop on T194 and this activation allowed Greatwall to
autophosphorylate but it did not display the full hyper-shift in the gel seen for mitotic
Greatwall. This suggests that further modifications are acquired by Greatwall in mitosis.
The insights provided from the analysis of potential PTMs of Greatwall using
PhosphoSitePlus analysis indicate a possible explanation in which regulation of
Greatwall activity could occur via a balance between phosphorylation, ubiquitination
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and acetylation of the protein. These observations hint that Greatwall activation might
require complex control mechanisms not yet understood.
Mechanisms in which protein activity is regulated by a balance between
phosphorylation, ubiquitination and acetylation modifications are known. Another AGC
kinase, p70 ribosomal S6 kinase (S6K), is known to be activated by phosphorylation on
multiple serine and threonine residues. It is also targeted by acetylation on lysine 516 by
the histone acetyltransferase (HAT) p300 which serves to modulate the functions of the
kinase in response to growth factor signalling (Fenton et al. 2010). Furthermore, S6K
ubiquitination has recently been shown to be an important regulatory event in S6K
signalling and serves to control the steady state levels of this kinase in human cells
(Wang et al. 2008). Additionally, the tumour suppressor p53 is activated by a
phosphorylation-acetylation cascade in response to DNA damage. Phosphorylations in
the N-terminus of the protein in response to DNA damage enhance its interaction with
p300 and the p300/CBP-associated factor (PCAF) thereby driving acetylation of p53 in
its C-terminus. Its acetylation on at least eight sites is essential for its dissociation from
its repressor Mdm2 and activation. This serves to prevent ubiquitination preventing its
export and degradation (Sakaguchi et al. 1998; Tang et al. 2008).
The analysis revealing potential ubiquitination and phosphorylation sites as well
as a potential acetylation site within the protein indicate that a similar complex mode of
regulation might apply to Greatwall. It is clear that a large electrophoretic mobility shift
is seen for human Greatwall at the G2/M transition that persists until mitotic exit. It is
conceivable that Greatwall activity is modulated via ubiquitination at one or all of the
six potential ubiquitination sites, by acetylation and by multiple phosphorylations which
could serve to facilitate the activation as well as stabilisation and/or localisation of
Greatwall. Some of these modifications could potentially be mediated by CDK1-
activated second messenger proteins. Alternatively, mitotic modification of the protein
via ubiquitination, acetylation and/or phosphorylation might serve to promote its
association with as yet unknown inhibitors or activating proteins required to modulate
its activity in mitosis. This complex model of Greatwall activation remains to be
elucidated but it would not be unprecedented considering the mechanisms controlling
other proteins, such as S6K and p53.
The evidence presented in this chapter (Figure 5.2 C) indicates that CDK
phosphorylation is capable of activating Greatwall to its full capacity. This activating
phosphorylation of Greatwall is likely to occur via phosphorylation by CDK1 for the
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reasons discussed previously. However, in RO-3306-treated cells, in which CDK1
activity was repressed, Greatwall has been repeatedly detected at seemingly low levels
despite careful equalisation of total protein levels. This suggests that the PTMs that
Greatwall acquires at mitotic entry may have already begun to be added to the kinase in
this late G2 phase block. Therefore, preventing its detection by the anti-Greatwall
antibody as has been noted for the active kinase in mitotic extracts. Alternatively, in the
absence of CDK1 activity at the G2/M transition the protein might be unstable and
possibly actively degraded. RO-3306 treatment is known to result in downregulation of
anti-apoptotic genes such as Bcl-2, survivin and p21 in human cells (Kojima et al.
2009). Its mechanism of action is unknown but it is possible that Greatwall is affected
in the same manner after treatment with RO-3306. Another explanation could be that, as
discussed, CDKs other than CDK1 are able to phosphorylate Greatwall and activate it.
Therefore, in the absence of CDK1 activity in late G2 it is destabilised/degraded to
ensure early Greatwall activity is not triggered aberrantly by phosphorylation by other
CDKs such as CDK2 which remains active in G2 (Hochegger et al. 2008). Further
experiments with other CDK and proteasome inhibitors could clarify this observation.
Additionally, as mentioned previously, it is likely that Greatwall can
autophosphorylate itself as well as being phosphorylated by additional kinases. Kinase
autophosphorylation can occur via an intermolecular mechanism (when one kinase
molecule phosphorylates another) or via an intramolecular mechanism (when a kinase
molecule acts upon itself). Recently a paper published by Dodson et al. (2013) reported
a biochemical method for testing an individual kinase to determine its activation
mechanism via derivation of its kinetic signature. Future work might seek to explore the
mechanism of Greatwall kinase autoactivation to gain further insights into the cellular
regulation this novel kinase.
Once in mitosis, Greatwall and other mitotic CDK-substrates must then be
dephosphorylated to allow proper mitotic exit (Queralt et al. 2008; Manchado et al.
2010). The results presented here suggest that PP1 and PP2A are not the main CDK-
antagonising phosphatases that remove mitotic phospho-epitopes in human cells. These
results indicate that PP2A is, however, required to dephosphorylate and inactivate
Greatwall. Further recent work from our laboratory carried out by Dr. Nadia Hégarat
has confirmed that the α and δ isoforms of the B55 subunit of PP2A are required in 
human cells to remove T194 phosphorylation in Greatwall. The siRNA-mediated
depletion of the α and δ isoforms of the B55 subunit of PP2A following CDK inhibition 
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in STLC-synchronised mitotic HeLa cells significantly reduced dephosphorylation of
T194 in Greatwall. It did not completely block this dephosphorylation, possibly due to
incomplete depletion of the B55 subunits in the cells. This confirms that PP2A-B55 is
required to inactivate Greatwall by targeting the T194 site, although, the removal of
other PTMs/phosphorylations by an unknown okadaic-acid insensitive phosphatase
likely also contributes. Furthermore, Arpp19/Ensa is targeted by another phosphatase
and recent work from our laboratory suggests that this enzyme is Fcp1. This helps
explain the observation that this phosphatase is required for mitotic exit (Visconti et al.
2012) and implicates it as yet another intrinsic element of the mitotic switch.
Intriguingly, neither PP1, PP2A nor Fcp1 are required for the majority of CDK
substrate dephosphorylation (concluded from the results presented here and personal
communication from Dr. Nadia Hégarat). In yeast this function is performed by the
Cdc14 phosphatase (Stegmeier et al. 2004). Cdc14 is a dual-specificity phosphatase that
belongs to a phosphatase family quite distinct from PP1 and PP2A and is insensitive to
okadaic acid (Queralt et al. 2008). As discussed (Chapter 1 section 1.13) there are two
orthologues of Cdc14 in human cells (termed Cdc14A and B). Both have been
implicated to have a role in mitotic progression and exit (Bembenek et al. 2001; Kaiser
et al. 2002; Dryden et al. 2003). To our knowledge a double deletion of these
phosphatases has not been generated, but single knockout cells and mice and show only
weak cell cycle phenotypes (Mocciaro et al. 2010; Guillamot et al. 2011). It could still
be possible that this function is conserved between yeast and humans after all and that
Cdc14 A and B play a redundant role in mitotic exit.
A manuscript reporting these findings is currently in revision for publication.
Further work will be required to reveal the regulation and cross talk of these
phosphatases. Moreover, biochemical assays will be required to prove that these
enzymes act directly on the phosphorylation sites of their respective targets. Thus, the
work presented here suggests a complex hierarchy of phosphatases acting during mitotic
exit.
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CHAPTER 6. Taking a chemical genetic approach to inhibit Greatwall
kinase
6.1 Introduction
Using endogenous gene targeting to modify an individual gene, or part of it, is
exquisitely specific. It offers a way in which to study the effect of a single gene product
by its loss (a ‘knockout’) or by its replacement with an altered version (a ‘knockin’).
This targeting strategy is based on homologous recombination and is achieved through
the careful design of a specific targeting vector to the gene of interest. Alterations that
can be introduced in this manner can vary widely and can include the deletion of
specific exons, introductions of specific point mutations, introduction of a specific tag
or even the addition of a gene. Moreover, gene targeting can be permanent or
conditional and it can be used for any gene regardless of its transcriptional activity or
size.
The strength of this technique is evident, but despite its use with great success in
bacteria and yeast, it traditionally has a very poor efficiency rate in mammalian cells. In
general, the gene targeting efficiency for mammalian cells is only 10-5 to 10-7 targeted
cells per transfected cell (Deng et al. 1992; Yanez et al. 1998; Khan et al. 2011).
Moreover, the prevalence of non-homologous end joining in mammalian cells increases
the chances of the targeting vector DNA being integrated randomly (Khan et al. 2011).
This technique can also be very slow to exert its effects and cannot be titrated to induce
variable levels of inactivation. Alternatively, small molecule inhibitors can be used to
inhibit kinases and overcome these limitations (Vassilev et al. 2006; Lenart et al. 2007;
Scutt et al. 2009). They can induce inhibition rapidly and in a dose-dependant manner.
However, due to the conservation of catalytic kinase domains between cellular protein
kinases completely specific drugs are rare and many existing ‘specific’ kinase inhibitors
can have unforeseen impacts on other kinases (Davies et al. 2000; Tyler et al. 2007;
Garske et al. 2011). This is highlighted by results obtained in which different
phenotypes were observed from genetic and pharmaceutical approaches used to target
the same kinase (Weiss et al. 2007).
Recently a range of new techniques have been developed to improve gene
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targeting speed and efficiency in human cells. These include the use of simplified
methods for construction of gene targeting vectors and the use of viruses to improve the
efficiency of targeting (Iiizumi et al. 2006; Khan et al. 2011). Moreover, genetic
targeting and the use of small molecule inhibitors has been combined via a
comparatively new technique termed ‘chemical genetics’. This encompasses the
strengths of both techniques and has pioneered the inhibition of a single engineered
kinase using small molecule inhibitors. Chemical genetics allows inhibition of a kinase
with complete specificity to be achieved in a rapid, titratable and reversible manner.
This technique takes advantage of the conserved structure of the ATP-binding site of
protein kinases (Bishop et al. 1998; Bishop et al. 2000; Alaimo et al. 2005). Using this
approach a critical conserved bulky hydrophobic residue found in the ATP-binding site,
also known as the ‘gatekeeper’ residue or ‘molecular gate’, that restricts access to a pre-
existing cavity within the ATP-binding pocket, is mutated at the gene level to a smaller
amino acid. The resulting enlarged engineered kinase pocket is then able to accept a
bulky ATP-analogue that blocks it, preventing binding of wildtype substrates thus
rendering the kinase non-functional (Figure 6.1 A). Wildtype kinases are naturally
resistant to inhibition as they are unable to accept the bulky ATP-analogue as a result of
a steric clash with their natural larger gatekeeper residue. The mutant kinase is then
expressed from the endogenous gene locus under normal transcriptional regulation
overcoming the draw backs of off-target effects from inhibitors and eliminating doubt
over specificity (Alaimo et al. 2005; Hochegger et al. 2007; Scutt et al. 2009; Garske et
al. 2011; Hegarat et al. 2011).
In this chapter I attempt to use these techniques to adopt a chemical genetics
approach to inhibit Greatwall kinase by creating a stable human cell line expressing an
ATP-analogue sensitive (as) Greatwall.
6.2 Identification of the gatekeeper residue in Greatwall
In order to identify the gatekeeper residue in the ATP-binding pocket of
Greatwall I aligned the amino acid sequence with that of another AGC kinase, PKA
(Figure 6.1 B and Appendix E for the full alignment). In 2002, both the α and β 
isoforms of the catalytic subunit of PKA were engineered to modify their structures so
that they acquired novel inhibitor sensitivity (Niswender et al. 2002). This was achieved
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Figure 6.1 Identifying the gatekeeper residue of human Greatwall kinase
(A) Using a chemical genetic approach to inhibit a kinase. Only an engineered kinase with an enlarged
ATP-binding pocket is able to accept the bulky ATP-analogue resulting in the inhibition of that kinase
specifically. Adapted from Alaimo et al. (2005). (B) Sequence alignment of Greatwall with the α isoform 
of the catalytic subunit of PKA. The kinase N-terminal subdomain is shown in a CLUSTAL 2.1 multiple
sequence alignment. An asterisk (*) indicates positions that have a single, fully conserved residue. A
colon (:) indicates conservation between groups of strongly similar properties - scoring > 0.5 in the
Gonnet PAM 250 matrix. A period (.) indicates conservation between groups of weakly similar properties
- scoring =< 0.5 in the Gonnet PAM 250 matrix (Larkin et al. 2007; Goujon et al. 2010). Key features:
A
B
M110C
Mutant
kinase Inhibitor
Adenosine
Adenosine
P P
P P
Protein
substrate
Protein
substrate
WT
kinase
Inhibitor
Adenosine
Adenosine
P P
P P
Protein
substrate
Protein
substrate
P
P P
P
Greatwall
Greatwall
Nucleotide binding site (Glycine rich loop)
DFG motif
Ion pair
Gatekeeper methionine
Greatwall
PKA
PKA
PKA
ISRGAFGKVYL--GQKGGKLYAVKVVKKADMIN-KNMTHQVQAERDALAL
LGTGSFGRVMLVKHKETGNHYAMKILDKQKVVKLKQIEHTLNEKRILQAV
:..*:**:*.* .::.*..**:*::.*..::. *.:.*.:..:*...*:
SKSPFIVHLYYSLQSANNVYLVMEYLIGGDVKSLLHIYGYFDEEMAVKYI
N-FPFLVKLEFSFKDNSNLYMVMEYVPGGEMFSHLRRIGRFSEPHARFYA
: .**:*.*.:*.:..:*:*:****:.**::.*.*...*.*.*..*..*.
SEVALALDYLHRHGIIHRDLKPDNMLISNEGHIKLTDFG
AQIVLTFEYLHSLDLIYRDLKPENLLIDQQGYIQVTDFG
:::.*..:***...:*:*****:*:**..:*:*::****
167
CHAPTER 6
glycine rich loop, DFG motif, ion pair and the gatekeeper methionine are indicated. (C) Schematic
representation of the Greatwall protein indicating the position of the gatekeeper methionine 110 in the
kinase N-lobe. The kinase N-lobe (aqua) and C-lobe (orange) are indicated as well as the hydrophobic
motif (pink). (D) Mapped features of Greatwall. The kinase N-lobe is indicated in aqua font and the
glycine rich loop, DFG motif and ion pair (K62 and E81) are indicated. Residues mutated (including the
gatekeeper methionine) in this investigation are indicated by diamond parentheses. (E) Sequence
alignment of human, Xenopus and Drosophila Greatwalls. The kinase N-terminal subdomain is shown in
a CLUSTAL 2.1 multiple sequence alignment as described for (B). Coloured as for (D). (F) Structural
model of the ATP-binding pocket of Greatwall. Here the small N-lobe (aqua), large C-lobe (orange), and
activation loop (grey) are indicated (as in Figure 4.2). One molecule of ADP is shown in the ATP-
binding site in green. This was generated up the superposition of CHK2 (PDB: 2CN5) on the Greatwall
model (introduced in Chapter 4). The gatekeeper M110 and V94 are shown in grey and the dotted
surface indicates the van der waals radius of M110. (G) Structural model of the ATP-binding pocket of
Greatwall targeted for engineering. This is coloured as for (F). One molecule of the bulky ATP-analogue,
1NM-PP1, is shown in the ATP-binding site in yellow. This was generated by overlaying CHK2 (PDB:
E
D
Gatekeeper M110
DFG motif
Ion pair
Nucleotide binding
site (Glycine rich loop)
V94
Y107Y59
V61
1 MDPTAGSKKEPGGGAATEEGVNRIAVPKPPSIEEFSIVKPISRGAFGKVY
51 LGQKGGKLYAVKVVKKADMINKNMTHQVQAERDALALSKSPFIVHLYYSL
101 QSANNVYLVMEYLIGGDVKSLLHIYGYFDEEMAVKYISEVALALDYLHRH
151 GIIHRDLKPDNMLISNEGHIKLTDFGLSKVTLNRDINMMDILTTPSMAKP
Human
Xenopus
Drosophila
Human
Xenopus
Drosophila
DFG motif
Ion pair Nucleotide binding site (Glycine rich loop)
Gatekeeper methionine
Human
Xenopus
Drosophila
KPISRGAFGKVYLGQK---GGKLYAVKVVKKADMINKNMTHQVQAERDALALSKSPFIVH 95
KPISRGAFGKVYLARRKN-NSKLFAVKVVKKADMINKNMVQQVQAERDALALSKSPFIVH 94
KPISRGAFGKVFLGYKNNDSKRLFAIKVMRKSEMINKNMVSQVITERNALALSRSQFCVS 120
***********:*. : . :*:*:**::*::******. ** :**:*****:* * *
LYYSLQSANNVYLVMEYLIGGDVKSLLHIYGYFDEEMAVKYISEVALALDYLHRHGIIHR 155
LYYSLQSANNIYLVMEYLIGGDVKSLLHIYGYFDEEMAVKYISEVAMALDYLHRHGIIHR 154
LFYSLQSLSYVYLVMEYMVGGDLKSLLAMFGYFDEPTARFYVAEMVMALQYLHQHGIVHR 180
*:***** . :******::***:**** ::***** * *::*:.:**:***:***:**
DLKPDNMLISNEGHIKLTDFGLSKVTLNRDINMMDILTTPSMAKPRQDYSRTPGQVLSLI 215
DLKPDNMLISNKGHIKLTDFGLSKVTLKRELCMMDILTTPSMAKPKRDYSRTPGQVLSLI 214
DIKPDNMLLSSSGHVKLTDFGLSKIDMRRDLEISDLINCSPNLN-----ARTPGQLLSLT 235
*:******:*..**:*********: :.*:: : *::. .. : :*****:***
168
CHAPTER 6
4LGH) on the Greatwall model. This clearly illustrates the steric clash that occurs between the ATP-
analogue and the naturally occurring gatekeeper methionine that renders the wildtype kinase immune to
inhibition with the ATP-analogue. It is this M110 that can be mutated to a smaller residue to allow the
engineered kinase to accept the bulky ATP-analogue inhibitor.
by mutating the gatekeeper methionine at position 120 in the ATP-binding pocket to a
smaller amino acid residue, either to an alanine or a glycine respectively. In this manner
both the α and β isoforms were successfully rendered sensitive to specific bulky ATP-
analogue inhibitors. These inhibitors did not inhibit the wildtype PKA but allowed
M110
V94
ADP
1NM-PP1
G
F
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effective inhibition of the engineered isoforms separately and thus allowed the roles of
the two isoforms to be better defined.
Comparison of the amino acid sequence of the ATP-binding pocket of PKA
catalytic subunit α isoform with that of Greatwall indicates that they share the same 
methionine at the gatekeeper position in the ATP-binding pocket (Figure 6.1 C and F).
The gatekeeper methionine at position 110 (M110) is located in the kinase N-terminal
subdomain (Figure 6.1 C, D and F) at the beginning of exon 3 in the Greatwall gene
locus and is conserved across Drosophila, Xenopus and humans (Figure 6.1 E and
Appendix C for full alignment). Based on this we hypothesised that mutation of this
gatekeeper methionine to a smaller alanine residue (M110A) should render it ATP-
analogue sensitive. This space-creating substitution of the gatekeeper residue would
alter the size of the ATP-binding pocket of the kinase allowing it to accept the bulky
ATP-analogue (Figure 6.1 G). Thus, inducing sensitivity to bulky ATP-analogues in
the same manner as for PKA (Niswender et al. 2002; Alaimo et al. 2005). This as
Greatwall would then be able to be rapidly inhibited by the addition of a cell permeable
bulky ATP-analogue in a titratable and reversible manner. Allowing the effects of the
loss of Greatwall kinase activity specifically to be studied in an otherwise ‘normal’ cell.
6.3 Targeting vector construction
I used the MultiSite Gateway® system from Invitrogen to create a gene targeting
vector to introduce the M110A mutation of the ATP-binding site into the Greatwall
gene locus. This system provides a quick and simple method for the creation of gene
targeting constructs (Iiizumi et al. 2006). For this method, the design of primers to
allow the PCR amplification of genomic DNA fragments for homologous DNA arms is
the critical step. Once these have been created there is no requirement for ligation
reactions or extensive restriction site mapping that can be laborious and time consuming
when using traditional techniques.
This cloning method is based on the bacteriophage λ site-specific recombination 
system which allows λ integration into the E.coli chromosome and for the switch
between the lytic and lysogenic pathways. This system has been modified here in order
to allow the rapid and efficient transfer of heterologous DNA sequences into multiple
vector systems. The site-specific recombination occurs between attachment (att) sites in
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a conservative manner such that there is no net gain or loss of bases and no DNA
synthesis is required. The recombination is catalysed by a mix of enzymes that bind to
the att sites, bringing the target sequences together and facilitating strand exchange and
ligation of the DNA in a novel form. This results in the DNA segments flanking the att
sites being switched in a manner so that the resultant att sites are hybrids of the
sequences donated by each parental vector. The mixture of recombination enzymes used
is dependant on whether the λ phage utilises the lytic (as for the BP recombination 
reaction between attB and attP sites) or the lysogenic pathway (as for the LR
recombination reaction between the attL and attR sites) (also see Chapter 2, section
2.2.5 Figure 2.2.1). For this purpose entry vectors are generated by PCR amplification
of the genomic DNA for the homologous DNA arms flanked by appropriate att sites
and assembled with the backbone of an entry vector via a site-specific recombination
reaction (the BP reaction). This method then allows for the assembly of four DNA
fragments; the destination vector backbone, a selection cassette and the two (subcloned)
homologous DNA arms, together in a single step via independent site-specific
recombination reactions (the LR reaction). This powerful new cloning technology
allows for the replacement of endonucleases and ligase with site-specific recombination
(Iiizumi et al. 2006) (for more information refer to the Gateway® Technology with
Clonase™ II manual from Invitrogen).
The targeting strategy for the Greatwall gene locus (shown in Figure 6.2 A)
involved the design of primers to generate a 1058 bp left (5’) homology arm situated in
exon 2 of the Greatwall gene and a 951 bp right (3’) homology arm that included the
beginning of exon 3 of the Greatwall gene. The M110A mutation was introduced at the
beginning of exon 3 in the 3’ homology arm by the 3’ primer as indicated in Figure 6.2
A. These homology arms were amplified by PCR from genomic DNA extracted from
human HeLa cells. Here the 5’ homology arm contained an additional NdeI restriction
site introduced by the 3’ primer within the non-coding sequence for later screening by
Southern blotting. Specific recombination att sequences were inserted at either end of
the arms to allow the site-specific homologous recombination into the correct entry
vectors via the BP recombination reaction. The resulting left homology arm and right
homology arm entry vectors were confirmed by sequence analysis. These were then
taken into a final recombination step involving a four way recombination reaction with
a selection cassette entry vector (providing a drug resistance gene) and the backbone of
the destination vector (pAAV-Dest) to create the final targeting vector using the LR
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Figure 6.2 Strategy for creating an as Greatwall knockin human cell line
(A) A schematic representation of the targeting strategy to introduce the M110A mutation (indicated by a
violet stripe in exon 3) into the ATP-binding pocket of Greatwall kinase. Here the primers (indicated by
pink arrows) were used to amplify the left (5’) and a right (3’) homology arms (LA and RA respectively)
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that were then incorporated into a destination vector (pAAV-Dest) with a puromycin resistance gene
(Puror, indicated by the purple block arrow) in a four-way recombination reaction. The resulting targeting
vector is indicated, containing the AAV vector backbone that allowed for viral infection in human
HCT116 cells. The resulting targeted allele generated from homologous recombination with the targeting
vector is shown, as are the expected fragments sizes from NdeI digestion of the targeted allele containing
the incorporated selection cassette or with it deleted from this site by Cre. Exons are indicated by black
rectangles, att sites are indicated with aqua and orange rectangles, loxP sites are indicated by black arrow
heads, NdeI restriction sites are indicated by black arrows and the position of the probe used for Southern
blotting is indicated by a clear rectangle. (B) NotI digestion of the final gene targeting vector. The
expected bands are indicated: 951 bp for the 3’ homology arm, 1058 bp for the 5’ homology arm, 2460 bp
for the puromycin resistance gene, and 2884 bp for the pAAV-Dest vector back bone.
recombination reaction. The selection cassette I used contained a gene to provide
resistance to the antibiotic puromycin for selection of cells containing integrated
constructs. The final gene targeting vector was confirmed by restriction digestion
(Figure 6.2 B).
6.4 Targeting Greatwall in human cells to make a stable knockin cell line
Traditional methods for gene targeting have commonly had very low efficiency
in human cells, as mentioned previously (Khan et al. 2011). To obtain higher
frequencies of gene targeting of the Greatwall gene in a human cell line, I used novel
adeno-associated viral (AAV) technology (Kohli et al. 2004). The pAAV-Dest
destination vector backbone I used for the gene targeting vector contained the att
recombination site-containing cassette, required for the site-specific recombination
reaction, inserted into a pAAV-MCS vector that carried genes required for use in an
AAV system. The adeno-associated viruses (AAVs) are replication-deficient
parvoviruses that traditionally require co-infection with a helper adenovirus or herpes
virus to allow effective infection. The system I used allows production of infectious
recombinant human adeno-associated virus-2 virons without the need for a live helper
virus. Instead, co-transfection of the pAAV-MCS with a pHelper plasmid provides most
of the gene products required for the production of infectious AAV particles. The rest
are supplied by the AAV-293 host cells that are derived from HEK-293 cells and have
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been modified to produce higher viral titers. In the wildtype AAV-2 virus, the genome
contains both rep genes (encoding genes for replication) and cap genes (encoding
caspid genes) flanked by inverted terminal repeats (ITRs) containing the cis-acting
elements required for viral replication and packaging. Here the rep and cap genes have
been removed from the viral vector leaving the ITRs only which allows for the targeting
sequence to be inserted into the viral genome. The rep and cap genes are instead
supplied in trans on the pAAV-RC plasmid. Because the viral vector containing the
AAV-2 ITRs (in this case pAAV-MCS) does not share any homology with the pAAV-
RC plasmid, the wildtype virus cannot be regenerated through recombination, as can
potentially happen in other systems. The pAAV-MCS target sequence-containing
plasmid is thus co-transfected with the pHelper and pAAV-RC plasmids resulting in
viral replication and packaging in the AAV-293 cells. The recombinant AVV-2
particles can then be prepared and used to infect any mammalian cell line of choice
(Kohli et al. 2004) (for more information see the AAV Helper-Free System Instruction
Manual from Agilent Technologies).
The advantage of using this system is that gene targeting rates of 1% to 13% can
be achieved in human cell lines (Russell et al. 1998; Porteus et al. 2003; Kohli et al.
2004). Moreover, defined sequence changes to the chromosomal loci can be introduced
with high fidelity and without genotoxicity (Khan et al. 2011). The targeting
frequencies achieved are several logs higher than can be obtained using conventional
transfection or electroporation techniques. The reasons for this high efficiency rate are
not fully understood but likely results from the delivery of large numbers of single-
stranded vector genomes to the cell nucleus. The large numbers of the genomes present
in the nuclei serves to enhance the targeting efficiency and, while the vast majority of
the vector genomes are transcriptionally inactive, they are available to participate in
homologous pairing with chromosomal loci. That the vector genome is delivered as
single-stranded DNA also likely promotes homologous recombination, and the
formation of hairpin structures by the ITRs at the AAV vector termini further serve to
stabilise the vector genomes and decrease random integration events (Russell et al.
1998; Khan et al. 2011).
I co-transfected the AAV-293 cells with the Greatwall gene targeting vector, the
pHelper plasmid, and the pAAV-RC vector using calcium phosphate transfection and
allowed 72 hours for the production of infectious recombinant AAV-2 virons (rAAVs).
Viral stocks were then prepared and incubated with the human colorectal cancer cell
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line; HCT116 cells. I selected this human cell line for genetic targeting of the Greatwall
gene because it is known to have high gene targeting rates and has been successfully
used to target a number of human genes previously (Waldman et al. 1995; Waldman et
al. 1996; Bunz et al. 1998). Importantly, these cells are mismatch repair deficient and
have been demonstrated to be amenable to successful gene targeting by homologous
recombination (Waldman et al. 1995; Horiuchi et al. 2012). Selection for positive
clones was carried out in puromycin-containing media for three to four weeks in 96-
well plates. Once single colonies had formed, the clones were expanded into 6-well
plates and allowed to grow up for an additional week. Each clone was then trypsinised
and divided into two halves. One half of the cells from each clone were frozen down
and stored. The second half of the cells were used to extract genomic DNA for
screening for the presence of targeted alleles.
6.5 Screening to detect the first targeted allele
In order to detect the presence of locus-specific targeting events in these clones
PCR screening was used. Genomic DNA from groups of five clones were pooled
together in PCR reactions designed to allow screening for the presence of targeted
Greatwall alleles. I designed a forward primer (primer C) that would anneal to a portion
of the selection cassette sequence and the beginning of exon three containing the
M110A inserted mutation. This was paired with a reverse primer (primer B) situated
outside of the right homology arm in the unchanged exon four. As a positive control
another forward primer (primer A) was designed that annealed only to the wildtype non-
mutated beginning of exon three and could also be combined with reverse primer B.
These primers are indicated in Figure 6.3 A. If a targeted allele is present in the
genomic DNA from one of the clones in a particular pool then a PCR product of the
correct size (~ 1.5 Kb) should been seen when the PCR reaction with primers A and C is
run on an agarose gel. Thus, indicating a specific targeting event at the Greatwall gene.
In order to determine that genomic DNA (containing wildtype alleles) was present in
detectable quantities and that the PCR reactions were working correctly a PCR product
(of ~1.5 Kb) should been seen from all the PCR reactions carried out using primers A
and B.
Over 160 clones were picked and prepared. Fortunately however, the PCR
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Figure 6.3 Detecting the first targeted as Greatwall allele
(A) Screening strategy for detection of the wildtype or targeted allele in clones. Coloured as described for
Figure 6.2 A. PCR reactions with primer pair A and B amplify a ~ 1.5 Kb fragment from wildtype exon 3
to exon 4. PCR reactions with primer pair C and B amplify the inserted att sequence with the inserted
M110A mutation of exon 3 producing a ~ 1.5 Kb fragment only when these extra and altered sequences
are present at this gene locus. Thus allowing the presence of a targeted as Greatwall allele to be detected.
(B) The results of the PCR screens using primer pairs A and B (AB) or C and B (CB). The first two lanes
contain a molecular weight marker ladder (M). Run in the next lane is a PCR reaction with primer pair
AB using genomic DNA from wildtype HCT116 cells (HCT) which shows the expected ~ 1.5 Kb product
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from the wildtype alleles. Run in the lane after is a PCR reaction with primer pair C and B with wildtype
HCT116 cell genomic DNA showing no product, indicating that they do not amplify any product from
these cells DNA as no targeted allele is present. This pattern of loading is repeated for clones H6-10,
H16-20 and H31-32. Positive clones are indicated by the presence of a product of ~ 1.5Kb in lanes loaded
with PCR reactions using primer pair C and B. Pink circles indicate positive clones H10, H18 and H32.
(C) Southern blot to confirm targeted alleles in the positive clones identified. The expected bands after
NdeI digestion of genomic DNA are indicated schematically on the right. These are 9.9 Kb for wildtype
alleles and 6.2 Kb for targeted alleles. The autoradiograph is shown on the left. The first lane shows the
digestion of wildtype HCT116 cells (WT). This shows only the presence of the 9.9 Kb wildtype allele as
expected, while clones H10, 18 and 32 show the presence of an additional targeted 6.2 Kb allele (circled
in pink).
screening from the first eight pools (the first 40 clones) revealed the presence of a
targeted allele in three of the pooled groups. Each clone from a positive pool was then
screened individually (Figure 6.3 B). Three positive clones (H10, H18 and H32) were
identified as potentially containing a targeted M110A mutant Greatwall allele as well as
a wildtype Greatwall allele.
Southern blotting analysis was used to confirm the presence of a targeted allele
in these three clones. The genomic DNA of the clones was digested with restriction
enzyme NdeI. The PCR primers used to amplify the left homology arm for gene
targeting were designed to introduce an additional NdeI site into targeted alleles
(Figure 6.2 A). This meant that the Southern probe I had designed would anneal to a
9.9 Kb band of NdeI-digested genomic DNA downstream of the right homology arm
(indicated in Figure 6.2 A) from wildtype alleles but would anneal to a shorter 6.2 Kb
band of NdeI-digested genomic DNA in any targeted alleles. These bands could then be
detected by running the digested DNA out on an agarose gel, probing with the
radiolabeled probe and using an autoradiograph to visualise the band sizes. The
presence of a targeted allele was confirmed in this manner in all three of the clones that
had been indicated previously by PCR (Figure 6.3 C). That these targeted alleles
carried the M110A mutation in exon three was subsequently also confirmed by
sequence analysis.
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6.6 Cre-mediated excision of the drug resistance gene in targeted cells
In order to recover puromycin sensitivity and ensure that the drug resistance
gene did not interfere with expression of as Greatwall from the targeted allele, the
resistance gene was excised using Cre recombinase. This then also allowed the use of
the same procedure as had already been fine-tuned for these cells during the first round
of targeting to target the second allele, to enable selection of homozygous targeted
clones again using puromycin.
This was achieved using an adenovirus expressing Cre recombinase (Ad-CMV-
Cre, Vector Labs) that mediated excision of the puromycin resistance gene by virtue of
the flanking loxP sequences. Cre recombinase is a Type 1 topoisomerase from the P1
bacteriophage that catalyses site-specific recombination between loxP sites. The loxP
sites comprise two inverted 13 bp repeats flanking an 18 bp spacer region that confers
directionality (these sites are indicated in Figure 6.2 A). The presence of loxP sites in
the same direction flanking the puromycin resistance gene causes it to be excised by Cre
recombinase leaving a single loxP site (Park et al. 2001; Kohli et al. 2004).
To excise the puromycin resistance gene I chose to use clone H18. The cells
were infected with virus with a multiplicity of infection (MOI) of 100. The cells were
incubated with virus-containing media for 24 hours after which cells were plated in 96-
well plates. Clones were then selected for deletion of the puromycin resistance gene by
double selection in media with or without puromycin. Clones that died in puromycin but
remained growing in media without puromycin were taken for analysis by Southern
blotting. Five clones (H18-puro C1, 3, 4, 5, and 6) that no longer contained the
puromycin resistance gene were identified by the presence of a 3.7 Kb band indicating
that the gene had been excised (Figure 6.4 A).
6.7 Targeting the second allele
The next step was to carry out a second round of gene targeting to mutate the
remaining wildtype Greatwall allele to obtain a homozygous cell line expressing the as
Greatwall from the endogenous gene locus of both alleles.
For this I chose to use clone H18-puro C5. The cells were re-infected with
freshly prepared viral stock and selection carried out in puromycin-containing media for
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Figure 6.4 Targeting the second allele to create a homozygous as Greatwall knockin human cell line
(A) Southern blot to confirm the deletion of the puromycin resistance gene from targeted alleles in the
positive clone H18. The expected bands after NdeI digestion of genomic DNA are indicated
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schematically on the right: a 9.9 Kb for wildtype alleles (+/+), 6.2 Kb for targeted alleles (+/mutpuro), and
a smaller 3.2. Kb band of targeted alleles with the puromycin resistance gene successfully deleted (+/mut-
puro). The autoradiograph is shown on the left. The first lane shows the digestion of the wildtype HCT116
cells (WT). Only the presence of the 9.9 Kb wildtype allele is detected as expected. The next lane shows
the digestion of the clone H18 indicating a wildtype allele and a 6.2 Kb targeted allele containing the
puromycin selection cassette as expected is present. The following lanes are digestions of genomic DNA
from clones of H18 after infection with Ad-CMV-Cre that showed re-sensitisation to puromycin. The
deletion of the puromycin resistance gene from the targeted allele in the clones C1, C3, C4, and C5 is
indicated by the presence of the smaller 3.2 Kb band in these lanes (indicated by pink circles). (B) A
screening strategy for detection of targeted alleles containing the puromycin resistance gene. The primer
pair C and B detects the targeted alleles by amplifying DNA sequence that includes the inserted att
sequence and M110A mutation of exon 3 producing a ~ 1.5 Kb fragment only when these extra and
altered sequences are present at this gene locus. The primer pair DB anneal inside the puromycin
resistance gene and will only produce a product of ~ 1.6 Kb if this gene is present in an allele. Thus,
allowing newly targeted alleles to be identified. (C) The results of the PCR screens using primer pair C
and B (CB) or D and B (DB) are shown. The first lane contains the molecular weight marker ladder (M).
The next two lanes contain the PCR reactions of the wildtype HCT116 cells (HCT) with primers C and B
and D and B. As expected no products are present due to the complete absence of any targeted alleles.
The next two lanes show PCR reactions of the H18 clone with primers CB and DB and both show PCR
products indicting the presence of a targeted allele containing the puromycin resistance gene as expected.
The following two lanes contain PCR reactions with primers CB and DB with clone C5 genomic DNA in
which the puromycin resistance gene has been deleted. Correspondingly only primers CB give an
expected ~ 1.5 Kb product indicating a targeted allele with no puromycin resistance gene. The next two
lanes indicate the control PCR reactions with no genomic DNA template added. Following these are the
results of new (AS) clones generated from the second round of targeting. The clones that show products
in PCR reactions with both primers CB and DB indicate the presence of a targeted allele containing the
puromycin resistance gene. These clones AS2, 6, 8, and 28 are indicated circled in pink.
three to four weeks in 96-well plates. Once single colonies had formed over 200 clones
were expanded into 6-well plates and allowed to grow up for a further week. Each clone
was then frozen down and a sample of the cells used for genomic DNA extraction. The
genomic DNA was again pooled in groups of five clones in PCR reactions using
primers designed to detect the targeted allele as a positive control or the targeted allele
containing the puromycin resistance gene, indicating a new targeting event (Figure 6.4
B). In order to detect any newly targeted alleles I designed a forward primer (primer D)
situated within the puromycin resistance gene (indicated in Figure 6.4 B) that was again
paired with the reverse primer B. If a newly targeted allele is present in the genomic
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DNA from one of the clones in a particular pool then a PCR product of the correct size
(~ 1.6 Kb) should been seen when the PCR reaction with primers D and B is run on an
agarose gel. As a positive control a PCR product (of ~1.5 Kb) should been seen from all
the PCR reactions carried out using primers C and B designed to detect the presence of
the first targeted allele (as described in section 6.5).
Each clone from positive pools was then screened individually. The first ten
clones were screened in this manner and three potential positive clones (AS2, 6 and 8)
were identified (Figure 6.4 C). The results of the PCR reactions with these clones
showed a PCR product in the reaction with primers D and B as well as with primers C
and B. This suggests the presence of newly targeted alleles containing the puromycin
resistance gene as well as an original targeted allele, indicating that these clones were
potentially homozygous clones expressing only the as Greatwall from both alleles.
These promising results were soon proven to be flawed and further PCR analysis
reveled that these clones additionally all contained a wildtype allele (Figure 6.5 A).
This was indicated by the presence of a PCR product from a PCR reaction with primers
A and B and confirmed that a wildtype allele remained at this gene locus in these
clones. This disappointing result indicates that re-targeting of the original targeted allele
occurred and the remaining wildtype allele was not targeted. This finding was repeated
with all further clones screened.
6.8 In vitro analysis of as Greatwall activity
The result from the second round of gene targeting led me to question if
mutating Greatwall at this site could render it inactive, thus causing this mutation to be
lethal or severely growth inhibitory if both alleles are altered.
At the time that the results of the second round of targeting were obtained, I also
completed development of a number of new tools that would allow me to investigate the
as Greatwall mutant. I had cloned the human Greatwall cDNA and flag-tagged it (as
described in Chapter 3). I had also finished validating the anti-Greatwall antibody.
Furthermore, a paper describing an in vitro kinase assay using MBP as a substrate for
human Greatwall was published by Burgess et al. (2010). They had also attempted to
create an as Greatwall by mutation of the gatekeeper to a glycine and found that this
rendered the kinase inactive (author communication). This supported my suspicion that
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Figure 6.5 Analysis of as Greatwall cells
(A) The results of the PCR screening of the positive AS clones using primer pair A and B (AB) or D and
B (DB) are shown (described in Figure 6.4 B). These AS clones should no longer contain a wildtype
allele, only two targeted alleles: one with a puromycin resistance gene and one without. To test this, PCR
reactions with primer pair AB (to detect the presence of a wildtype allele) and with the DB primers as a
control (to detect the puromycin resistance gene containing-allele) were carried out using the potentially
positive clones detected in Figure 6.4 C. As indicated by the presence of a product of ~ 1.5Kb in lanes
loaded with PCR reactions using primers AB (indicated circled in pink), all the potentially positive clones
contained a wildtype allele. This suggests that the original targeted allele is likely to have been re-targeted
to produce a positive result when screened by PCR with primers DB. (B) Flag-tagged Greatwall or the
M110A mutant was expressed in human HEK 293T cells. Cells transfected with a GFP control were
analysed as well. After 24 hours the cells were treated with Nocodazole. The flag-tagged proteins were
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then immunoprecipitated using anti-flag magnetic beads. An in vitro kinase assay was then performed
using MBP as a substrate for the kinase. The top panel shows the results of SDS-PAGE analysis
indicating the expression of the flag-tagged protein in the cell lysates (L) and the immunoprecipitate (IP)
detected using the anti-Greatwall antibody. The autoradiograph is shown in the second panel.
Quantification of the kinase activity of the mutant kinase relative to the wildtype is shown in the graph
beneath. This represents results averaged from three independent experiments and the standard deviation
is represented by the error bars.
the problem may lie in the mutation of the kinase and not the targeting strategy adopted.
These factors prompted me to now test the kinase activity of the as Greatwall compared
to the wildtype kinase.
I created the as Greatwall mutation (methionine 110 to alanine) in the flag-
tagged cDNA by site-directed mutagenesis. The flag-tagged as and wildtype Greatwall
were transfected into human HEK 293T cells and expression allowed for 24 hours.
After this, the media was replaced with Nocodazole-containing media and the cells
incubated for a further 16 hours to arrest the cells in mitosis, when Greatwall is
maximally active. I then harvested the cells and immunoprecipitated the recombinant
flag-tagged proteins using magnetic beads coated with an anti-flag antibody. The
purified kinase was then taken into an in vitro kinase assay using MBP as a substrate.
The lysates and immunoprecipitates were assessed for expression by immunoblotting
and kinase activity against MBP was visualised on an autoradiograph (Figure 6.5 B).
The as Greatwall showed severely reduced activity with only 15% of wildtype
Greatwall kinase activity (on average, when normalised for protein amount). This result
indicates that expressing two copies of as Greatwall would effectively render the cells
Greatwall null and consequently non-viable.
6.9 Attempting to rescue the as kinase activity
It is known that the gatekeeper mutation renders a subset of kinases inactive,
although the precise reasons for the intolerance to the mutation are not well understood
(Zhang et al. 2005; Garske et al. 2011). This result unfortunately means that Greatwall
falls into this 30% of kinases tested that will not tolerate the space-creating mutation of
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the gatekeeper residue required for this type of chemical genetics approach to inhibit
them (Zhang et al. 2005; Garske et al. 2011).
Recently, a method to rescue the activity of such intolerant kinases was
described by Zhang et al. (2005) that should enable the chemical genetic methodology
to be extended to render such kinases amenable to study using this approach. To rescue
the kinase activity they attempted to identify second-site suppressor mutations that
could rescue the activity of kinases that have suffered a severe loss of activity as a result
of the introduction of the gatekeeper mutation. They termed these sogg mutations for
‘suppressors of the glycine gatekeeper’ (as the gatekeeper residue can be mutated to
either a smaller alanine or glycine residue but glycine is most commonly used) (Zhang
et al. 2005). Using structure-based sequence alignments of both tolerant and intolerant
kinases they looked to distinguish key positions that could determine tolerant from
intolerant kinases and allow second-site mutations to rescue kinase activity of intolerant
kinases. The sogg mutations they identified were all located within the antiparallel β 
sheet of the kinase N-terminal subdomain, in a region that included the twelve residues
of the three central β stands (the two edge strands - β1 and β4 - were excluded from the 
analysis as they are relatively exposed and often involved in protein-protein
interactions). The single space-creating gatekeeper mutation likely destabilises this five-
stranded antiparallel β sheet that contains numerous residues which are important for 
ATP binding and catalysis. It is therefore logical that targeted second-site mutations
within this β sheet might correct the defects caused by the gatekeeper substitution. In 
this manner they identified successful sogg mutations for five highly divergent
intolerant kinases that were able to suppress the loss of activity which had resulted from
the single alanine or glycine gatekeeper substitution (Zhang et al. 2005).
 A structure-based sequence alignment of Greatwall with the antiparallel β sheet 
in the N-terminal lobe of c-Src (a known substitution-tolerant kinase) indicated the
twelve residues that comprised the central β strands which could be targets for rescuing 
sogg mutations in the as Greatwall (Figure 6.6 A). By comparison of successful sogg
mutations introduced into the five other intolerant kinases (Cdc5, GRK2, MEKK1, Pto
and APH(3’)-IIIa) at these sites by Zhang et al. (2005), three residues were identified
that could be potentially altered to restore kinase activity to the as Greatwall (Figure
6.6 B). These residues were tyrosine 59 (Y59), valine 61 (V61) and tyrosine 107 (Y107)
(Figure 6.1 D and Figure 6.6 B).
These sites were mutated by site-directed mutagenesis in the wildtype kinase
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Figure 6.6 Creating second-site sogg mutants to rescue as kinase activity
(A) Structure-based sequence alignment of the antiparallel β sheet in the N-terminal lobe of Greatwall 
with that of c-Src. Indicated are the twelve residues that comprise the central β strands that could be 
targets for rescuing sogg mutations in the as Greatwall. Created by Dr. Anthony Oliver from the GDSC at
the University of Sussex. (B) Central strands of the antiparallel β sheet in the N-terminal lobe of 
Greatwall with sites for potential rescuing sogg mutations indicated. This information is based on work
B
A
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by Zhang et al. (2005). Again created by Dr. Anthony Oliver. (C) Flag-tagged Greatwall or mutants
Y59V, Y59T, V61I, Y106V, Y107T and M110A were expressed in human HEK 293T cells,
immunoprecipitated and taken into a kinase assay as described for Figure 6.5 B. (D) Flag-tagged
Greatwall or mutants V61I, M110A and double mutant V61I+M110A were expressed in HEK 293T cells,
immunoprecipitated and taken into a kinase assay as described for (C).
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initially to ensure that these mutations alone did not significantly alter the kinase
activity or stability. Five mutants were made: Y59 was altered to either a valine (Y59V)
or a threonine (Y59T), V61 was changed to an isoleucine (V61I) and Y107 was
changed to either a valine (Y107V) or a threonine (Y107T). These mutants were then
expressed with a flag-tag in HEK 293T cells and an in vitro kinase carried out (as
described in section 6.8). The results (Figure 6.6 C) indicate that mutation of Y107 to
either a valine or threonine severely reduces kinase activity, with these mutants
displaying only 6% and 9% of the activity of the wildtype kinase, respectively.
Mutation of Y59 also reduced kinase activity, with threonine mutant displaying only
54% of wildtype kinase activity and the valine mutant having even less activity with
only 11% of that of the wildtype kinase. This suggests that any mutation of the residues
at these positions negatively effects kinase activity and would therefore be undesirable
sogg mutations. Mutation of V61 to isoleucine, however, led to a significant increase in
activity of the kinase (with 178% of that of wildtype kinase activity). This led me to
attempt to rescue the as Greatwall kinase activity by mutating V61 to isoleucine (V61I)
in the as Greatwall mutant. The results of the kinase assay carried out with the potential
sogg mutant in the as Greatwall are shown in Figure 6.6 D. Unfortunately, the double
V61I+M110A Greatwall mutant showed only 42% kinase activity as compared with the
wildtype kinase. This is an increase in activity to that of the as Greatwall mutant alone,
but is a long way from fully restoring the kinase activity to that of the native enzyme
and is unlikely to be sufficient to support the cellular function in vivo.
6.10 Further mutagenesis to rescue kinase activity of as Greatwall
The mutation of M110 to a glycine instead of an alanine could have been
attempted but, as mentioned previously, another group had reported to us that this was
unsuccessful and rendered the kinase equally inactive (Burgess et al. 2010). These
unpromising results from the as and sogg mutations of Greatwall led me to try a
different approach. The Calcium-Dependant Protein Kinase 1 (CDPK1) is a naturally
analogue sensitive kinase found in the parasite Toxoplasma gondii (Sugi et al. 2010). It
has a glycine residue at the gatekeeper position in its ATP-binding pocket and is
efficiently inhibited with the bulky ATP-analogue, 1NM-PP1. In fact, mutation of the
gatekeeper residue from a glycine to a methionine has been shown to result in resistance
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to the inhibitor (Sugi et al. 2010). By overlaying the structures of CDPK1 and the
threaded Greatwall kinase domain, the residues involved in binding to the bulky ATP-
analogue 1NM-PP1 (and related compounds) could be examined. Based on this
sequence analysis performed by our collaborator, Dr. Anthony Oliver from the GDSC at
the University of Sussex, I created a further mutant to try and achieve an as Greatwall
with full kinase activity.
I mutated valine 94 to a methionine in combination with the M110A by site-
directed mutagenesis. The mutation of the gatekeeper residue to a small amino acid can
lead to attenuated kinase activity likely by disruption of a ‘hydrophobic spine’ which is
required to stabilise the active conformation (Garske et al. 2011). This double mutant
should have the effect of shifting the methionine from one side of the pocket to the
other to restore the hydrophobic spine critical for the active conformation and thus for
kinase activity as well as providing a stacking interaction with the bulky ATP-analogue
inhibitor (Figure 6.1 D, F and G). This mutant was expressed flag-tagged in HEK 293T
cells and their activity assessed by an in vitro kinase assay (Figure 6.7 A). The double
mutant V94M+M110A did not show much improved kinase activity, with only 30% of
wildtype kinase activity, which is unlikely to be sufficient to support kinase function in
vivo.
6.11 Creating an es Greatwall
A paper published in 2011 described an alternative chemical genetic strategy for
targeting protein kinases (Garske et al. 2011). This strategy aims to overcome the
problems of kinase activity loss as a result of mutation of the gatekeeper residue to
achieve specific inhibition via shape complementarity with a bulky ATP-analogue. This
alternative strategy is based on covalent complementarity between an engineered
gatekeeper cysteine and an electrophilic inhibitor. The introduction of a cysteine
gatekeeper enables specific and potent inhibition with an electrophilic small molecule
inhibitor by covalent complementarity without the need to enlarge the ATP-binding
pocket. This cysteine gatekeeper also preserves the geometry and hydrophobicity of the
ATP-binding pocket better than substitution to an alanine or glycine, allowing the native
conformation to be retained as well as the kinase stability and activity. This is an
important advantage as increasing evidence suggests that the conformation of the ATP-
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Figure 6.7 Creating other mutants to allow selective inhibition of Greatwall kinase
(A) Flag-tagged Greatwall or mutants M110A and V94M+M110A were expressed in human HEK 293T
cells, immunoprecipitated and taken into a kinase assay as described for Figure 6.5 B. (B) Flag-tagged
Greatwall or mutant M110C were expressed in HEK 293T cells, immunoprecipitated and taken into a
kinase assay as described for (A).
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binding pocket has additional non-catalytic functional roles, such as in facilitating
priming phosphorylation events and membrane recruitment (Cameron et al. 2009;
Okuzumi et al. 2009; Garske et al. 2011). Kinases engineered with a cysteine
gatekeeper are known as electrophile-sensitive (es) kinases (Garske et al. 2011).
Based on this work I attempted to create an es Greatwall by mutating the
gatekeeper methionine to a cysteine by site-directed mutagenesis. I then expressed this
es Greatwall with a flag-tag in HEK 293T cells and tested the mutant kinase activity in
an in vitro kinase assay (Figure 6.7 B). The es Greatwall showed a promising 75%
activity compared to the wildtype kinase. Investigation of the ability of this es Greatwall
to support cellular function in vivo now needs to be determined and this work is
currently underway.
6.12 Conclusions and discussion
My attempts to make a stable human cell line expressing an as Greatwall by
substituting the gatekeeper methionine for a smaller alanine were unsuccessful. Despite
this, the Gateway® cloning technology and AAV system utilised here were highly
successful and were used to good effect to perform gene targeting in a human cell line.
Furthermore, the PCR screening strategy developed to detect locus-specific targeting
events was highly successful allowing for rapid and reliable screening of positive
clones. The reason that this work failed was made clear by the finding that the loss of
the methionine from the ATP-binding pocket likely caused the active conformation of
the kinase to become inactive/unstable. The leads to the inevitable conclusion that any
cells homozygous for an as Greatwall would have been rendered non-viable as they
would have effectively been Greatwall null.
My attempts to rescue the stability of the active as kinase by creating a series of
second-site sogg mutations in the antiparallel β sheet of the kinase N-terminal 
subdomain were also not successful. One mutant, V61I, seemed to achieve a slight
increase in activity (to 42%) when combined with the as mutant but this improvement
would not be sufficient to support the cellular function in vivo.
More encouragingly, the es mutant, created in a final attempt to produce a
selectively inhibitable Greatwall kinase, showed a good level of kinase activity.
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Furthermore, the es Greatwall might have sufficient activity remaining (with 75%
kinase activity) to be functional in vivo and this is now being investigated.
In order to definitively determine if either of the gatekeeper residue substitutions
(as or es) are sufficient to support cellular function in vivo, a siRNA rescue system
would be invaluable. Creating these gatekeeper substitutions in a siRNA resistant
Greatwall would allow them to be used to perform a rescue in human cells after
Greatwall knockdown by RNAi. This system is currently in development and will
ultimately allow the assessment of the gatekeeper substitutions functionality in vivo.
Until such a system is available to validate these findings I can only draw conclusions
based on the results reported here.
In general, it seems that for Greatwall kinase, substitution of the gatekeeper
methionine with a glycine or alanine impacts negatively on its activity and is not a
feasible method to engineer an inhibitable kinase. More encouraging are the results of
substitution of the gatekeeper with a cysteine residue. The initial analysis of these
mutants described here indicate that engineering the ATP-binding pocket with a
cysteine residue may offer a promising future strategy for inhibiting human Greatwall
using a chemical genetic approach.
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CHAPTER 7. Investigation of Greatwall kinase as a target for cancer
therapy
7.1 Introduction
Greatwall has been implicated to play a critical role in mitotic entry,
maintenance of the mitotic state and mitotic exit in Drosophila larvae and tissue culture
cells, Xenopus egg and CSF extracts, primary mouse embryonic fibroblasts, and
transformed human cell lines (Yu et al. 2004; Yu et al. 2006; Burgess et al. 2010;
Manchado et al. 2010; Voets et al. 2010). As a result, it is now generally accepted that
Greatwall is an essential player in mitotic control that is conserved from flies to
humans. These systems all represent early embryonic cell cycles or transformed
unnatural cell cycles that have been manipulated and selected specifically for artificial
or unnatural growth. That these systems have been extremely successful in the past at
identifying and defining critical components of cell growth is undeniable. However,
during my work on the human Greatwall, some of the results I obtained (that are
presented here in the final results chapter of my thesis) have led me to question if
Greatwall is truly the widespread regulator of normal cell growth that recent studies
might suggest.
The only human disease that has been linked to a loss of Greatwall activity to
date is a relatively mild autosomal dominant thrombocytopenia in which patients
display defective megakaryocyte maturation (Gandhi et al. 2003). This results from a
single inactivating point mutation of Greatwall (E167D). Clinically, this mild-moderate
thrombocytopenia results in easy bruising but few serious complications from bleeding
(Johnson et al. 2009). Additionally, its knockdown in zebrafish does not affect
development but was associated with a reduction of platelet levels. Moreover, Johnson
et al. (2009) reported that expression of Greatwall in human tissues is restricted to
megakaryocytes and cancer cell lines. Greatwall mRNA was undetectable in all other
human tissues tested, including: brain, thalamus, pituitary gland, spinal chord, heart,
stomach, kidney, lung, testis, and ovary (Johnson et al. 2009). These data strongly
contradict the concept that Greatwall is a cell cycle regulator required in all proliferating
cells. As a consequence, it remains unclear whether Greatwall is essential for cell cycle
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control in all cells and to what extent Greatwall inactivation effects survival of
transformed and non-transformed cell lines. It is possible that human Greatwall is not
widely expressed or required for the proliferation of normal somatic cells but is instead
up-regulated and/or utilised specifically in rapidly dividing tumor cells. Thus, cancer
cells could be exquisitely sensitive to Greatwall inactivation. This would make
Greatwall an extremely attractive target for cancer therapy because its inactivation may
have only very limited side effects in non-cancerous proliferating tissues leading to a
wide therapeutic index.
The data presented in this chapter represents preliminary experimental evidence
that this might indeed be the case, indicating that Greatwall has potential as a key
clinical biomarker and an important target for cancer therapy.
7.2 Characterising Greatwall knockdown in HeLa and RPE cells
During my initial characterisation of Greatwall in human cells I worked with
two cell lines: the well characterised transformed human cervical cancer HeLa cell line,
and the non-transformed hTERT-immortalised human RPE cell line. Greatwall
knockdown in HeLa cells led to severe mitotic phenotypes that ultimately resulted in a
cell cycle arrest and apoptosis (described in depth in Chapter 3). In the RPE cells,
however, I saw no apparent effects on their growth after Greatwall depletion (Figure
7.1 A). At 72 hours after Greatwall knockdown, all the HeLa cells were dead or dying
while the RPE cells continued to grow and reach full confluency. That Greatwall had
been fully depleted in both these cell lines was confirmed by western blot (Figure 7.1
B). An additional positive control siRNA that depleted the essential mitotic kinesin,
Eg5, showed that it caused a cell cycle arrest as expected in both cell lines, further
confirming that transfection and knockdown in these cells was successful (Figure 7.1
A). It also indicates that the knockdown of essential mitotic proteins in the RPE cells
produces a phenotype.
In order to confirm that Greatwall knockdown has no effect on RPE cell growth,
I depleted Greatwall in both cell lines again, this time using two different siRNA
oligomers to target Greatwall mRNA transcripts. Again, the HeLa cells were arrested
and died upon Greatwall knockdown in both cases while the RPE cells remained
unaffected (Figure 7.1 C). Another knockdown was performed in the RPE cells using
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Figure 7.1 Greatwall depletion in HeLa and RPE cells
(A) Cell cycle (FACS/PI) profiles of HeLa and RPE cells that had been treated with 25 nM Greatwall
siRNA for 72 hours. A negative control scrambled siRNA and positive control Eg5 siRNA were also
used. (B) SDS-PAGE analysis of the HeLa and RPE cells that had been treated with 25 nM Greatwall
siRNA (GW) for 72 hours. The negative control scrambled siRNA (Cont) was also used. In the top panel
Greatwall levels were assessed using the anti-Greatwall antibody and it is clearly depleted in the samples
treated with Greatwall siRNA but is detected in cells treated with the control siRNA. An anti-α Tubulin 
antibody was used to assess tubulin levels in the cells as a loading control, shown in the lower panel.
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(C) Cell cycle (FACS/PI) profiles of HeLa and RPE cells that were treated with 25 nM Greatwall siRNA
for 72 hours. The control scrambled siRNA was used as a negative control and two different Greatwall
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siRNAs (#1 and #2) were used. (D) SiRNA titration in RPE cells. Cell cycle (FACS/PI) profiles are
shown of RPE cells that had been treated with varying concentrations (from 25 nM to 200 nM, as
indicated) of Greatwall siRNA for 72 hours. The negative control scrambled siRNA and positive control
Eg5 siRNA were also used. The Eg5 siRNA phenotype seen indicates that knockdown of essential mitotic
proteins leads to cell cycle arrest and cell death in RPE cells.
increasing concentrations (25 nM to 200 nM) of Greatwall siRNA (Figure 7.1 D). Even
when 200 nM siRNA was used to deplete Greatwall in these cells, no effect was seen on
their growth. These results were completely unexpected and led me to begin to question
if Greatwall might in fact represent a kinase specifically utilised to license cell cycle
progression only in certain cell types, rather than as a universal cell cycle regulator for
all cells. When I looked back through the available literature concerning Greatwall and
the types of systems used to study this kinase so far my suspicions were compounded,
suggesting further investigation in other cell lines was warranted.
7.3 Evaluating Greatwall knockdown in other human cell lines
In order to further explore this observation, that HeLa and RPE cells respond
very differently to Greatwall knockdown, I decided to examine if there are differences
in the responses of other cell lines. HeLa cells are a transformed cancer cell line, while
RPE cells are non-transformed and thus are considered to represent more ‘normal’ cells
for studying growth. This led me to hypothesise that transformed and cancer cell lines,
like those used to study human Greatwall thus far, might have up-regulated Greatwall
expression in order to drive their cell cycles in a manner not utilised or required in
normal non-transformed cells.
I obtained several transformed and non-transformed cell lines and tested the
effect of Greatwall knockdown in these lines. I used the transformed cell lines; HeLa
Kyoto cells (a derivative line of HeLa cells from Japan) and human colorectal cancer
HCT116 cells. In addition, I used the non-transformed cell lines: human fibroblast
1BRhTERT cells and human fibroblast 48BRhTERT cells. I again used HeLa and RPE
cells to act as control cell lines. The results obtained, as judged by FACS analysis
(Figure 7.2 A), showed a similar trend that I observed for the HeLa and RPE cells. The
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Figure 7.2 Evaluating Greatwall in other human cell lines
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(C) SDS-PAGE analysis of a cohort of human breast cancer cell lines. Greatwall expression levels were
detected using the anti-Greatwall antibody (top), and an anti-α Tubulin antibody (bottom) was used as a 
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loading control. The in vitro translated Greatwall (In vitro GW) and RPE cells were also loaded as
controls. Quantification of the immunoblot (carried out by Dr. Victoria Haley from the Trafford Centre at
the Brighton and Sussex Medical School) indicating Greatwall expression levels relative to tubulin are
shown in the graph below. (D) SDS-PAGE analysis of a cohort of human lung cancer cell lines.
Greatwall expression levels were detected and quantified as for (C). The in vitro translated Greatwall (In
vitro GW) and a normal human lung cell line (P2G) were also loaded for comparison.
non-transformed 1BRhTERT and 48BRhTERT cells showed no cell cycle arrest or cell
death after Greatwall depletion, as also seen for the RPE cells. The transformed HeLa
Kyoto and HCT116 cells showed a cell cycle arrest and apoptosis after Greatwall
depletion, as also seen in the HeLa cells.
Although this is only a very small number of cell lines to have tested, the trend
that Greatwall depletion results in cell cycle arrest and apoptosis in transformed cell
lines but does not effect normal non-transformed cell lines holds true in this experiment.
This finding is intriguing and clearly suggests further exploration of the effect is
required. To this end, I decided to evaluate Greatwall kinase in a further cohort of
human cancer cell lines.
7.4 Evaluating Greatwall expression in a cohort of cancer cell lines
In order to characterise Greatwall in human cancer cell lines I collaborated with
Professor Peter Schmid’s team in the Clinical Oncology Laboratory at the Brighton and
Sussex Medical School. Together, we initiated a preliminary study of Greatwall in a
cohort of breast and lung cancer cell lines.
I began by assessing the expression of Greatwall in these cancer cell lines by
immunoblotting. A panel of twelve human breast cancer and twelve human lung cancer
cell lines were used. For all cell lines, 1 x 105 cells were lysed in sample buffer and
loaded. In vitro translated Greatwall and RPE cells were loaded as controls and a
normal human lung cell line, P2G cells, was also loaded for comparison. The results of
the immunoblot revealed that Greatwall expression varied widely across the different
cell lines (Figure 7.2 C and D).
I then selected four of the breast cancer cell lines to begin to investigate if
Greatwall activation varied between the cancer cell lines. For this, two cell lines
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expressing high levels of Greatwall, and two medium level expressing cell lines were
used. The RPE cells and a normal breast cancer cell line (MCF10a) that had been
recently obtained were also loaded as controls. The results indicate that Greatwall
activation levels also vary between breast cancer cell lines and may not necessarily
correlate with the levels of Greatwall protein expression (Figure 7.2 B).
In order to determine the sensitivity of these cells to Greatwall knockdown using
siRNA, colorimetric (MTT cell proliferation) and clonogenic (crystal violet) assays are
currently in development. A limitation of this approach is that different cell lines have
very different growth rates and transfection efficiencies as well as varying tolerance to
transfection reagents, making it difficult to precisely quantify and compare the effects of
Greatwall knockdown. It will of course be crucial to produce a clear and in-depth
evaluation of these aspects of Greatwall in these cell lines before any conclusions about
Greatwall as a potential biomarker or anti-cancer drug target can be drawn.
7.5 Conclusions and discussion
The preliminary work presented here supports the idea that Greatwall could
potentially be an important prognostic biomarker and therapeutic target for cancer
therapy. Greatwall knockdown causes cell cycle arrest and apoptosis in transformed cell
lines but has little impact on survival of non-transformed cells. Moreover, the
expression and activation of Greatwall varies greatly among breast and lung cancer cell
lines. Intriguingly, this suggests that some cancer cells could be exquisitely and
specifically sensitive to Greatwall inactivation. These data are clearly insufficient to
definitively draw conclusions about the true nature of the role that Greatwall plays in
cell cycle control in somatic or tumor cells. Further experiments will be necessary in
order to confirm these findings and evaluate Greatwall as a therapeutic target.
While Greatwall is clearly critical for early embryonic cell cycles in Xenopus
and Drosophila and is required for survival of at least some cancer cells, the findings
discussed here suggest that it might not be an essential protein in all somatic cells. This
could mean that the essential cell cycle control mechanisms have changed in specific
tumor cells, reverting them back into a state similar to early embryonic cell cycles, that
critically requires the activity of Greatwall. If this hypothesis is correct then Greatwall
could be an ideal target for cancer therapy that shows high specificity for selective
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tumors. If this hypothesis can be verified, further in depth work will be necessary to
elucidate the precise mechanism of the switch from one state, in early embryogenesis, to
the other in somatic cells.
Greatwall is a particularly promising therapeutic target because it combines an
essential role in mitosis as well as a function in recovery from a DNA damage-induced
cell cycle arrest (Peng et al. 2010; Voets et al. 2010). The development of new drugs
and therapies to target cancer are a major focus of current endeavors to improve patient
survival. Many of the most widely used chemotherapy agents target DNA damage
checkpoints (e.g. Cisplatin, camptothecin) or the mitotic spindle checkpoint (e.g.
Taxanes, Vinca Alkaloids) (Sudakin et al. 2007; Ljungman 2009). These
chemotherapeutic agents are relatively non-specific and result in many unwanted side
effects and a narrow therapeutic index. The development of more selective agents with
a wide therapeutic index is highly desirable. DNA damage response factors and mitotic
kinases have been at the vanguard of these endeavours (Girdler et al. 2006; Perez de
Castro et al. 2008). Greatwall combines an essential role in mitosis and recovery from
the DNA-damage response making it a novel target. This dual role for Greatwall in cell
cycle control sets Greatwall apart from other kinases. This, combined with the evidence
presented here that its role in cell cycle progression and proliferation is limited in
somatic cells but may be essential for survival in certain cancer cells, strongly suggests
that further investigations should be undertaken. It means that Greatwall could
potentially represent an ‘Achilles heel’ for some tumors which could be exploited
therapeutically for synthetic lethality strategies that might allow more selective killing
of cancer cells with only limited effects on normal proliferating tissues.
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CHAPTER 8. General discussion and future directions
8.1 General discussion
The work presented here has focused on elucidating the role of Greatwall kinase
in human cells. The development of tools, including an anti-Greatwall antibody and a
flag-tagged Greatwall, allowed the investigation of the kinase. Using these tools I
determined that the human Greatwall protein is expressed at similar levels throughout
the cell cycle and is activated by phosphorylations at the G2/M transition and remains
phosphorylated until mitotic exit. The overexpression of the protein is well tolerated in
human cells while its depletion, by siRNA, leads to problems at G2/M transition and
numerous mitotic defects that correspond to the level of knockdown achieved. This
data, in combination with other studies published during this work (Burgess et al. 2010;
Voets et al. 2010), indicate that human Greatwall kinase’s role in cells is likely
equivalent to that of the Drosophila and Xenopus Greatwalls. It is required to inactivate
PP2A, via phosphorylation of Ensa/Arpp19, at the G2/M transition to allow CDK1
mitotic phosphorylations to dominate and drive entry into mitosis.
The use of structural modeling, phosphorylation site mapping and mutagenic
analysis has allowed the investigation of Greatwall’s mechanism of activation. It is a
particularly unusual kinase because it has a rare bifurcated kinase domain that is split by
a large stretch of approximately 500 non-conserved amino acids. This initially led to
scepticism about if this was a true protein kinase at all. It is now clear that this is a
functional kinase and the work presented here has identified key features of the kinase
fold. A model of the predicted kinase domain structure was produced using the
computational protein structure prediction engine PHYRE by Dr. Anthony Oliver from
the GDSC at the University of Sussex. This, combined with phosphorylation site
mapping of the kinase using PhosSitePlus, allowed the identification of key residues
that could contribute to Greatwall kinase activity. Production of mutant forms of
Greatwall validated the predicted structural model and allowed identification of the
activation loop, P+1 loop, and turn motif of Greatwall kinase. The work present when
amalgamated with the investigations carried out in two other studies (Vigneron et al.
2011; Blake-Hodek et al. 2012), led to the proposal of a potential novel three-step
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mechanism for Greatwall activation. In this model, activation is begun by priming
phosphorylations of threonines, T194 and T207, in the activation loop. This results in
initial low kinase activity that allows autophosphorylation of the turn motif on S874 in
the C-terminal tail. This then likely mediates the docking and/or interaction of the
hydrophobic motif binding pocket with a phosphorylated hydrophobic motif of another,
as yet unknown, AGC kinase. Once bound Greatwall is then fully active. This
mechanism of activation is somewhat unexpected but is supported by the experimental
evidence and is in keeping with the highly intricate mechanisms that control other AGC
kinase activities (Pearce et al. 2010). A crystal structure of the kinase would provide an
invaluable insight into the exact mechanisms of activation of this novel kinase. The
Greatwall artificial splicing variants that I generated as part of this work have
subsequently been purified from E.coli and are currently in use for crystallography as
well as for large-scale inhibitor screening.
The kinases and phosphatases governing Greatwall activity throughout the cell
cycle were also investigated here. A critical phosphorylation on T194 was identified
that is essential for Greatwall activity and is in a conserved CDK phosphorylation
consensus motif. This led to the hypothesis that human Greatwall, like Xenopus
Greatwall, is phosphorylated and activated by CDK1 at the G2/M transition. Subsequent
experiments using a phospho-specific antibody that exclusively detects Greatwall only
when it is phosphorylated at this residue confirmed this both in vitro and in vivo in
human cells. The phosphorylation of T194 corresponds to Greatwall activation and
occurs at the G2/M transition only in the presence of CDK1 activity and persists until
mitotic exit. This site is phosphorylated by CDKs and is able to fully activate Greatwall
in vitro. Thus, it can be concluded that Greatwall activation is begun at the G2/M
transition by CDK1. However, this is unlikely to be the whole story concerning
regulation of Greatwall activity in mitosis and other PTMs and possibly additional
regulatory proteins likely participate as well.
The phosphatases that act to regulate mitotic exit and Greatwall inactivation to
allow cells to return to interphase were also investigated. It was determined that PP2A is
the phosphatase that is responsible for the majority of Greatwall dephosphorylation and
inactivation at mitotic exit. Interestingly, it was found that Ensa dephosphorylation at
mitotic exit was controlled by another phosphatase, the RNA polymerase II C terminal
domain phosphatase Fcp1. Surprisingly, the results of this work indicate that neither
PP1, PP2A nor Fcp1 are the major CDK-antagonising phosphatases that remove mitotic
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phospho-epitopes in human cells and the identity of this phosphatase(s) remains
unknown at present.
Another major part of this thesis work was dedicated to the pursuit of the
generation of an ATP-analogue sensitive (as) Greatwall mutant using a chemical
genetics approach in human cells. This would allow the specific, rapid and reversible
inhibition of the kinase in an otherwise normal cell, enabling elegant studies of the
function of this kinase in cells to be performed. A successful knockin targeting strategy
in human cells was developed. Despite this, unfortunately, it was found that the as
Greatwall mutant was not viable as a functional kinase. The mutation of the gatekeeper
methionine residue within the ATP-binding pocket to an alanine was not tolerated by
the kinase and subsequent mutations to rescue the kinase activity were unsuccessful. A
final attempt to produce an analogue sensitive mutant by mutation of the gatekeeper
residue to a cysteine, creating an electrophile-sensitive (es) kinase, proved promising
with three quarters of the activity as compared to the wildtype kinase remaining. This
chemical genetics work is currently being further developed as part of a Marie Curie
Fellowship and the es Greatwall mutant will be used for target evaluation in xenograft
experiments.
Finally, during this work inconsistencies were observed between the manner in
which transformed cell lines and non-transformed immortalised cell lines responded to
the siRNA-mediated knockdown of Greatwall. Greatwall knockdown causes cell cycle
arrest and apoptosis in the transformed cancer cell lines but has little impact on survival
of the non-transformed cells. It means that Greatwall could potentially represent an
‘Achilles heel’ for some tumors and, while its role in cell cycle progression and
proliferation is limited in somatic cells, it may be essential for survival in certain cancer
cells. The preliminary work presented here supports the idea that Greatwall could
potentially be an important prognostic biomarker and therapeutic target for cancer
therapy. This work has formed the foundation of a large collaborative drug discovery
project at the University of Sussex to develop Greatwall as an anti-cancer drug target
and potential clinical biomarker.
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8.2 Greatwall kinase controlling mitotic progression – phosphatases come into focus
The emerging view of mitotic control as a delicate balance of kinases and their
counteracting phosphatases is now becoming increasingly accepted and vigorously
studied. Since the historic discovery of MPF, succeeding studies have revealed that
entry into mitosis is regulated by the highly coordinated activities of multiple protein
kinases and their opposing phosphatases (Bollen et al. 2009; Lindqvist et al. 2009). The
phosphorylation of more than a thousand proteins by CDK and other mitotic kinases
drive mitotic entry (Dephoure et al. 2008). These must then be subsequently removed
by phosphatases as cells exit mitosis (Wurzenberger et al. 2011). This mitotic kinase
and phosphatase activity is therefore inversely regulated to avoid futile cycles of
phosphorylation and dephosphorylation (Domingo-Sananes et al. 2011; Medema et al.
2011). Furthermore, mitotic kinases are themselves regulated by phosphorylation and
dephosphorylation, resulting in a complex feedback system of cell cycle control. This
allows for these regulatory feedback circuits to act in a highly sensitive switch-like
manner to ensure sharp phase transitions required for progression throughout mitosis
(Domingo-Sananes et al. 2011; Krasinska et al. 2011). Moreover, it allows for
bistability and hysteresis to exist within the system to further ensure a robust and
efficient switch-like mechanism governs mitotic entry and exit (Domingo-Sananes et al.
2011).
In interphase, CDK1 is negatively regulated by phosphorylation at T14/Y15 by
Wee1 and Myt1 kinases, and dephosphorylation of this site by Cdc25 constitutes the
decision point to enter mitosis (Lindqvist et al. 2009). CDK1 then participates in its
own activation by negatively regulating its inhibitor, Wee1, and activating its activator,
Cdc25 (Hoffmann et al. 1993). This switch is counteracted by PP2A-B55δ which in 
turn is antagonised by Greatwall which phosphorylates and activates the PP2A-B55δ 
inhibitors Arpp19 and Ensa. Moreover, CDK1 can phosphorylate and activate Greatwall
at multiple sites. This suggests a model by which CDK1 and Greatwall activation are
locked in a complex feedback system at the G2/M transition. A recent paper that
explored this relationship in frogs and starfish oocytes in depth concluded that cyclin B-
CKD1 and Greatwall must now both be considered essential components of the MPF
(Hara et al. 2012) as both are required for mitosis in these systems.
In order to gain a more precise understanding of this switch-like transition,
identification of the phosphatases that target Greatwall itself and Arpp19/Ensa was
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important. This thesis initiated work that led to the discovery that PP2A-B55 α and δ 
isoforms inactivate Greatwall at mitotic exit in human cells and that another
phosphatase, Fcp1, serves to inactivate Arpp19/Ensa. These findings indicate a complex
phosphatase regulation to mediate these transitions. This work is at the vanguard of our
current progress in delineating mitotic entry and exit. Further focused work will be
required to build on this emerging picture of these intricate and highly sensitive
pathways.
8.3 Interactions with other key mitotic kinases and other emerging roles for
Greatwall?
How does Greatwall interact with other key mitotic kinases, if indeed it does at
all? There has been much conflicting data and hypotheses in the literature and work is
ongoing to precisely define the interactions of Greatwall. In Xenopus Greatwall does not
phosphorylate Plx1, Plx3, CDK1, cyclin B, Cdc25A, Cdc25C, Chk1, Wee1, Myt1 or
Pin1 in vitro (Zhao et al. 2008). Moreover, the exact sequence phosphorylated by
Greatwall in Arpp19 and Ensa is found only in these two proteins, although the
stringency of the substrate recognition sequence is not known (Mochida et al. 2012).
Blake-Hodek et al. (2012) reported that in their hands Plx1, Aurora A, PKA,
Nek2 and p42 MAPK do not contribute to Greatwall activation alone or synergistically
with CDKs. Yu et al. (2006) found that Plx-treated Greatwall could not rescue the
mitotic phenotype in Greatwall depleted extracts and showed no autophosphorylation or
phosphorylation of MBP in in vitro kinase assays. Additionally, co-treatment of
Greatwall with Plx and MPF again did not yield a synergistic increase in activity. In
agreement with these studies, the results obtained here do not give reason to suspect the
involvement of additional kinases, other than CDKs, in the activation of Greatwall to
promote mitotic entry. However, other key mitotic kinases might serve to add
phosphorylations to Greatwall during mitosis to facilitate its stabilisation or localisation.
That PLK1 was reported to activate Greatwall in vitro by Vigneron et al. (2011)
seems not to fit with this analysis. It might be that PLK1 can phosphorylate human
Greatwall in its NCMR and stabilise the kinase giving it the activity seen in vitro by this
group. This might not represent a key mechanism for activation in vivo under normal
cell cycle conditions but could suggest a role for PLK1 in the control of Greatwall
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activation in circumstances other than normal mitotic entry. In this case, under certain
circumstances, PKL1 would serve to activate Greatwall to inactivate phosphatases
mediating specific cell cycle signalling to promote cell cycle progression. This has
already been reported to occur after a DNA damage-mediated cell cycle arrest (Peng et
al. 2011). This could be interpreted to mean that PLK1 is capable of activating the
human Greatwall, at least partially, but that it does so only if a specific set of cellular
conditions are present. A surge in Greatwall activity was observed here in human cells
immediately after release from S phase following a cell cycle block induced by
Thymidine. This requires further analysis but supports a role for Greatwall in restarting
cell cycle progression in a manner similar to that described after a DNA damage cell
cycle arrest (Peng et al. 2010; Peng et al. 2011). It would be interesting for future work
to determine if this activation is PLK1 dependant.
In addition, a version of the Greatwall pathway has recently been reported to be
conserved in budding yeast (Yu et al. 2004; Talarek et al. 2010; Bontron et al. 2013). In
these yeast cells, instead of controlling mitotic entry and exit however, it appears to be
involved in entry into the reversible quiescent or G0 state in response to limited
nutrients to ensure maximum long-term survival; known as the chronological life span
(Talarek et al. 2010). The proposed yeast Greatwall homologue, Rim15, is activated in
response to nitrogen and/or carbon limitation. It then phosphorylates Igo1 and Igo2, the
yeast orthologues of Arpp19 and Ensa, which directly inhibit yeast PP2ACdc55
preventing its dephosphorylation of certain transcription factors that are then able to be
recruited too and activate transcription of genes that promote induction of the
quiescence program (Bontron et al. 2013). Rim15 phosphorylated Igo1 can also directly
interact with proteins at the 3’ UTR of mRNAs to protect them from degradation during
the initiation of the quiescence state during which only certain genes remain expressed
(Talarek et al. 2010). Loss of Rim15 or Igo1/2 prevents initiation of the G0 program.
Human Arpp19 and Ensa were able to partially replace Igo1/2 function in the yeast cells
suggesting an interesting potentially conserved role for Greatwall in the regulation of
mRNA stability in higher eukaryotes (Talarek et al. 2010; Lorca et al. 2012). This thesis
has specifically focused on examination of the role of Greatwall at the G2/M transition
and in mitosis, but the potential for roles of the Greatwall pathway outside of this remit
are fascinating and will provide important avenues for further investigations.
Another paper has recently described a study in which human Greatwall loss
synergised with the loss of p53 in HCT116 cells (Krastev et al. 2011). They performed
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an RNAi-based synthetic interaction screen and identified Greatwall as a gene whose
knockdown selectively affected p53 knockout HCT116 cells. They found that Greatwall
expression was required for efficient growth of the knockout cells and its loss slowed
their rate of proliferation, raising the possibility that Greatwall acts in conjunction with
p53 to maintain proliferation in these cells.
These studies point to possible functions and potential interactions of Greatwall
that are as of yet relatively unexplored and will require further investigations to
elucidate.
8.4 Greatwall and human diseases
There is a dilemma with the emerging role for Greatwall in control of the cell
cycle. If it is essentially required for cell cycle progression how do organisms that lack
Greatwall successfully progress through the cell cycle? It is only found in certain
evolutionary lineages (Yu et al. 2006). In yeast Rim15 is nonessential and there are no
close relatives of Greatwall known in Caenorhabitis elegans for example (Kim et al.
2012). Additionally, the available data in humans indicates that inactivating mutation of
Greatwall (E167D) in patients only impacts mildly on platelets (Johnson et al. 2009). It
is, therefore, conceivable that the Greatwall pathway is in fact not an essential
component of the G2/M transition switch in normal somatic cells. The switch between
interphase and mitosis is the result of many integrated inputs and could be differentially
balanced so that Greatwall is not required in most cells. It might instead represent a
subsidiary feedback loop that is only required under certain cell cycle conditions, such
as in early development, and has been upregulated and become a ‘pathway addiction’ in
artificially growing or tumour cells. In this case, Greatwall would normally only be
required to reduce/inactivate PP2A-B55 when high levels of this phosphatase activity
are present to drive (multiple) rapid cell cycle divisions/transitions, such as in gametes.
It is possible that tumour cells have utilised this auxiliary pathway to drive their cell
cycle artificially and that targeting this characteristic of their growth could represent a
unique therapeutic intervention. Thus, allowing tumour cells to be specifically killed
with relatively minor implications for other normal cells. The inhibition of several cell
cycle protein kinases with small molecules are already being tested in phase I and II
trials for cancer therapy (Girdler et al. 2006; Perez de Castro et al. 2008). Additionally,
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inhibition of Greatwall might also act synergistically with other DNA damaging agents
or mitotic inhibitors to further increase its efficacy and clinical applicability.
It is also important to note that a role for Greatwall in normal cells that are not
somatic cells, such as the gametes, is not insignificant. As Adhikari et al. (2012a) point
out, it is important for future work to determine if Greatwall regulates CDK1
phosphorylations at the resumption of meiosis in human oocytes. It is known that Ensa
is expressed in these cells (Von Stetina et al. 2008). Determination of a role for
Greatwall could therefore have significant implications for the treatment of female
infertility that results from failure to resume normal meiotic maturation (Adhikari et al.
2012a).
There are tantalising hints that the full story of Greatwall kinase is not yet
known and that further research is warranted to elucidate the true function(s) of
Greatwall in human cells. Precise determination of the role of Greatwall kinase could
potentially yield insights that could have important implications for treatments of
human conditions that range from infertility to cancer.
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Appendix A – NCBI Greatwall and cloned Greatwall sequence alignment
NCBI_MASTL 1 MDPTAGSKKEPGGGAATEEGVNRIAVPKPPSIEEFSIVKPISRGAFGKVY 50
||||||||||||||||||||||||||||||||||||||||||||||||||
Cloned_GW 1 MDPTAGSKKEPGGGAATEEGVNRIAVPKPPSIEEFSIVKPISRGAFGKVY 50
NCBI_MASTL 51 LGQKGGKLYAVKVVKKADMINKNMTHQVQAERDALALSKSPFIVHLYYSL 100
||||||||||||||||||||||||||||||||||||||||||||||||||
Cloned_GW 51 LGQKGGKLYAVKVVKKADMINKNMTHQVQAERDALALSKSPFIVHLYYSL 100
NCBI_MASTL 101 QSANNVYLVMEYLIGGDVKSLLHIYGYFDEEMAVKYISEVALALDYLHRH 150
||||||||||||||||||||||||||||||||||||||||||||||||||
Cloned_GW 101 QSANNVYLVMEYLIGGDVKSLLHIYGYFDEEMAVKYISEVALALDYLHRH 150
NCBI_MASTL 151 GIIHRDLKPDNMLISNEGHIKLTDFGLSKVTLNRDINMMDILTTPSMAKP 200
||||||||||||||||||||||||||||||||||||||||||||||||||
Cloned_GW 151 GIIHRDLKPDNMLISNEGHIKLTDFGLSKVTLNRDINMMDILTTPSMAKP 200
NCBI_MASTL 201 RQDYSRTPGQVLSLISSLGFNTPIAEKNQDPANILSACLSETSQLSQGLV 250
||||||||||||||||||||||||||||||||||||||||||||||||||
Cloned_GW 201 RQDYSRTPGQVLSLISSLGFNTPIAEKNQDPANILSACLSETSQLSQGLV 250
NCBI_MASTL 251 CPMSVDQKDTTPYSSKLLKSCLETVASNPGMPVKCLTSNLLQSRKRLATS 300
||||||||||||||||||||||||||||||||||||||||||||||||||
Cloned_GW 251 CPMSVDQKDTTPYSSKLLKSCLETVASNPGMPVKCLTSNLLQSRKRLATS 300
NCBI_MASTL 301 SASSQSHTFISSVESECHSSPKWEKDCQESDEALGPTMMSWNAVEKLCAK 350
||||||||||||||||||||||||||||||||||||||||||||||||||
Cloned_GW 301 SASSQSHTFISSVESECHSSPKWEKDCQESDEALGPTMMSWNAVEKLCAK 350
NCBI_MASTL 351 SANAIETKGFNKKDLELALSPIHNSSALPTTGRSCVNLAKKCFSGEVSWE 400
||||||||||||||||||||||||||||||||||||||||||||||||||
Cloned_GW 351 SANAIETKGFNKKDLELALSPIHNSSALPTTGRSCVNLAKKCFSGEVSWE 400
NCBI_MASTL 401 AVELDVNNINMDTDTSQLGFHQSNQWAVDSGGISEEHLGKRSLKRNFELV 450
||||||||||||||||||||||||||||||||||||||||||||||||||
Cloned_GW 401 AVELDVNNINMDTDTSQLGFHQSNQWAVDSGGISEEHLGKRSLKRNFELV 450
NCBI_MASTL 451 DSSPCKKIIQNKKTCVEYKHNEMTNCYTNQNTGLTVEVQDLKLSVHKSQQ 500
||||||||||||||||||||||||||||||||||||||||||||||||||
Cloned_GW 451 DSSPCKKIIQNKKTCVEYKHNEMTNCYTNQNTGLTVEVQDLKLSVHKSQQ 500
NCBI_MASTL 501 NDCANKENIVNSFTDKQQTPEKLPIPMIAKNLMCELDEDCEKNSKRDYLS 550
||||||||||||||||||||||||||||||||||||||||||||||||||
Cloned_GW 501 NDCANKENIVNSFTDKQQTPEKLPIPMIAKNLMCELDEDCEKNSKRDYLS 550
NCBI_MASTL 551 SSFLCSDDDRASKNISMNSDSSFPGISIMESPLESQPLDSDRSIKESSFE 600
||||||||||||||||||||||||||||||||||||||||||||||||||
Cloned_GW 551 SSFLCSDDDRASKNISMNSDSSFPGISIMESPLESQPLDSDRSIKESSFE 600
NCBI_MASTL 601 ESNIEDPLIVTPDCQEKTSPKGVENPAVQESNQKMLGPPLEVLKTLASKR 650
||||||||||||||||||||||||||||||||||||||||||||||||||
Cloned_GW 601 ESNIEDPLIVTPDCQEKTSPKGVENPAVQESNQKMLGPPLEVLKTLASKR 650
NCBI_MASTL 651 NAVAFRSFNSHINASNNSEPSRMNMTSLDAMDISCAYSGSYPMAITPTQK 700
||||||||||||||||||||||||||||||||||||||||||||||||||
Cloned_GW 651 NAVAFRSFNSHINASNNSEPSRMNMTSLDAMDISCAYSGSYPMAITPTQK 700
NCBI_MASTL 701 RRSCMPHQTPNQIKSGTPYRTPKSVRRGVAPVDDGRILGTPDYLAPELLL 750
||||||||||||||||||||||||||||||||||||||||||||||||||
Cloned_GW 701 RRSCMPHQTPNQIKSGTPYRTPKSVRRGVAPVDDGRILGTPDYLAPELLL 750
NCBI_MASTL 751 GRAHGPAVDWWALGVCLFEFLTGIPPFNDETPQQVFQNILKRDIPWPEGE 800
||||||||||||||||||||||||||||||||||||||||||||||||||
Cloned_GW 751 GRAHGPAVDWWALGVCLFEFLTGIPPFNDETPQQVFQNILKRDIPWPEGE 800
NCBI_MASTL 801 EKLSDNAQSAVEILLTIDDTKRAGMKELKRHPLFSDVDWENLQHQTMPFI 850
||||||||||||||||||||||||||||||||||||||||||||||||||
Cloned_GW 801 EKLSDNAQSAVEILLTIDDTKRAGMKELKRHPLFSDVDWENLQHQTMPFI 850
NCBI_MASTL 851 PQPDDETDTSYFEARNTAQHLTVSGFSL 878
||||||||||||||||||||||||||||
Cloned_GW 851 PQPDDETDTSYFEARNTAQHLTVSGFSL 878
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An EMBOSS Needle-Pairwise Sequence Alignment (PROTEIN) of the mRNA
sequence of human MASTL (NCBI, Accession NM_032844) with my cloned human
Greatwall cDNA (Length: 878 Identity; 878/878 (100.0%); Similarity: 878/878
(100.0%); Gaps: 0/878 (0.0%); Score: 4582.0). This cloned sequence is also confirmed
by the published amino acid sequence in Vigneron et al. (2011).
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Appendix B – Growth data and ANOVA for HEK 293T, C1 and C7 cells
Growth data of the wildtype HEK 293T cells and cell lines, C1 and C7, used for the
single factor ANOVA showing no significant main effect (F(2, 255) = 0.14, p =
0.87), indicating that there is no significant difference between the growth of the
wildtype HEK 293T cells and the two cell lines’ growth (Chapter 3 section 3.5).
Data was collected using the IncuCyte system from Essen Biosciences.
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Appendix C – Sequence alignment of Greatwall kinases
APPENDIX C
A CLUSTAL 2.1 multiple sequence alignment of human, mouse, Xenopus and
Drosophila Greatwalls. The key features and significant residues of the human kinase
are indicated; the N-lobe is indicted in aqua font, the C-lobe is indicated in orange font,
the hydrophobic motif is indicated in pink font, and significant residues are indicated
with white font. All potential CDK phosphorylation (T/S-P) sites are highlighted in
aqua with confirmed sites indicated by purple font and predicted sites (by
PhosphoSitePlus analysis) indicated by orange font. Lysine 72, the residue reportedly
altered in the Drosophila Scant mutation (K72M) (Archambault et al. 2007), is
indicated highlighted in violet. E167, the residue reportedly mutated (E167D) and
responsible for Thrombocytopenia in humans (Gandhi et al. 2003), is indicated
highlighted in orange. The gatekeeper methionine 110 is highlighted in pink and the
critical phosphorylated residue of the C-terminal tail of Greatwall (S874) is indicated in
violet highlight. An asterisk (*) indicates positions that have a single, fully conserved
residue. A colon (:) indicates conservation between groups of strongly similar properties
- scoring > 0.5 in the Gonnet PAM 250 matrix. A period (.) indicates conservation
between groups of weakly similar properties - scoring =< 0.5 in the Gonnet PAM 250
matrix.
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Appendix D – Exon structure of Greatwall
1 MDPTAGSKKEPGGGAATEEGVNRIAVPKPPSIEEFSIVKPISRGAFGKVY
51 LGQKGGKLYAVKVVKKADMINKNMTHQVQAERDALALSKSPFIVHLYYSL
101 QSANNVYLVMEYLIGGDVKSLLHIYGYFDEEMAVKYISEVALALDYLHRH
151 GIIHRDLKPDNMLISNEGHIKLTDFGLSKVTLNRDINMMDILTTPSMAKP
201 RQDYSRTPGQVLSLISSLGFNTPIAEKNQDPANILSACLSETSQLSQGLV
251 CPMSVDQKDTTPYSSKLLKSCLETVASNPGMPVKCLTSNLLQSRKRLATS
301 SASSQSHTFISSVESECHSSPKWEKDCQESDEALGPTMMSWNAVEKLCAK
351 SANAIETKGFNKKDLELALSPIHNSSALPTTGRSCVNLAKKCFSGEVSWE
401 AVELDVNNINMDTDTSQLGFHQSNQWAVDSGGISEEHLGKRSLKRNFELV
451 DSSPCKKIIQNKKTCVEYKHNEMTNCYTNQNTGLTVEVQDLKLSVHKSQQ
501 NDCANKENIVNSFTDKQQTPEKLPIPMIAKNLMCELDEDCEKNSKRDYLS
551 SSFLCSDDDRASKNISMNSDSSFPGISIMESPLESQPLDSDRSIKESSFE
601 ESNIEDPLIVTPDCQEKTSPKGVENPAVQESNQKMLGPPLEVLKTLASKR
651 NAVAFRSFNSHINASNNSEPSRMNMTSLDAMDISCAYSGSYPMAITPTQK
701 RRSCMPHQTPNQIKSGTPYRTPKSVRRGVAPVDDGRILGTPDYLAPELLL
751 GRAHGPAVDWWALGVCLFEFLTGIPPFNDETPQQVFQNILKRDIPWPEGE
801 EKLSDNAQSAVEILLTIDDTKRAGMKELKRHPLFSDVDWENLQHQTMPFI
851 PQPDDETDTSYFEARNTAQHLTVSGFSL
The 12 exons that comprise translated human Greatwall kinase. The alternate black and
purple font indicates alternate exons and blue font indicates amino acids encoded across
a splice junction. The N-lobe of the kinase fold is indicted in aqua highlight, the C-lobe
is indicated in orange highlight and the hydrophobic motif is indicated in pink highlight.
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Appendix E – Sequence alignment of human PKA and Greatwall
Greatwall MDPTAGSKKEPGG-------GAATEEGVNRIAVPKP--PSIEEFSIVKPISRGAFGKVYL 51
PKA MGNAAAAKKGSEQESVKEFLAKAKEDFLKKWESPAQNTAHLDQFERIKTLGTGSFGRVML 60
*. :*.:** . . *.*: ::: * . :::*. :*.:. *:**:* *
Greatwall G--QKGGKLYAVKVVKKADMINKNMTHQVQAERDALALSKSPFIVHLYYSLQSANNVYLV 109
PKA VKHKETGNHYAMKILDKQKVVKLKQIEHTLNEKRILQAVNFPFLVKLEFSFKDNSNLYMV 120
:: *: **:*::.* .::: : .:. *: * : **:*:* :*::. .*:*:*
Greatwall MEYLIGGDVKSLLHIYGYFDEEMAVKYISEVALALDYLHRHGIIHRDLKPDNMLISNEGH 169
PKA MEYVPGGEMFSHLRRIGRFSEPHARFYAAQIVLTFEYLHSLDLIYRDLKPENLLIDQQGY 180
***: **:: * *: * *.* * * :::.*:::*** .:*:*****:*:**.::*:
Greatwall IKLTDFGLSKVTLNRDINMMDILTTPSMAKPRQDYSRTPGQVLSLISSLGFNTPIAEKNQ 229
PKA IQVTDFGFAKRVKGR--------------------------------------------- 195
*::****::* . .*
Greatwall DPANILSACLSETSQLSQGLVCPMSVDQKDTTPYSSKLLKSCLETVASNPGMPVKCLTSN 289
PKA ------------------------------------------------------------
Greatwall LLQSRKRLATSSASSQSHTFISSVESECHSSPKWEKDCQESDEALGPTMMSWNAVEKLCA 349
PKA ------------------------------------------------------------
Greatwall KSANAIETKGFNKKDLELALSPIHNSSALPTTGRSCVNLAKKCFSGEVSWEAVELDVNNI 409
PKA ------------------------------------------------------------
Greatwall NMDTDTSQLGFHQSNQWAVDSGGISEEHLGKRSLKRNFELVDSSPCKKIIQNKKTCVEYK 469
PKA ------------------------------------------------------------
Greatwall HNEMTNCYTNQNTGLTVEVQDLKLSVHKSQQNDCANKENIVNSFTDKQQTPEKLPIPMIA 529
PKA ------------------------------------------------------------
Greatwall KNLMCELDEDCEKNSKRDYLSSSFLCSDDDRASKNISMNSDSSFPGISIMESPLESQPLD 589
PKA ------------------------------------------------------------
Greatwall SDRSIKESSFEESNIEDPLIVTPDCQEKTSPKGVENPAVQESNQKMLGPPLEVLKTLASK 649
PKA ------------------------------------------------------------
Greatwall RNAVAFRSFNSHINASNNSEPSRMNMTSLDAMDISCAYSGSYPMAITPTQKRRSCMPHQT 709
PKA ------------------------------------------------------------
Greatwall PNQIKSGTPYRTPKSVRRGVAPVDDGRILGTPDYLAPELLLGRAHGPAVDWWALGVCLFE 769
PKA ------------------------TWTLCGTPEYLAPEIILSKGYNKAVDWWALGVLIYE 231
: ***:*****::*.:.:. ********* ::*
Greatwall FLTGIPPFNDETPQQVFQNILKRDIPWPEGEEKLSDNAQSAVEILLTIDDTKRAG----- 824
PKA MAAGYPPFFADQPIQIYEKIVSGKVRFP---SHFSSDLKDLLRNLLQVDLTKRFGNLKNG 288
: :* *** : * *::::*:. .: :* .::*.: :. :. ** :* *** *
Greatwall MKELKRHPLFSDVDWENLQH--QTMPFIPQPDDETDTSYFEARNTAQHLTVSGFSL---- 878
PKA VNDIKNHKWFATTDWIAIYQRKVEAPFIPKFKGPGDTSNFDDYEEEEIRVSINEKCGKEF 348
::::*.* *: .** : : ****: .. *** *: : : . . .
Greatwall ---
PKA SEF 351
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A CLUSTAL 2.1 multiple sequence alignment of human PKA and Greatwall. The key
features and significant residues are indicated; the N-lobe is indicted with aqua font, the
C-lobe is indicated in light orange font, the hydrophobic motif is indicated in pink font
and significant residues are indicated in white font. Important phosphorylated residues
are indicated by purple font and highlighted in aqua, the gatekeeper methionine (M110)
is indicated highlighted in pink. An asterisk (*) indicates positions that have a single,
fully conserved residue. A colon (:) indicates conservation between groups of strongly
similar properties - scoring > 0.5 in the Gonnet PAM 250 matrix. A period (.) indicates
conservation between groups of weakly similar properties - scoring =< 0.5 in the
Gonnet PAM 250
